var title_f33_25_34192="Doxepin: Pediatric drug information";
var content_f33_25_34192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxepin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/59/24503?source=see_link\">",
"       Doxepin (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/54/14181?source=see_link\">",
"       Doxepin (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13253 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34192=[""].join("\n");
var outline_f33_25_34192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/59/24503?source=related_link\">",
"      Doxepin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/54/14181?source=related_link\">",
"      Doxepin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_25_34193="Intravascular hemolysis";
var content_f33_25_34193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intravascular hemolysis due to C. perfringens sepsis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a peripheral blood smear from a patient with severe intravascular hemolysis due to sepsis with Clostridium perfringens. Neutrophils show toxic changes, including toxic granulation and vacuoles. There is an increased number of spherocytes (blue arrows) and polychromatophilic red cells (ie, reticulocytes, red arrow). The major finding on this slide is the large number of red blood cell ghosts (black arrows), due to the intravascular lysis of red cells from the phospholipase and other lytic enzymes elaborated by the Clostridial organisms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly provided by Dr. German Pihan, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34193=[""].join("\n");
var outline_f33_25_34193=null;
var title_f33_25_34194="Acetic acid, propylene glycol diacetate, and hydrocortisone: Drug information";
var content_f33_25_34194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetic acid, propylene glycol diacetate, and hydrocortisone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/19/1332?source=see_link\">",
"    see \"Acetic acid, propylene glycol diacetate, and hydrocortisone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acetasol&reg; HC;",
"     </li>",
"     <li>",
"      VoSol&reg; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Otic Agent, Anti-infective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Otitis externa (superficial): Otic: Instill 3-5 drops in ear(s) every 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F129910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;3 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, otic [drops]: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acetasol&reg; HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) [contains benzethonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     VoSol&reg; HC: Acetic acid 2%, propylene glycol diacetate 3%, and hydrocortisone 1% (10 mL) [contains benzethonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2989079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     After removing cerumen and debris, solution may be applied by inserting a cotton wick into the ear canal and saturating with  the solution. Wick may remain in place for 24 hours and then removed; however, drops should continue to be instilled into ear canal as long as indicated.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by swelling",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6053408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       VoSol&reg; may be confused with Vexol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Otic: Transient burning or stinging may be noticed occasionally when the solution is first instilled into the acutely inflamed ear",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2989078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to acetic acid, propylene glycol, hydrocortisone, or any component of the formulation; perforated tympanic membrane; herpes simplex; vaccinia, and varicella",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F129900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acetasol HC Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-1% (10 mL): $251.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hydrocortisone-Acetic Acid Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2% (10 mL): $203.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (VoSoL HC Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-1% (10 mL): $215.00",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9417 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34194=[""].join("\n");
var outline_f33_25_34194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129903\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129914\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129905\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129910\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129906\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129897\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129889\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2989079\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129898\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6053408\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129912\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2989078\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129911\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129895\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129900\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9417\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9417|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/19/1332?source=related_link\">",
"      Acetic acid, propylene glycol diacetate, and hydrocortisone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_25_34195="VF temp crescent sparing HH";
var content_f33_25_34195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Temporal crescent-sparing homonymous hemianopia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Goldmann visual field showing a right temporal crescent-sparing homonymous hemianopia in a patient with a left occipital infarction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34195=[""].join("\n");
var outline_f33_25_34195=null;
var title_f33_25_34196="Enzalutamide: Patient drug information";
var content_f33_25_34196=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Enzalutamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16103?source=see_link\">",
"     see \"Enzalutamide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15036121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xtandi&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15036548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15036550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat prostate cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15036549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3896757",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to enzalutamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15036554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15036555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698156",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hot flashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15036556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cloudy or pink-red urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15036552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695715",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or melt.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15036553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15036557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15036558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86614 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34196=[""].join("\n");
var outline_f33_25_34196=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036121\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036548\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036550\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036549\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036554\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036555\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036556\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036552\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036553\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036557\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036558\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16103?source=related_link\">",
"      Enzalutamide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_25_34197="Pathogenesis of spontaneous bacterial peritonitis";
var content_f33_25_34197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of spontaneous bacterial peritonitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/25/34197/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/25/34197/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/25/34197/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/25/34197/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/25/34197/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/25/34197/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/25/34197/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous bacterial peritonitis (SBP) is defined as an ascitic fluid infection without an evident intra-abdominal surgically treatable source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of infection is documented by a positive ascitic fluid bacterial culture and an elevated ascitic fluid absolute polymorphonuclear leukocyte (PMN) count (&ge;250",
"    <span class=\"nowrap\">",
"     cells/mm3).",
"    </span>",
"    The absolute PMN count is calculated by multiplying the total white blood cell count (or total \"nucleated cell\" count) by the percentage of PMNs in the differential. The cell count and differential are performed manually without formal quality control. The accuracy of these tests is totally dependent upon the skill and interest of the medical technologist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12296?source=see_link\">",
"     \"Diagnosis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our current understanding of the pathogenesis of SBP will be reviewed here. Other issues related to this disorder are discussed separately. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the phrase spontaneous bacterial peritonitis was coined in 1964, the descriptor \"spontaneous\" was used because the pathogenesis of the infection was not apparent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/1\">",
"     1",
"    </a>",
"    ]. Over the past decades, this void of information has been at least partially filled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/2\">",
"     2",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef52311 \" href=\"mobipreview.htm?12/29/12752\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Microbiology and bacterial entry into ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the early steps in the development of SBP is a disturbance in gut flora with overgrowth and extraintestinal dissemination of a specific organism, most commonly Escherichia coli (",
"    <a class=\"graphic graphic_table graphicRef80188 \" href=\"mobipreview.htm?22/8/22667\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Cirrhosis predisposes to the development of bacterial overgrowth, possibly because of altered small intestinal motility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/5\">",
"     5",
"    </a>",
"    ], and the presence of hypochlorhydria due to use of proton pump inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In addition, patients with cirrhosis may have increased intestinal permeability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the role of bacterial overgrowth in the pathogenesis of SBP remains unsettled. In one study, small bowel motility and bacterial overgrowth were compared in 20 patients with cirrhosis and a history of SBP and 20 patients with cirrhosis without a history of SBP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/10\">",
"     10",
"    </a>",
"    ]. The prevalence of bacterial overgrowth was higher in the patients with a history of SBP (70 versus 20 percent); these patients also exhibited more severe small intestinal motility disturbances. In contrast, in another study, the presence of bacterial overgrowth was not associated with the development of SBP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11990?source=see_link\">",
"     \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether or not they are present in increased numbers, bacteria within the gut lumen can traverse the intestinal wall, and colonize mesenteric lymph nodes. This phenomenon is called translocation and has been documented to occur in animal models of cirrhosis and SBP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Bacterascites can occur if the lymphatic carrying the contaminated lymph ruptures because of the high flow and high pressure associated with portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/11\">",
"     11",
"    </a>",
"    ]. Alternatively, the organism can move from the mesenteric lymphatics to the systemic circulation and then percolate through the liver and weep across Glisson's capsule to enter the ascitic fluid.",
"   </p>",
"   <p>",
"    Several studies have demonstrated that bacterial translocation is also increased in patients with advanced cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In an illustrative study, mesenteric lymph nodes were obtained from 101 patients with cirrhosis and from 35 non-cirrhotic controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/13\">",
"     13",
"    </a>",
"    ]. Enteric organisms were grown from culture in only 8.6 percent of controls compared to 3.4, 8.1, and 30.8 percent of patients with Child class A, B, and C cirrhosis, respectively. Selective intestinal decontamination reduced the rate of positive cultures to that of non-cirrhotic patients.",
"   </p>",
"   <p>",
"    Other studies have shown molecular evidence of bacterial translocation and suggested that it occurs prior to the development of clinical SBP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Patients with cirrhosis and ascites can have bacterial DNA in their serum and ascitic fluid even when viable organisms cannot be cultured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/16\">",
"     16",
"    </a>",
"    ]. Low levels of translocation of intact bacteria or pieces of bacteria may lead to activation of tumor necrosis factor (TNF), which may explain the higher levels of TNF that have been observed in patients who ultimately develop SBP compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/17\">",
"     17",
"    </a>",
"    ]. The presence of bacterial DNA in serum and ascitic fluid is a risk factor for death in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/18\">",
"     18",
"    </a>",
"    ]. Proton pump inhibitors increased bacterial translocation in an animal model of SBP and also increase the risk of SBP in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacteria that eventually cause SBP can also originate in sites other than the gut via bacteremic seeding. These include urinary tract infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/19\">",
"     19",
"    </a>",
"    ], pneumococcal sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/11\">",
"     11",
"    </a>",
"    ], cellulitis, pharyngitis, and dental infections. These infections are labeled \"spontaneous\" because they are not amenable to surgical therapy. Surgically treatable infections, eg, perforated duodenal ulcer, that lead to ascitic fluid infection are called secondary bacterial peritonitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12296?source=see_link\">",
"     \"Diagnosis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .) The pathogenesis of this form of peritonitis is quite different than that of SBP; millions of bacteria flood into the peritoneum through the rent in the gut wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Host defenses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the organism enters ascitic fluid, a battle ensues between the virulence of the bacteria and the host's resistance to infection. Microbes that cause SBP are usually serum-resistant, ie, they cannot be killed by serum alone but also require functional phagocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/20\">",
"     20",
"    </a>",
"    ]. Foreign matter is first \"opsonized\" with complement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    globulin so that it is more identifiable by and digestible to phagocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The resident macrophages represent the first line of defense of the peritoneal cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/21\">",
"     21",
"    </a>",
"    ]. If these phagocytes fail to eradicate the colonizing microbes, complement is activated and cytokines are released. PMNs enter the peritoneum to seek and destroy the invading organisms. If, however, complement levels are inadequate or the PMNs are dysfunctional, then colonization may not be contained and a potentially fatal infection may ensue.",
"   </p>",
"   <p>",
"    Cirrhosis is actually one of the most common forms of acquired immune deficiency, creating an environment that facilitates the persistence of peritoneal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum complement deficiency is quite common in patients with liver disease that is advanced enough to produce ascites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/23\">",
"       23",
"      </a>",
"      ]. Furthermore, ascitic fluid is frequently a fivefold or even 10-fold dilution of serum in patients with cirrhosis; thus, ascitic fluid complement concentrations may drop to levels similar to those of the serum of patients with congenital complement deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The function of both motile (eg, PMNs) and stationary phagocytes (eg, Kupffer cells) is reduced in patients with advanced liver disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/25-27\">",
"       25-27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with SBP have advanced cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/1\">",
"     1",
"    </a>",
"    ]. Other risk factors (most of which are associated with cirrhosis) include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/23,28-31\">",
"     23,28-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ascitic fluid total protein concentration less than 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (&lt;10",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      Prior episode of SBP",
"     </li>",
"     <li>",
"      Serum total bilirubin concentration above 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Variceal hemorrhage",
"     </li>",
"     <li>",
"      Possibly malnutrition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Use of proton pump inhibitors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/7,32\">",
"       7,32",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of certain clinical and laboratory features is also associated with an increased risk of SBP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An ascitic fluid total protein &lt;1.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (&lt;15",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      with",
"     </li>",
"     <li>",
"      Child-Pugh score &ge;9 points with serum bilirubin &ge;3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or with",
"     </li>",
"     <li>",
"      Plasma creatinine &ge;1.2",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      blood urea nitrogen &ge;25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or plasma sodium &le;130",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who meet the above combination criteria should be considered candidates for antibiotic prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4121?source=see_link\">",
"     \"Treatment and prophylaxis of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignancy-related ascites and cardiac ascites can become infected, but this is rare enough to be the subject of case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. When peritoneal carcinomatosis is associated with SBP, the organism is unusual and quite virulent, eg, Salmonella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/36\">",
"     36",
"    </a>",
"    ]. Nephrotic ascites can also become spontaneously infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34197/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117406752\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spontaneous bacterial peritonitis (SBP) is defined as an ascitic fluid infection without an evident intra-abdominal surgically treatable source.",
"     </li>",
"     <li>",
"      When the phrase spontaneous bacterial peritonitis was coined in 1964, the descriptor \"spontaneous\" was used because the pathogenesis of the infection was not apparent. Over the past decades, this void of information has been at least partially filled (",
"      <a class=\"graphic graphic_figure graphicRef52311 \" href=\"mobipreview.htm?12/29/12752\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of patients with SBP have advanced cirrhosis, but additional risk factors have been identified. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352906513\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/1\">",
"      CONN HO. SPONTANEOUS PERITONITIS AND BACTEREMIA IN LAENNEC'S CIRRHOSIS CAUSED BY ENTERIC ORGANISMS. A RELATIVELY COMMON BUT RARELY RECOGNIZED SYNDROME. Ann Intern Med 1964; 60:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/2\">",
"      Sheer TA, Runyon BA. Spontaneous bacterial peritonitis. Dig Dis 2005; 23:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/3\">",
"      Guarner C, Runyon BA, Young S, et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/4\">",
"      Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994; 21:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/5\">",
"      Madrid AM, Cumsille F, Defilippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci 1997; 42:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/6\">",
"      Bauer TM, Steinbr&uuml;ckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001; 96:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/7\">",
"      Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/8\">",
"      Sanchez E, Soriano G, Mirelis B. Effect of long-term inhibition of acid gastric secretion on gastric pH and on bacterial translocation in cirrhotic rats (abstract). Hepatology 2007; 46 Suppl:604A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/9\">",
"      Scarpellini E, Valenza V, Gabrielli M, et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol 2010; 105:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/10\">",
"      Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998; 28:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/11\">",
"      Guarner C, Runyon BA. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Gastroenterologist 1995; 3:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/12\">",
"      Casafont F, S&aacute;nchez E, Mart&iacute;n L, et al. Influence of malnutrition on the prevalence of bacterial translocation and spontaneous bacterial peritonitis in experimental cirrhosis in rats. Hepatology 1997; 25:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/13\">",
"      Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/14\">",
"      Runyon BA. Early events in spontaneous bacterial peritonitis. Gut 2004; 53:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/15\">",
"      Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/16\">",
"      Such J, Franc&eacute;s R, Mu&ntilde;oz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/17\">",
"      Such J, Hillebrand DJ, Guarner C, et al. Tumor necrosis factor-alpha, interleukin-6, and nitric oxide in sterile ascitic fluid and serum from patients with cirrhosis who subsequently develop ascitic fluid infection. Dig Dis Sci 2001; 46:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/18\">",
"      Zapater P, Franc&eacute;s R, Gonz&aacute;lez-Navajas JM, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2008; 48:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/19\">",
"      Ho H, Zuckerman MJ, Ho TK, et al. Prevalence of associated infections in community-acquired spontaneous bacterial peritonitis. Am J Gastroenterol 1996; 91:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/20\">",
"      Runyon BA, Morrissey RL, Hoefs JC, Wyle FA. Opsonic activity of human ascitic fluid: a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology 1985; 5:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/21\">",
"      Dunn DL, Barke RA, Knight NB, et al. Role of resident macrophages, peripheral neutrophils, and translymphatic absorption in bacterial clearance from the peritoneal cavity. Infect Immun 1985; 49:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/22\">",
"      Runyon BA. Bacterial infections in patients with cirrhosis. J Hepatol 1993; 18:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/23\">",
"      Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/24\">",
"      Runyon BA. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. Hepatology 1988; 8:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/25\">",
"      Laffi G, Carloni V, Baldi E, et al. Impaired superoxide anion, platelet-activating factor, and leukotriene B4 synthesis by neutrophils in cirrhosis. Gastroenterology 1993; 105:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/26\">",
"      Rimola A, Soto R, Bory F, et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984; 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/27\">",
"      Tritto G, Frances R, Shah N, et al. Plasma from stable patients with cirrhosis transmits severe neutrophil phagocytic dysfunction which is independent of the presence of bacterial DNA and associated with increased expression of TLR-4. Hepatology 2009; 50:311A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/28\">",
"      Tit&oacute; L, Rimola A, Gin&egrave;s P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/29\">",
"      Llach J, Rimola A, Navasa M, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992; 16:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/30\">",
"      Andreu M, Sola R, Sitges-Serra A, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/31\">",
"      Rimola A, Bory F, Teres J, et al. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985; 5:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/32\">",
"      Goel GA, Deshpande A, Lopez R, et al. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012; 10:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/33\">",
"      Fern&aacute;ndez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/34\">",
"      Kurtz RC, Bronzo RL. Does spontaneous bacterial peritonitis occur in malignant ascites? Am J Gastroenterol 1982; 77:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/35\">",
"      Runyon BA. Spontaneous bacterial peritonitis associated with cardiac ascites. Am J Gastroenterol 1984; 79:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/36\">",
"      Woolf GM, Runyon BA. Spontaneous Salmonella infection of high-protein noncirrhotic ascites. J Clin Gastroenterol 1990; 12:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34197/abstract/37\">",
"      Ackerman Z. Ascites in Nephrotic syndrome. Incidence, patients' characteristics, and complications. J Clin Gastroenterol 1996; 22:31.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1246 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34197=[""].join("\n");
var outline_f33_25_34197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H117406752\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Microbiology and bacterial entry into ascites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Host defenses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H117406752\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H352906513\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1246\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1246|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/29/12752\" title=\"figure 1\">",
"      Pathogenesis of SBP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1246|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/8/22667\" title=\"table 1\">",
"      Bacteriology of SBP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11990?source=related_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12296?source=related_link\">",
"      Diagnosis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4121?source=related_link\">",
"      Treatment and prophylaxis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_25_34198="Gluteal and sciatic hernias";
var content_f33_25_34198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Gluteal and sciatic hernias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Sciatic hernias are rare. The hernia can pass through the greater sciatic foramen above (1) or below (2) the pyriformis muscle or&nbsp;through the lesser sciatic foramen medial to the sciatic nerve.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland, MW, Lillemoe, KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34198=[""].join("\n");
var outline_f33_25_34198=null;
var title_f33_25_34199="Bronchial tree anat";
var content_f33_25_34199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Bronchial tree anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 459px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Porth, CM. Pathophysiology Concepts of Altered Health States, Seventh Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34199=[""].join("\n");
var outline_f33_25_34199=null;
var title_f33_25_34200="Cephalocele";
var content_f33_25_34200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77074%7EOBGYN%2F56949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77074%7EOBGYN%2F56949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetus with posterior cephalocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 270px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEOAY0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDLsINP1G3S7s3jExi4K9XGOhB7/wCRmuAvo5LPxNIHJggnbbIyqUXIHH51r+Bbl9P064RwxmjjybeVTlRx09+tV/EX9o3NxLJLamSzkIKZwHGRyGz060AO0rW7eX7TpsqmK8RiBdIu4Hjjnn0rqdN8QapgQkpcWUoKrKY+NwHU+nPr+lUNG0rS4rcTadKLXUcFXik/jwBxz171tWmo21z+5EKhwxXgZUtg55xx6/iKAMyHTLs2rTMYnGctbsQAqnB4J+n+c1qae9nFcytIHty+BJHkHecex6Z7VmyQLFcTSusjwqOF24IwOMc8d65xr1Y9TjhsX/czsh/etgq/XAzQB6ppOvi10x3jCw3Zk+Q/xEZ6/l39KzbzUbe5W2nvp0IU7d+MEMc4zx1zgGs60sPM/dyv58mQ29Dzk59Pw61LJ4Za3SJ9Sjm+dR5SYxswc/n9cUATDU72MRz2bKywsFcHGdvqR6Vos01wonijcRSLkSoAFLbiefzxXL3BsbQsbe5mMGdgfcRnJ5J/z9a6rSbuOSyWK6LxOUCxHfjLdM/iP6igDSsLaxXT3e6u445uCkLRgq+ByeOhxx/Wq2s6bp13NYvYWRS48oBhG5cH1GD9D0zWnbpoDaYi3FncXF9GAr+XJlDnkd+Tx19q5iw3SajAlpJcW8jxggM+Qck9aAK0fhm5Go3EUdnKPOIVtrbuAOOfoa3Wgga4gRrS7ZEJBA+9gHg46EA10MN9f+FL4rqDR3DKF8q4DZZAwyOnsfTHFRL4pNlclruGO8t3JMagFAoySw2459s96AKUnht9ftHk8Ps0l9CPM8kjATOdq+mODj/9VZVsbjRJv+Pua2vE/wBbCwzzzk9/QVPb6xcyavNdeHBc2TzN8xBO1lPTJ9Mnr9a6/wAL+F9VtIRqGqwW+os8YdpfN3Hvzn1wf5UAIutX1hBdTl7S8SZVSVI4vlYkevr0rk7jUYb23FtcqiyNIX3BSHyB3I7ew/wrT1LXZbvVGh0ixjt4Y2xJCx3K5wex6N9PantBot5JCyWmotc53sgwBv8AbuBigDk7Y3Etx9milkchgvKblUYPBA5xzz/Otzw/aanbYOhTSrdrgFTwzE+uPQDNdNB4H1A+H4Zo7MQXpn37Bw2wjgE9sZP5VdfwXq2nXMFxZXyROX25gBPlHHvkkcc80AclZxXmm20x8TWbXMszlgpjKncTktnt9Rjv9aj03Trie/W60XRHjt/LLMY24bHQkfX27CvWPEFnugs/7QctPCu6SeOPdnGDkg9Bw3p1qGHxXZW8Sx2UUOCSsa42Hb2/OgDL07w7LrdjPdXymO7jzD9ngIQZ7En1wf8APfWtfC1zB9nVbxYGdyZdnUrjoPf14rP/AOEiSa5+1wTS/aipLW0HIkx2PHBwDz78Uy51e51i5lVNJ8m8gXMgmmwynbxjB47f/roA3NG8IW1tA/2oLNIzNwwO0DPQYPTA/M0zUri10zzNNktp57OQGRpI0GF+bJUn27d65ebx9qWl28UMkEEsiKSzMWJx/iMHpWTf+Obu/t76O8uHhAUlVgORjPt2+vrQBevtce4vUk0uCK3sowMpctkkDqB1x6++aztS1AXl5JPq9qI4MYgii+UZzjcx9eBj6/WuYtbhtqh5zI8gLqokIYkYOTkd88cfhVnWNTkmsorVYdqoSuFJbJwOcn/9dAGuuvQx21lJHboI4rdk83uSOc9eOnb+XNZ1p4g1QNeG0mlMTDCrI33gOCf8+lcwbN5czxmfydp+ZjuTt8v1/Xj2pivJPdqkcm22xsyrEk7fQ9uMUAdOfFK2nlXF5aRG5BID53E9uPx9KpXvxA17Uxez/aHtkVxG37sKSg5+XuAc1k31pPvkmKodhOMc4Ucg/wCfWmaksxKR3N150fBdcFQxJPBx6Y6UAV77UJbvU4Sb+SaXyy4jY5IJbj+h/CrSzXi3Fl9pbanmbQwjHQ7uC3Y989utQXVjaNLFduu0cJvUDIH9OntjNbtl/Zb2DK63bvFgKMnaoPcNnngnntQBmNr13aXXlRIwVTvOxeGHOASenJ+nNUW125W5fzZDBcTYHljLMqknkt1GMdT6+1dRqN3oMOiyWkVnI106bWlLZZv97Poc/jj6VxI0S5tLxbu6dI4VxArKCWfsP6flQBLLq0yeXFZrE6Mu8sASxIHJ+uc1m3XiK/ulkjtzJBhhuiZCRnBOAM9elaw0a4/eTRYSLbkCQ7QOBnA71mTxQQzzbZTLJu3424B+XGcn/PFACSaxNap9pjd5kBJdfuquB3GfbpVTXPE1/qN5BFCbeRDlixGFVc89etS32lpeRtFLM4V8u8MOOTycHvxTH8M21hpks19dMilSMkBiQMDbmgDnvFmoEQrE175/zBDFGBt6nj+tebXDujd9x/Suw1eLSmlzZzNF5DDOVzu9vx4rnr+3invMW6O24YOBwXOemPegDM811wQad9olC7Q5H9abdwS287xTBlcHkH9KiYYPBzxQBKJnwAGwPagSybcZOKiBqzpk8dtfQzSwR3Ecbqxil+7IAc7Wxg4PQ4oAuXuk6nYaVYald2skNlf7/s0j8CYIQGKjrjJxnofwrO82Qsc+p49K9i+O/jrR/G/hjwbc6RFHZy20UsE9gmALcjaAFx/D6f8A1q8ac5JPckmgBwkfIAOKnhumjLYJYflVXPP0NOU46ZH41pSnKnNSg9RNXPe/FVnHewmWydI22A7uh9xkf5/Or0N559gsDSxlztMTSxgZIXuQK5W6ubeSKdUlRWSIeZHzkDGNwGPx/Gul0KSW4WCK+hUW+eLqM5A+XjjHBHSsxnOWL399qbNcWVo0UPJw218Edj68V0chtrG2eeOaQZPmCM/KzfL1HvxTr62uYriS0kUyxSIdhiIXdxjv36VJ4R0uUy3DXReZYyVUytwQQTwSaANK3llvlhe5QmApu8xhjj0P0yP1qppfhu3ju5ZbcJcxsxKsy8r6nnr/APXqRLW3sbiUy3bNaOfkRxhY/YbhispJ71Wuo7C4FxhlLx546Dke+KANt4p7VUtihMYlByBg7cDpyfX+dbVtPJLGwuoPtEKR5WR+pJyPX2rB0u4kmtrZ9UIjmQ4RehOAc59TwRitvSdSuISyRRxT2br0Zcsh5xj8T/SgB2kaFBc3e+4miidtv7udduee3b1pNW0P7bfy2/kgrgkLF8wXjPHXH/1vxpJJZLvzHSXZKcbiy5Zlzj/gPHOf51uaBr93YXPlJc20mQhAL5Ygcjd9cev60AZug+GxYaQ4uJXnnbCuJc/Iex6+hPH1rq9C8KSL5cENzELpxtdSmSnPVT0+v0rdvPFGoWdrDqWraJbmzkAG8HOB27fXj3rZ0/xXpNzpj36wGJ0XPlqMNjP4frQBxd74BvzqUKzRJLaFwpZZRnvzj8vz7Yo8SfDySylVdNWNrKdkVnkcbo3z1+nuOnpWVrM99fs1xZSyurTKWZHIfGeQT2/kPetPXLzTbe7WN7m+ggwDcRSZw55y2c+2PfFAF/w34ROmSyW+oslu9zHsVwQUfHOB9frXRf8ACDaebaKC0v7qGMMd6xy/K/U4x0HPP4Vyvh7xHp1vcxPBc3OoiGNUgilwBHkc47dvwpmo/EUf22gs9NVUgGJkeTG4Y9uOD/OgDZvPCOj6bqgQJK0t2h2TA/MknRRx2PP0qaXUX0qKN7bTdy2p5kKHJJBGcgfMM55qBPiSpIja1InK7gCCV2+uao2HxKuwjrcRQysW4cjaB/s8f5GR160APk8fatPAYIdNlWZ84m2/d6YwB/X1q7Yza1Jflr69gtEgyzCZwC52/eAx3z2+lc/q/im+1F8JILdXHlokYI4K84GOQeOv6Vx15ObhAGvXuXVCgeQkkcDAH9Me9AHpN947jtDJY3Fs+oeaXDORlemcLxyMVxV7cz6lqmI4SotwWKRLlccbSM9xnge1a3hrwKL3RrK7uNVmV7hRM0YiBUHkY69K25vA1oqyFbubduyXVACcDA7+hoA4ttTltUddNklhvEc7F24Zju6+/Hr6VUXXNSstbubhmSS6YBWaQ5yQOMj1/wDr1b1ay/4RvXGU3quI/mRsbWUHB5Xnuf8APahLL9qvrV44m+0Fvm8knEh9CO2efrQA7Umu49OeW5nEt9N1KnJGegx/hiskWMjh3KMrsu1FycHnqTn/ACRWpqiTxFoyVhLPnYAM4I6E9sVLDb3VxcmHTSzEIzSBzjAxkY7de/0oAw59Gu3uDMSylRlZj8ox0AA7V1f9i3ZgaaGwKmKIs5m6Y6ZHr0FdL4S8PTajaiPU0EKBmkRnk4Zgckbc8jnr7V3tla29/FdTC23xyptCuTknGCPb8PWgDyKDw5qmpWNtHAqxRAMxQHJcngnA6nitay8C3VxYM32ZI7lXBSNWGOOp9OfX1r0k2On6bpgZ4GSG3G/y/vfMewPfrirmn3duxWG2haMkbmGMAevPr/jQBwOl/DS3i1IT6ncEpMm0whsZPH19P/103V/BQtWVLYSz+a3yoicqeCSxHTgD/Jrv7mEz3xedGiWHHlSiTG7PX/PsKxr3T9RkBtLM7Iwu4zSSE7yScr9KAPLU8NpqNzcRpLsmik534CgA+3Xk9KqtpVzaxhvLztkKmMJjOT1wRwPc/SvQdE0xriJZF+eKOUCQeVy4zk++MCn6tYpda9uks8WpQvhjt6cZYf3SRQB5Hc6bqd5L5lrab237iUGcYJPGM8Yx+Y96ku7C6hu7eCdXiYMrNFjcwI9QPr1Hp9a7i5l1G1SS900S29puMfyfNhumRx92s+WBb7UFZVZ52Xc+QPnH0464/WgDk754biXZbLJIqbRlkC889+4wMVlatpbpEinHmowLdGONuPxH41193YW8hmzGytCPnkBwueflH+fWrGom2h0OO3eeNZEBGyBMk/L/ABN16/h/KgDz6306NZrloipLEncOGOAM4/KpNbtp53V/OE9pHhWgHfOMnA/2efx6V08NpJdwrLIEsosFV5HORkD6/wAqnudDhSKYLdbZnXfM2AVUYPHPUnjjnr+YB4/r2i5eTUY7ARxmRY8Lnnp83HHp6Vxt3Y/ZLpRa/vH6/Ln7wz0Fe6X0RjnW2HmMGYbWdcDjAz1xnPqayLzTUgeWSIhZlBI243HOeOOOeeO9AHi97oOpTXAF1AY53TfudgM8dD+n51zjqVcqeor1zUrC8uZnnlaNJeQiEZ4xgD68GvPte017G5UTMzTHLSDGMdPSgDGhby5FcqrBWB2sMg47H2rX8T68uvahHdLpWlaYETZ5WnweVG3JOSMnnnr7CsbHNHG/p3oANxIPHY03JLZIFA5oPWgAH1qaByN3ylvocVCBx0496lhXOevbpW2HlKNROG/9d0/yE9tT1nw5p1vqWo+deXO6aSPZuOCp5GP5GvTrTR5NGjVgEksXk6YyoyP0/wA/hzOiWi3Dz29vEvmRKEYEdx3B49f85roba+u4jIt8ksBZ+VIOOmMA5rEZBqj2oklaEKqA4VJWBUZ9D2xjGPeudv76+Fo9ppNzEtyGJkSIHp68/hz3rb1Z0vYJRbyMjMWwpI3Nx3/M/pWPHFqFvqlu9tF8+w73VM54OeP+A/pQBTkstTmtkfVrkBwnKFQo6jIGO+MD05qC3xa35Wxb7NBJ1kPzF+OwNdbbXawaq0d0qTuULKHwcj+nviqeqafYSwT7oV2y7SFViW6foP8APagB9jbvNCrzxi7WGXO9hkDg59P/AK1WbNY45rZYp0WTPIJIC59OfQGqunEabYwta3LyEuRIrnO0bT+Pc/SoJZFit9yrmSQ7UKdickc59DmgDpU1fyfNLW3mRdAwOCg/ryTVfVbpLOSG+FqsTlRhjyO3P9fxrltY16aO0t3t7UuAypLnhvbJ6ZzVe/lup/KTLiAqGYTNuw2ei844oA9ah8VSa7p8MMs5mcqC20FljUAc49/603Utba0hggEklzb7S0ZaEAdOSR3zXlR1m5h1CCKxZhNICrlCAFXFWoZ5Cyi5utxgXCBnC7ck9Rnn/wDX9KAPWdX8bSwWdrLa2EEClQrSwxjLk98cfifr9a5XWtTkvLiO6vZY5Ygp3bwPl9MD06f5zXMDVCkxc3gkt/M2HySP5U1o3vSs0l2fMXIEe3GRj1H9PftQB0Iu45nSOzTypy24dQGOODnPI49uoqnNIkbYmLRzNj98ZOJCM559KptcSXKR3ah5ZI0EaIFHI9ST+P5VWu9OuryWBXglZA4kKKM9Rxg56dfp60AdNb6r8wuL5lLxYQxEgKBg/wCfyq3ZamjLI3kQsrMcPuIAPQHv781gaXpWo3JliFnNDZqV2u8fVh6e3vXV6f4P12eUwz2vlGP5wFUfMvqvrx9KAObutaiSaSCztZ5mTbu8sZHII6+mRXe+FtEsPEOmrPDG0N5CwDwyg7DgcMp64I4796ykj/sG8j8q0S5kbAwyZJA6nPBHUVdsfFl4uvH7DbRx20WVkgfjAym4Z/E4oA9P8PadJZ6Xa2zkNJCqq53Zzz+orRntd0pO9ERcc56n6VnadfLMsMsMqvDNyGU8EH/69W9Tm2qkakbuvWgDm9T8Pafdapc3d5BAWGAtwzZ+UDkkdPXkntXCaj4vSTWPK0rT4o7JW3xzIAHBA+8eMDqT+Vd540t5U8OmRbmOCDdiYliG2+nAzz1PsMd64XTfCxu7eW8G2GPeEzjh84x+PQZ96AMC/lvPtHmXUvmRTfNIzDjOB+pI6+grbsNTs9N8zUC8c13IWKqQfpgn1x9OldFN4OjSxluf7SgeOBiBub5EPp746Zrg/FUqQQFUaKZbdi4KDgEewP16+lAHougeLxf3scbiwYFdsjeWQyqM87un5+tdo19Bo8k8tzcW62RGVCDBT0zzz+FfLVtrckjRS2sDxqQwaQuDu69P159xW7qfiX7THZQ3U7sUGFVumAOw7f54oA9fv/ijp41F7W0sbm42xsQdoAfn+Vc0/wAU72SG4EUQjc8rhMFBjn+WcmvNtT8TWcd3cmNjLI6YQlicHjp6DP8AnrWTfa3cWxmgkJSJ8sty2H2AjnOOnSgD1GLxhqJtWOo3hKmTeSTknnjA/p6fo1vHojvl8iVpIwd7Ln5QevY8854968U1/W/MSJIpAsSlWRyp+dgOM+nWpbTUpLm3RxH5krnf5qfKgB44H4j8qAPZU+I9/p8V4YGgijOTyhKqd2PlJPesTUPiRcxg3F/PI74DgOoG8E9PQDivLtQ8QXkusQafNFFsiUHYCfmJIOc/hVO48QwXVpMdRZnT5hhVyWAYdT1x2/GgD2O5+IN3NpZ/sZ7ezikjzIWAGTz1Ptz+lReHfHDwo0cweW5mAXMQIYj3Y8eteFTa2kl1ausfmW5I2wAEBlz1YdzxWvd67cXd6I7G4a2jdQrsQoCd8D9B/wDroA9yi1LS3m2OrLEGDPvG4sTnnFa15rfhrVGOLZvJXC528rxknk9eeBXgui+Iri4s5hdzwqkP7tnPRmJAGOepxWsmpw/bTHaz7Ix1UYYZ2k9xgd/pQB6ZKum22oI6vJHZSMCIz1II4OM/Wrt5qdpd3yWMEG22ABkVV2lm4zlvy/OvM21+H7Kb26abywfLQls4XpkH16dK0LDUp/tga2YQRlmJZm54xk8cZJoA73UYrG7ljSGCU3JcZIAAXBHGe3Tn61z+t6b9nmIhlMoRSWKLhc4PHt0/n0NRw6hdQXE00lwsjH7ofaCM4yD/AJ9arvdHUbkwtLKDIS0hUD58Zz+nQgUAcXqEWo3E8slkqwoRtV5l3biO4/HB6fzrzzxLDFZahmeVrm42nzZOgLEdMdsV77PZtLYq9pE85/1an7qKQvU+/GeuK4HxZoNuNPuBeYLYMqiJeXc9MnrigDxORSGyQAGGR3qLvkGuyvNF/s3S2e4tZJGuBjzG6R4549//AK9cnOmyQjBC54z3oAhxjnPbFN5J/WlIypx0pNuT1/GgBAaenfrTQMr+NT2yBt27jp3xW1ClKtUUI7sTdlc9z1mbU9Mae7tOFkjVX2gZ564x+FP07xB/aEe93kZ/NZWEinqF6rz9KiRriUiWaR2QxqGQDhSBk9P5Yq3pd2LrxDNDMwFuZQFGwBQcHv8A4ViM2oJNto0s0qSzhTk4wcHjH55GP8ONYZgtob1GtTG5yRuBKAjAyCO/A6/zrN1CzMd1+6UNBLkcEfLjgY9/06VnPbTqyiGRCyr/AKtn6jkkYx6fyoA39R02w1KUyTwmSUsHjIb5c8cH346ZqlqkA0u1kaJBE5wu24HIYYHB9McZ/wD11VfVbmwt5PtEsSOq5RQmeAP4W7/nWdqurN4g0wlR9nfcNwc8kdMc9B0oAxNd8SXEQlkiAiw3lOpAK7sHkfh/OqHhvU9W1SV5bZSXVBuyeMYPOOvpzTNQ0a+2wyDbLAWO4HkgleCRTdHsVtLkW91cSpNEo3BOBjJ4z9O4oA147y4F1NHOsN0vG7PDKemSAccVVEkM7y2z38v2dAv7tRk59MDrj+n1qATy5W0jt0kv2Y5kAIATtn34rMsBeWN7ClxGEdT882ckDbjn8+nvQBvRolklneRWoZNpTzTkZ9OPfIq7ez2d1cGSTS5Wl2COWRj8m0A4OPbmoI7ObULsRtDNJEgDRvEduTjqR+FdXaTEWLoQFLDbukXBUD/Pv9KAMvw9ZadIWctKi8MpwQAMHofXp1re0rTNORhLcS7EzujiZ8Hdk7iR7gZ56Vm3epJHJDbiSINESy5OAc5zgdeSentWTb6j/pRknjWC6UYSFvug84OR9PTtQB6RcalBDepbXUEEymMCNowMhuOTj1q5occc9tdyXQmE0u0RGKPhBjHP5V5xbXkUt0J8hFjBGFbgn1A/Dim2HieWPUDasJYIsB1+cAcg+p+tAHpl3quo/ZEt1vBhcNsZNoK7ffqf5VixazdjUQz3l20SHli5G3j7uAfcfSso67YveKNbuSIpcFJkTKg9hz368US3drFLvsrlp7USHKlTu2Y6989DQB6I+pWOuxTyJBDBJGu5jG5BOBkj3bHcf/XrHvLO3j043FufKmYgCIKTszzhifYfqOtUNO1ywmng8i3MkmAeFwfqTnpnn+tdTe66dWuobS1tIY4wokAU8kr2I4556fzoApeBtZj0fVX0jUpxtlYNArMFAboQPTOBxXYeJNaOn2j3LQ7pCNka5xuPfPsOv6VxOvaJPqt5NNaaVue3ADhepYrgkc9ua5XxG+rXGq20+qXYZIYRH5LHaBjGdwOPm6nPf9KAOzs/GNk+jTWN9Ym5luMgSytnLEjrkjHrwe9ZniTxHcyWVvHh7aFSRsVccAcYPbk4/OuG1nWrC2tt7k2iqG5/vn8s9DiuS1HWptWW1tUuZ4oJl+WeYgK3qAOmaAOq1PxReCAxAzSxt95gCVT69v8AP0rC1m5eS3u9+qQySeWxVMZ49F6YzwKzLm8lsbtLS+1TzISMMikncOMZPTpWDfCV76aWxMawsWUeYQSMZ/L+tACafezfZYpxIY9xeKJS/MZ4/lXTRxS6ikSvcyTi3Ylii8H5Rnn05/nXLpqC6vpUcNwFR4JCfPVQN3Qkc9utdho8Vr5Sw6deKzxE79rYJPUA/h9e9AFqZUsxax2dom8b1aVhkAH1zz2qtBoqtPcyPIjhmB3sfk6cjb0x3/OrqwRyQXNt9kYSE7FmU7iM89e3/wBeprtRFY+VHEEUIecj5j68Dk8jpmgDA1GxSz5gkDgf64E8Kn+znpXOSamttEPssTx26vtVsbTkfd6/19a27tFtVhkDxyNGcuZJN28nt9OnX0qnr2rWs1qI5LWEwxuCEiPB6cgj8aAKq3Yv4U8ywUpGNvnLJiR+ff64/Cs25N3NdNCYfNh+7+5j5Hz9CeO9Lbz2M90sjmS38xSHZVAjU9sfkKj/ALSkHmxw3EiwrLuTDffBOeTQBStLprC6T7J+9c5AjkH3DuOKt6bCbjU4ku4ZI7c5DbT3HHX15qld2Cx/vDMhkKb3G7kfN09zzWzbNcaHZxzz3EErOAFhDYIz2OPY0AYwn8hzDGJhEp6OOG5pX1MtJlWfeT91DgE4x0HFP1fV7m7eN8QhQmAFHAGMY/z61kiRIZXdkDMCCO4BIoA3LbWLmySQSQhy3KJKchPbH0Nbb6+ws4pnuf8ASdv3FHCjAyP6f/rNcVcXDP5kjRDax+vNT2f2eQlmyjKhIB5DHHOf1oA9Dj8Ry4gV5A0j7QkaSYAzjhj9c/l9K6qz1N0kt0Ygs6kkHADdccHoOeuf614lps073ayWwy/mDgDryMD88V2SPe2pa5mkae9kUqAvzFfvHnFAHq+l6ldXJAeSOOCP+BcqnTqT+WP61dkngMZNrCLmUD7+cKoI45/z0rjNGZJtPRdRiaC3XG2MHJY5Hbt078dK6Ma0HixbQpa2hbZnnecdRx37ZoA5jxPompatqiPHOq2seWaFF4Tn1x3J715/4/sLiK+EN3B9lliULFEUKs6knnGOmc/lXtN/qUCwMkZK5VndmAJ74PX1xx7V5V8Tjqer6hFf6nfXN4YkEcbTyF227ycc9Bk8fWgDzYjGKavXntmppiS3A/h9ahIGaAG44zVm2QvuwxGMd6rfSrFrn5sfyzXXgeX28ebbX8iZbH0q8sceoy2qpLsMePMWMdsfe7fhS3yWbLcQ3jJE+4lJVAUHjpxW9dxsiSXFtHE2EUkZGG/z6+lVmt7KQvcQxyqGkJZFwQGx1Hp1HFchRzsQ1G3skjuX863O4MygEn0IGfr0q5pVzBefvogfNGUcOnPXj8PbHSq91eLYLJaCaOaAAhUEPzJnvgVn6PrQtb+eJc+YvzHBB469/rigBnieG2urmJVuja3A+6nByT0bPf8A+vXPXdvNZTSzXdwguZcDhAykcfr/APWrqJpxrkpiuIRZXUQ3wlhnPcfQZ+lc94t0XVpEk/ewySxsjARMFIAGM+v50AY1jcy73WN8FXdJGkyyZIz/AF/WnR+Jprb5JbSMyOu2K4xjIzjPT8qyNQubrSJJYZkVfMOQmcqwGccimQ3crMkNwpWFkUhcg4Pf9TQB2AsLq5vLd9VuYI0zsIQbC4we/wDD0rf0TRbe5ib7IUjOzBEjAbzjHPrgjp/KuVuzPYXlncyRXD26EHO8YU+vXrWdpfihrW+kmswWaSUtszkbT0AB+lAHo9hp91YW6rICi5JZkXevf3+n+Qazm1RrWG5jRWeaMfNFPHhWGegp66ldtavILx4rZAp8grkIOvTJrCjuft0lte6hd2wijB2NypLHgZ9untQBa8TfYoItNuriBFfeFDr/AAEg/SsHVtVju7dEsnlmmRsMy9FXnofQdap+N9bF5cSRiKM20bbQAeAeOQB24rkrCd9siRTPETn5k4J4PH+fWgDr9ZihEfnR6hPI8KhxAVB7Djj8fyrJGotqDlo7eNPLGVXcck46c/WqVi1099DFbtJ50y+W+eRt7H34rRu9La0uZIYZEVFXezOMZJBPT2/qKANW38RCHVQ7r9qgCqVgfI2tt7euK6yx1i4v0kt5JIIIcBoo2fO3jIz+fTrXlOqXjySRfvf9Vja2MHpWhaPJbsZZbjzrZxuZhkHI/wD1igD2OzA+zgRmFL0KNxbo4wO+fUVe0/XJF1wu0dyLmJMiXG0ZwOfcdefeuJVL021vcibz7QQKzoh5Bxz+dJpGp30N/CLi2c2eWIYjJx2z3/8A1UAe3+HvGsiaoftFy0azMHklVQN/HGTjn/OaPHVxbag3mW6QJGpIJcgSM2CS2B/ujjPOK86munBdQNgOFG4AdO4zxx6de1Vmv59Nt2uL65a4iy4JXgHPfr0A4/xoA5XxtaTT3MtvDHO6up2kHjg56D9a51WuZba33M93HbhmkgZCFjHt3/8A1V0uua/Fc3C2ys8aOuRKgPUHp06Vx/iS4u4bgJHMRDLlFIHGDjigBmoskU0yBmYYV4w0hJz6jHPSsVJpHE3LbwxYAjOB3zU+oy3E169spA5AyO44qxHaxyots9w1vMoZneUcZ9AR+H60AVra9u4ra4hSNGicEn5BgHjn61t6DLNauYYVRIZiVeZzgqcDvXOrLNIsUars8tiA/b8TXQWFt9jnim1S5je15kManP4H86AO7hnltrOax0y9cSOjMjk53Gl1bTboLHuZ5peGxHNg5AHOc8j6egqjpuuaTc6nGka5Uxltyrt256gHpzz/APWp+r6zp9zJM9stzHPACqJsPzMQe/4/5xQBi6y1qYpllZ5WgLSyJ/fJAGevGKw9Hiln3NkquwgnG4c8g57Hrz7VLKEtLw3M0R85/uwsvDOScn6dPzqrcyyXcdyI5Y4iJBuTbsMjfy4oAg1SUQWKW0MqTRYBbAwwOeme/wBRVOZhO5WCARx5GSAcdaiu4PIjWOQ7JNvA65BPX8qZOstsoG4tk9VPB54/lQBJcIwkUgGRgf3jDpnPH4U9rdpgzSKxUDcCh4/zms8SOkZPIyeKQSySP97r29TQBbit5pbQumAhA6nO7r0qvcWs8MYeZHRHPG5evHWtDS5hZJ9pRg0kf3ULYGSPT2qvf6rd3t08lxMXOMcnjGMYFAFVvMMewjCRkk++aaGYbhuHIJ5HqBT7WaPzc3IZ4+cgNins0UjgQR7MA53GgCW3vvszHbGpbjDenNdL4f8AEFlp9qz+STdMSABzjOe59q557dPP5cTuCBtHAznp+tQCRrKf7ibwT9BzQB1J8aTCRxIjSbyDknH+e+Pwq3N4uvb2RYtNtv3zgqjgEtnHTn8a5O5kS6YS+VhmxubsBgdBWhpl5NaXEUm0RwDO0YwOnWgDv7SxuIdM83VrqUXLZJSI/MxPJPp0x+Vc7rdtd2oV55ZHVyFSNQflAPTPvmuk0e+sY7U3l/cKTk7Q/PfBwM/Wm6lrttqO2HTwo28lzz3PPp2/UUAcHfQRw2ywW0QmnKF5WPAUY/Q1zMilT35446V1GtXIj/0eAO6yZDyMPvkDnHt0rN1S0AJPCBeAAP50AYhOMnvmrFmcbsuE6de9RMjAnJ74qzp7D95+H9a9HKYc+LhH1/J9rET0ifR17dST2txBAVNwgUD97wwAHbvmr2i6ukE729w5t5FlP3cByCOcg9ucZqjLolpeTmYMPNDDEgO07foO3Tj37do9T0tIrsSxTIZo3OWcEjaeMHHH69q84s0PEFppkF010kxEsgOxlbkjg4Ix9TxXDyaLFqc32wSywXAyBC3ynjjtx0xzXd+TDf2jKblUlQnKs4yWHcHv2FY1xGqXXlqqyKerF+pBPGffj0FAHAwnVYNRnhW8lEKZUxuQcDHI/nV2a11KG5e+tLyRwqqmxlwCOnOffHStDxAlvplzPdfZkMbxkNsPJ4//AF/lXH31w5v5ILNZIopjvjO/hMgcHP1oAmsp5LvVoI9ShSVg7ZaQegPXr3q7rNuixSxTQITGcxyofmHHBxWFi3tFERvP9IL4k3fwt0yOelWbmyvdPvRKCZo2jyzZBDZ5zn/9VAFvxJd3CwxWNzcvKJNpjnTAHQYH8q5KKVFuY8htyjAKdiBwffoKs6pcx3F+kY3wLuy25t2MAVViiZ7144X8pXIAkk44x3NAHoHhS8la2fTtQni8qdgTKeShxkD2rF8ZaXLpcwjtjHJZtHuUryWwef8A9dc/MktvdLCHAnU53q2QRj/69dppJ0u68Px3N9I5uIlZG3vwwI/r0oA5aKCzfSUkaE/aGk27Q2dy4/Q5qlbWiQ34T7QEQxl1YjAJx0qfVoo2uX+xpshVsLgn5h2/rUFoLie3eKOTjBBU4xjk4yenNAHUeFJ4IbhI55I5EAJaU/Kw44we+OOK6rWotBv7CSZxvmAx5yKQR1wfy/lXnmg3llps00eowieNlC7ev+cVoXd/p0xuBYj7PGy5AZjg4zgAdh7UAUtX062tIo/MuFkWYgrt5Kcc59q3YNK0ufQwsIvFuNpU7jhXJ54+vHFcsdR+0NHGkcKbXXGB94gY/pXS/ZdU1CVLUtHJKxz5KcFVAODnpQBraRZ2thpJuLuSeCVDsPGQxxwcGon1yW2id7SdpIpXKb5QBg5HCjNVdZ0a5W5trbUJzHGRwW+UAkc8+1U30u5gkW4sPLmih3ff+6RkfN2496APRdMubq/tLcTwidURT3wenJI7/wCHeuZ1t4dQ1Z7CTzbeZSysituU5wevTqBWimtNF5UUVuHuZ1G45KjPTk9+ayddt4hbPeS2rR3xcsZlJ4GMj8On60ATXmjXt9ERLbxxEYH7jAzyOT+tXbbwnHq9o6XEoxEW8uLjH1z+FYehz6je6dKscqxw8Y3Nht3HftVTVNXvtLaaBglsH3DzIXJLDP16c0AUb/TdNtnnikE/lo7binLKcj39D+lc9dwSko1uZZYmY7UYckA9cVWmvriW4lBmJEr5Zj/F9asW+qT2hZWkEg5GSeQPagCj5jRIY33BV5AHYmrdrdFZ1wqtCOqSHg+v+RVLzm8o4I2E/d9alRoUI3w/eB796AOnh1G3jmiltYY0YAllU8D3/T+VaNzcXE98bi6YyxW5AwnByOcfyrn9HiFkGuLi4iVJUYBgN+09gR+H6ipoLlJZEhmJjtGfiQ8ZH96gBmp3n2zUWnlneMxucb+So65ArU0TUUVZDJPBudyGleLk/QDiuc1e2S1vXFvLHcQkbtwOceo/SpLWzMunyeYY4pEYsDIRz0/wNAGhr8sl3stXgiBjG7zlUZI4PbtyTWIrPazEAKwLcBudvv8ApUM1xKAEaXcU4BB6c0kly/ktG33mPJ9RmgCuH/eBs8g9DzT4ozPIQMA55J6Yqu2ATg5xVmMx7MMx5wTigCI5LjHCk9AadNEFmZQw2r3/AAq8bmMokcUSqmB9T9apXRaSdzgZ9FFABDEGEgyoA6Fjj8qlhtSUbB6DJbPtTIi23BXC/dBPRa2X0QW8Id7yJ3ZdwhAJI4746UAVZIJorZZiI4okbhc4L89azpDuBZ1+bnGfxqzqAl+0lZHG8HoDwKbPbGBMiUOCCWA9jQBErgj5icgZA96kmuTIiFwzEHnJqrFGXJODgDJpmGzjGccZoA1bjUDNaxxKgUDPz9+vSui8M6nHFaukUSAr0dzjBz1z0rjIw0jLGOrYHPAzmul8R+HL/wAJXsdnqT2sssiiVPs1yk6HDEclCQDkdDQBryCARSXZmSS58vIbGFx3wP0rmNQKPLIW5Yux8seue9Mtnkk3yNJyi7VI7cVqPbafZ27yib7TdSAhcHBBxnJoA5tiHXOBkcAD0qSyBG/JGeOtJLuSQllAYn7tPgSQAnH3gOvH9K9DK3bFQb8/yZE/hPe5vElvZSmCW3LI4AXBzsGAM/59K6G2MGosBBKkTK2Y2JABGOQP8iuC1rRJbWN4IfkWULlmLMwHGc80upXcml2qx2swaWF8FIyRu4ORn06V55ZP4tsTaNcPlgrLjBIBzjt/nvWBoltqUESTWWoI5dy2wpk+4rUiWz1izeDU1uY3x5pBlIxnP4VBazN/ZVzJakLHblthB/eFc+3Udf1oAgvPGfnXBTV7Mo8aFAU4HbOfeuQ1O7N7LJcyMVhUgBUIGOODWnJHFqcjyBj9owWf7QR8x+orDttNubnUZLSEcKfmG7A7dKAGLA00sQuGdYWYgzMM9jjmvTPDPh+GKwNxHqCtYyQYeN+cnGf1H8+K4y00m+uPOtrK5Xam8GEn5sAV2PhLR0uNLtZ7i4uESJSChXAJHBH0/wDr0AeaeILVrfUZA4IjZv3T4wCvYj14xSPutYoWaIl9oZXB6nGQfwrtvF9s1ndzyXEUV1G6L5BB3bW6dP1ribO6ltZ4mnAeIMBs4IHHoaAImunlI2ormRhgtyQSP8/lXZWmgM/h0G0JuJXALIQAQcfwn0yf0rEvTbSRs8UsUZkw21xg5KjP9fzNdX4R8RpaaLBax2Ml02wjCpksec4NAHJa0Z4ZEjuLWSFQoDburNjpj1rGN0VV4woUEfwjFe2N4bj1eCWSddjSYZUClfLAHv3xzXmut+G4bSd1a5kQgcM6gg9O4oA5uJkEpLj5Tx7nNdP4X0BdQWO7VlmjWTBhx82P8kVlnQJDGGS6t2k7ITjP0pNDfULSdjZ3AgcZUkvj3/xoA6rxVoNntilsRNbOACVZOOFrN8Pal9h1ENPNM3DKZY2IJPbr1FehWPirSHsFhuy0l86hmkZt2Tjn9efxrC1byPE999mtrNbWFGzKVIQkj2+lAFPXNVW/tmhL+c1w4WJzwQP/ANRrN1S0vYLD7HFPNFHGduGGFIGB1+vauvh8MtDLIFEEkqqroZ/nCL6AiuQ1v+07zUp1nKrDbjBjXK7umTz/AD9qAMa6W4s7jbcXJljYBgN/IGOx9K2p9Sia0VY7eQTNuwzuzL0Hbvxj/PFc1fssySSNIdq4CoDjHtWlYamILCLLEBSQuxhvGc+v+elAEN3rlxaEWY27I2IYgYyc/wAqyNQvJLob3kPUgKOw+vf8abfyrLPKS7nrt3c96W0s4pIt91diFSeFA3GgCkQmSct7U6GEz3KxM6oCdpZugrUgs7CSZD58otVz5jlQGPToK1LGbw2LORLqGWSRXISToSOcE4PPagDL0mKziM5mxNIinYCflJFZ0zb3Zg+WZvmAGAa1dcOjrZQjSklE/SRnPB/z1rHWQE4cBs9+mP8AOKANZbG7hRHaKOOGVcfM3BH+f51X1acfaAsWzYh/h6f5xitnT9Ys4LGaK4gL4U7EYZIPXr+X5VkwKJZZTDG4hmJwGUnGOcj19KAKLSYDgjkknIPTNRoWnbaWye2T0qa5V0zEEAwx5xyc1VIKsQCSM9aAHP8ALJgENxg470EqM7/mPamKDgY69eD2pGbLsSOc0ANBzx2oGdx/Kkxjml7kDNAE6SBYmGBux1pDN8gVAAT1Pc1D2wfShVZj8oyeuKAJhK+0K3QDC+1TMJI8SM5ww6A89B/j+lRCCXALoyg8gEdRUgI/uM0hH8XIH4UAWGlhldTCgjIIALck1XufnUYP7tAVU4x3NastrZW0EW6dTc7sttAKgZHH86NQ2TWKGO28lFX7xTBcg/8A1xQBixbyPl4A6+lNJy2F+UHNSl0EZXaw3Yyc9DURBPI5PNADCTk56+tKJGyBk/QU0mpYk3bc85bjHNAF6xjnktZBACSw5J9KJ28mIRRsG2ZDFec/U10HhvwzNe2zTzzNbWKKxeQ5HTPA/X/JrJ1YRWd20dtHvhJYLkZ78H34FAGZZOiXIlmTzAhztPfr/Wp3u3uZneTA4AAHAAqFyzhlcbXLfr6UQxfMwABPGQTjFduXSccRFpX3/J+pM9j6F8XWOpafBK8B820kZdq43Yz7/X9a53TLuLzYvt1vmfzSNrpyxxxk4Hoa9F1PU0s45FkXMDADazfIemCD27flXAeKdOkvdStbzSlUx7nR0Q+3X68VxFEGvyXUVxDPBaCOFUIkLKGPb8+nWsyGwg1S3kmttRKx/wAabcev6VZ0WR7USvckpIgZXLMWwPpnpx+lS6pff2XGL/TrVZNzEuEA2MvPJFAHM6jb2ulW7paX5ndlwEdAdxz6iqenX1vaauz6xp5zxkFiMY6cf54qz4q1awvollOmfZLsAFXVuG5HXH41oWmjR+IdIhvVuYxLDwyN147dOn50AbvhbVtFnu5LgWklt8j/ADiMEDjt6VHeeK7Oxa6tYgJ0C7knXq3HIP61iWVrrEVpNcwWqm3VSGicZwMHgevGa43V7jLlok8rJzgZ4PI6n6UAe2+H7nRNcthLNI0bqRtZ1yM44GB+PauF+IEU2l6lCkttam23KVeNNpOAOv8AP3rmtO1a6gsBDb7G2sDsAyewr0630CbxL4Ri8xTIY1DBvMG7OB/9fj2FAHlepawuopFDJaQoFYYdVw2MYx/n0rb0I3cckklvFN9nRPlRBn8se1YJ0K+N/JBHZzs0TAfdJ7Z/HqK7b4e+KhbyDTroRouQobZymOKANLw94zmfULiOe3lxgeUCM4OOjfXFYPjDXFv5BILd2YDBcDG3rwQOK6HxXrUGnXLSW1tHcrIoDyRnpweM9q891TUbC4gfyklinfJbB+XP0oAuaHHJqN4EaW3hjB3ANjMnYfnWZrdjLZ3jJMgTj+DkYHAP14p3hewub25Z7V4hKnTzTirWpaVqUeoB9VBjhJ+aRPnUeooAy4LUmWIw3JGep6Y4rrdCjgkkHkXjPcYOE3HLH+tZ2o3lqlmEsyhfhPNRdpI245H9ay4Gkt7l7i3bZMmctn5WI9BQB2k+s63EpIILIdojMeQQO4JrWur77ZZrFLDGmqTIQXnj2qP9kEdOcGuVTxNfX1nvtJbeCeIBSgGC3B5+tSaTrt3fX8I1S4+7uCEjk8DH0780Ac7q9jeWayJcwhEB5cKdrH1Bx+FZG4lFQAMD+lexalYWFwj2r6hLl8EjjCr/AJzx61xOt6To2mQg211K0wYg+YuVOB07e1AHGNjJIPTmnNIvlgBcMGJznr7fzqW4USXPybfnxgAY71pWugXN3eeRBG+9hkADP45oApQWl3NGTDBIeeWA68f/AFjVR1aNyhUq65yD616TpPhLXrK7X7aIkhT7247gvHI29z0pbjQIGvbuOaS3E+CY38vhjQB5rJIzIAcZ9hUP9TW/rulJYqFjuvPbqSEwAaq/2HfNEskUDSjdgrH8zDp1FAFaF0aJuSsh6fTvVlryVJo1MvniMYUgHGPSmraz2lwwu4vKbBJWUc4PtRDOLSQsiMXZTgsMYOaAK1xcSzy73OC2eDUBVuW9OOakuJpLiYyNyzHJxURB4yD75oAbzjijHJPv0qWI7SDwc+tSi2e5nIiHPU7jjHNAFUdQTyKQ4J7jtU9zZy25w5X6q2c84qAjGc55FACbhVy2vGtQfLRN3csM9sf1qmev1oB5zQBqx3qndLcqZWH3VzjH1qpPck3LSQjZ6DPSoixKnv70wqcmgDS0q/FpO9wyq83VCwzg5qS71me+dftZGAMnAxzzWfbzm3bdGAH7EjOKaA8p3EgYGSTQBKSZ34QkDAIA6ClWKIoCWIPP0pLe48rcq5MbcEDjdVjTrC51KfZawsVAJJxwMD1oAzieTg133gPw3BIVu9VjKJuDR7uhA7kVh2GiSJIFEH2ufcP3aZwB7mvU9F0a5le2OrTbBG6ksnAjXPOBxk44/KgCt4kE1zohitlit9OjjP3QAX2j7ufy/wA5ryS8vZJZy27DLkIoAAUZ6D8zX0h8f7bSrP4feFU8N3KR6U3nGSRAPMlYKud3+1knPpXzHIoaZvLzgEkZoAfjZjnMhP1xViJIhnLNnjnmqZYh+u41Ytkkk3ESFBx2612Zfz/WI+zim9dHts/NfmTO1tT6CfVra+kktJImjlQDMLnJ6jPB6g1k+IdFmt4pLnSJjBcpI25QfkfA7jqOtdv4w0G3vDKYxF9qjKnLfI7HqeR/KuA1az1H7Z++S8aJJG3bCMEY/WuMo5hdTtPtck+rOJVkXapTPXv6egqvq17a+Wo0662QEfOgXAPOcD/Pam3+mG4txJYlLpMOxVjhkbvkd/xrJs5IJbZ0vbbywSQGXHyk9MjqaAJlgjbzIxE91GFGHVSSh9/z/StTStWl0yR4muUSIH5oyuCQf0zg1TW31TSrfzoJv3DjDNHyQOOSPxFXvCt9H5Utpc2pujI4O9Pmz7HPT6+1AHo1p4iWPww8j2rS5Q5YDG8ba8Yu/N1G4u2iCuWO8xjqOe1dubnW7HTpoYbeQ224gRyDkLjpnv16VwBvJ7GcSWyvBMCWJxg/jQA+3imt3IMDx8gsJFIHbg8f5zXp/gHVLCDRI4xqAMitmVHbbzxnB/HFcdY6/Bqoij1uIu4YKkqnp07Ul14dl0+eKW3uYbi1YjeG42g9cj/PagD1PL6tNI+n3hhdGzhf3hYEZycdfwrkLix+y3L3Gu2kWxRnz0j2g5PAIGOfervguextbrFtfG3ZVy0Yk3A4AwR+laGu2I8S3Ki2lkZlQj73yuCT2yfQdKAOR1q/0W60+RLJZ45hjI34D444JrjdUktZxHJFF5Ld+c+n/wBevRvEfgdYNPXy7homUhtpAO47ef6ce9ecRWlyZ2hS38wgYIK4wBQB2fgbR/tsBktN0qggHBwc9xgdMVuayLz7KLWERN5OSXY7RgDkY4P4Vo/D66OlwJDcWSsAw+WRfl781e8dSWVlbvdiNDHtwEABZDnt+n5e9AHjE6GSSQxwbpCSvXG3A5P6/pVcNLayhmIdDgsuevTj1rc1qO0mgE1tebrlgCE2Yb7vIzWdZs9reqBbRvK6kjzWzk4oAsXGk3lxa77XTTFCcNvBzkYBOf0rLN9NZzfIXGDg7vU9cGu/Fn4n1G3VEgghtcAZbAHTB6H6fnXJ+IvDt5YbzPLbyHJOxHBPbNAGLLqUzyPJG5DtyT757elJNqEt5HsunzjkNjkn61RdSDtYHPSnYxjecUADSkEEMfxrodK8Tz2UkdxgmZBtDKcH8fXt+Vc0R82KFPAHvQB2lz4/1eeXcbhtmPuYGOg9qg1Dxxqt0Gw6JuGNwQBgPY1yx2kt0HoafaStCWkQKcDHzc0AdSniV49Bjie284MeZZkBG4YJwT7VPbeOpre4WcQqsgVkKpgAg49RXJ3GoTywLEz/ALoD7oHH/wCuqbEnJ75oA7N/EunXfnTahZtNcOTxkY9qfcXOmS4nu8S3MiHaqpsEI5wOOD3rj7OIT3SxtIsQPGW7VrXekx2kMjSX9rIRyqK2SeP0oAfotla3lxLHJKIR83z4zgemPzrZ03R9Mt3efUbxbmPP3APmY9640yNG52Ngex7U77ZNsx5rD8aAO1TVtMtoJWs7G1VVXaFfBY5I5HvwKxdS1ETO0kcCwmQLmMcktkVz7ykkjJ5re8Pz6Vbr9p1BJJbpH3IoJA6jFACJpdzeLumHlqq5UEc9Tx9f8ayru2aMurAjZjIJyRmuqv8Axhb3GAunoExj73T0xXLX18buR22IuTnIHNAFQBfpgUwjHQ5p2PlyOlSxwtIwCAgMQOehNAEJZiu3PHvTkBOBkc8DJq/d6fDCVWK7jmJHzbR92s9wFfCtkDuKAH8IwBxnjmnSvvfavAB/KmZJRj/Omk5575oAltwglQP93I3fTvW7/aF49rFDar9ms0BBCDG7Hr6msCNlV9w/KtaylutQnwIWmWMcjPCj1/rQB2NjeTNZwW9im51C72VOWGOpPfk16la6LooiEt14uuLnIwif2c6kY5x97/PSvJdA1kwXUsU6bYY0G1Ih9449ateIvF80UrrbpHCoY7R94kHH65zQA7x9Jf3SpZvcYtAxdLdX6E9yP89BXnFxCRcNGjA7SQD0zWibtpZGuL53eQgELnBxzUe8eWHEMcef4icsRjjAoAzU2rIAx49a0ILglAkUbMqgZ6dapTHbIOCf4skdTU1o9wWcwuEyBnj613ZapPEx5U29drN7PvoTPY+uNfuPOE0GoW7K+V/fL8oboR0rlo74Rs5uJcNHI4ViBhhj19TXY6zrd7FBIXtkaLcCEZfvYx+XX/Oazb3+xNWicSW4tbnLZj6jIBPH5k9q4Sjz24sYws09lprMjhgzA7fxH51wEyzecTGDIw3HYYz8p3dD69K9d1JL6GJ/JuopYcBk2JlgM55ry7Wp75LycvPGLduVlRSAvf04NAGXJc6nMUAh8kuoyOgcD2PFdjptxDaublIWZJMCQxx459SR/T0rI8M2w1BbmO5vt4X7uTkHI5HtxWsumiwvT5F2qt5mTE4+VgccY+lAGrb3eqMksSyw3ay7ig35PIJx+X8q888XNPLdMtxZCKYdHxjIye/417Ylmt1pkRhW184BkZkblBjt69Sfw964fXNDudQRobq6Z2VcxEAEd+PY9KAPOdPtLtZN/wBmlaBTklVPHtW/YeG9Vv7dS0qxq2CEJJOCoGeOn/166Pw9pUyXbI/nwMG2MgPD59AePWtx0NtEPNnDxx52seqrjnPTPORigCTwv4WgsiROAs7jJHl8cL2YfX+ddNZ6cIkOEi2MS3mRnJUc5/TNYmny6mDEY5YJYAAVJDKWyOB39sfWulstXENvI7ffKldqfKM474oAi1OyF5FGbeLG3BeR8Z4HY/Q4xXJ6v4Y8sTSRvIzrG2ySMgHoeOOvSuz0/XLt7fyopI035OJx2xx0PXgD8fep9QsL69tZ13Wkz4++j4I78+3+eaAPGNG0q5kR5bqW5iZJdvmI4yOPvYzXPa/qFy955P25rmJRtDZ6k9Tiux1fw3f6XJMz20khc58wycj/AD+ua891ISnassSK4O0MP8aAIpZBEwCyssijbnHBOP8AGs55WO3eT8g4x1rTNqqW4814Q+T1PzDis8hIhIC+9iOCKALml61PaXO53klTAGxpCADW/YaGNUmV9RvFtlLHG35+uP8A6351ytzHMkCGSEAEDBGOlLZXb27RyJMVdGyBjOKAOp1TQtNjt5o9Nu57y9XAA28D2/LNchNbzRsVlTDg4PqPrXXPqFumlO1nNKs5GXY7QWOOv61x80kksvmOxZmzkk+lAFdgVPI5xSohLYAyfSmk5PFW9PvJrKfzoNu/1YbhQBLbabd30pjtLSV24ICg8fjTb7TryxfZd20kT5I+YY6Cr7+KNWUuY7pk3DHyALj6VnXmp3d7LvuZ5JHJySTQBUEZJAUEt1xWlbWF3d3RS2s3lYj7qrntV3SNQ02106dJ7aVrl0KrIGHf+VaeleOJdL0f7Fa2kIds75SuWORz1+tAHLahaSWNw0M67JU+8M5xVYEljx2rpbHX4LV7p/sMMjz9Xl+cg+1bWgR+F1sN18n2vUbjO2Jei5HA9qAPP2xjIHOT0pvbp/8Aqr03RtDjg1aaa901Vtt5MShgQv1J6cVleLbGfULtl0vS1SKP5D5CfeP+ePwoA4fHI+lBJ5+vNbNxoOpQwq1zatCDkDzDtJ6etFp4a1S6jaRLciMdXchR29aAMYDjHp3oBwBWpqOmR2USh7lJLhjkog+6M96opazPCZxExizt344z6ZoAhyQMfnThIcjkgUjLtHUZNN6D0oAUknv2oCnqKTkinLuI2jPNACsSRzwBSH7n+0O9DHJ5z1pwCE8fdznmgBmOCT0NXba6ltox5cjIhyCAetMit/OjZ1ZVxg8/5+lS6Wii9QOoc5wA3Tp3oA6TQp7kwBjEHJBEbzfKoGOw7ngflUV7dW9tO8jASSk8Aj5VOevv0rO1K5Zpwq3QWFBhUjOQOKyZjvk3ZJXtmgAmk/ekk7sd6l+1khs8yHkFucVGiIwbcD0wAPWlWAAqWzg+goAjAd2Lvj15q1aI43bWJJxnaAcdfWmtGhA8ss3A+Xrz/nNKhnX/AFe+JccBR2/MV35ZKUcVFxTb1+F2ez2In8J9jXmowSxzwSjLSFW2NjYc4+Yd+/6VgalaGHTWurKIC3LEhHGT04GQM9c/5NJqWgXc0pSAyQ/OBgN83I/zn6VieIP+EmsLNXtRLcruY7ecFfw6jNcBZz9zHqEkUnkuYUxkRr/FntnPX/Gsg6ZrH9kyeSqFcZ2zE7xz9Paqkc+qXWrvPYpLbERZmikz82D1A/StPUptYa6Rmne2sJBhldMhMnv7/X6UAc9bahdaPbvNe6fHIrkZmTHynPt+FV9S1KS5QX8t1ulJyEJ2lQDwBXc366M9o9tcbJTsxiPJ3e/tXOWunwXusmzijaxgY/IspHYZyM+350AXPB14yTb7tppS5b5EG4beSD69fpXca3rLadYiSKBWgUBVDgZzzwRiqGm+HbjSXheRBcgKQJeBgcjp0FaWqabcX9p/o9uSY0wBvwPxxz2/UUAc54g1dbm3JuLdFiBDeZG20jGMYHUf5FcQb57mOKO1eWSTdhZGO4c9QfUdKt+L9Ont2AIkjnkIzg5QnHI9a4tGls2GWZe+0dR7igD1vSNbvbt2tJ7dRNGQjBHGCMccfjXXRTx/ZY1W38iZgd5I+bPc9/Q815B4R1J5NQwtxFGxLEq+fmGPX8K9d0cxSLEVVzMDhT1z04/z6e9AF3/hF57yJZhIxRCuBEMls+2c4/lt61r6XbS20AfcpkMbFllGwgY9f0ro/D1zeRSKy/Ybd1ACiXPzdOf5dfzqTxDetfM9ndG1mZ1YjycDHfGfT1oA871GKeeQYti0eRvJYkHjvzxnmuc1rQ/D95bSIFCOOd7YB68498V3U1rb2nmNLd4jZj8o4yRjj68/pXIa7DBfxPHZQOkgGFDKAQ2PX3xQB4/4p0WCynQ6d5kkRPLN34/z+dc6YTnGGY4J49hXqz3Wn3CvZXsk8NxA20uy5GSozzj/AD3qWHwZYTTL9kmEsRyxP3eD/PtQB5WNPv2tJJfJfyVA3EjFUWBjfBOcGvpq01HStGtjDe2kLAKow+MHj6deBXO69qGiyTzTTaNCsSHCJ5H3+Bz69O9AHhk1w02HJVSBj5Vx/nrUByeFyTXqN9F4T1W0cu8enDcSAkYVs9ulcle2ukQ3O3TpridQxG9125GP55oA56C3eeTADBQCxOCeK7zw14Bu9X09J91uFlQOmZPmxk11Hg7TZXiSOOCD+7LEc5c54r1nwj4eRrm2SbTCsRIXMSFQo9R6dvzoA8C174YalZW7S2yedt5GG6jbnAHc/wCNcFc6fdWsjR3EEkbjIYFelfoJc+CNNmtUjW5a3uAAfmwxX6ivJfiH8NhamQuqCLLH7TwHP4d8f1oA+VDaT+WjeUSO3fiozBMCyGJ9w5II9K9d1/SW06382zv47eIDkTptIB9OPbpXmGrXLS3DFXLkkrvzyaAKDK0b7XBGemaEkaORWjJVlOQVOMUjlt/JyeeaAThsHB/nQB1dh4k1CS2S3e4RIuELP6Y7nGa6e18YR2M32XTV8+UfLnA2senFef2OpLa28ka28DPJx5rjJXjtWekhWTcrEc5yKAPRNVMdzcSXevXEbEpmOJZc44zwPXp+VUrPV9Ojed5A9yxwI4ATtxxXFTEYUB3bjvVnT47MSK13O6qeqxrz+dAHSNpskyT3E81vaorkpbhwSw9qyHjJtY4EMzBiCUYFEPJ6+vUc0y31dLLUGlhi86EHCLPzx70X3iO9vFcSMoBOcYHy89qAKnkRJHKSN7AdAeF/H8qz3UckevFP3nnnOev51Hk4HWgAA4z70KcYI60Y5pV5YZPFAC4JVjilCM3PTBpQQT83K471etbaW7mKWyhndtqov+fSgDR03QZZ7Y3EnyDblY06nnp7VWi0mZYZ57gMAgPC8ke5/wA+lelaPoN3o2kqdTndIsEmCHksT6n6ZrHfRrmXTZ7OxgnjEjf6yXgDOeM9+KAPPVhYuDgAEYyT7VLMHmk2ALsTuvQ89a6P+xrfSyxuk+3Sfd2jKgcdc/Xj2q34qbRpb+3bQ9HudJsvLxJHJctcbm3ddxUY7cUAcvFZpFHmXezlsbQOMfUfjWjDaXJiKyxgE4wgPIHI5/MVY1d0khVbTbDaxqNpf7z56c/nWQb29uHCoXVioUAHGetAEl5G9jJFF5iLIQMhSDzkimSEiQmMytnqxxzyfWogstveCS5j8x+PlYZx9fzFTzXT3Mm9hGoxgc7R1P516GVSUcVBt231XoyJ/CfXGvy6l9nMtvPa3TsQCNwBwemefcH8KxbTxBPDCqyqLZSS3lsNyjvwfT0Fc8/9oWmptFJcJcQylNsikDDcEcdv16Ve1K0s5oDFqlvPFK7Njg8gKOeDk8+leeWZviBUvI1H7v7Rn+CTD9eoPTsP1q9Y3dtHata6vatNCyghyvGM/wCHNZ19pKXMcUcW97dWHls/PbPXseK24kWZCGtHyP7h4A55/l3oAqtpWhXKSJFcxR4AIZRtYE8gevp7c1RbRrC1klFwqz5cJuYfMQMYwSO3+NXNbgt1jZUtvLkABQFOSc9e2f8APviG01SB96ORbXceBKGBKsOAD+R7UAcxf6uNCuxLDdXIiblYXbcG5xwT2ya6/TNTFuBPaPJDLN8zL9/J9CD06+vasHVILHVVDS3PlGIneAgAH4/h2/8A1TwfY5ZWh051YIo4X7wwOp9On60AbupWb6vOBfafaSDcWUt8vTuPXJ/lXmPirw7Y6bK07WtwiSBv3cR3gA4x/Ij/ACK9NtYJXuwLeRJm6eTI20qAMkDPfp696wvGN59mSIPaSCdjhuNygdSR2HH8qAPDzcpaXiyWquhU52P7V6JoHjm3YRR3CPD33IcqPwrkvFNrbPcCWxdC5H7xQOpx+X/665u2d4ZiPu8cg+lAH0DB4+iS7htrl2ubSQ/KSeQfY59q7qK+s3mj+zJcebKDkMdwJ7ZI/wA/lXyzpuoO84gNuJifmUBsFeOo/LP4V02keMtRs7xPtLyNAgJ8ssOntQB7xJa29xeTNO6naVXZISTnuOPfOaz7pYtu5o3giC987vf0P0H6Vx9v45WbZJZGRJkGCsu0qeB6881rWXjVLycJqcJWU/L5jY6gHHQ89aAK0nhmW6vnurS5MURU74zEPm4659xVXUl1m30u4XTrSMxx5GdpB/4DXXP4vmgkktYlhktsZVXQkAehI61m6l410pLiNL0RGXd9yEk5xxjp3z+YoA81ey1I6Q81zYwzXBG5TIzeaDjJOK5bU9Z1NVFrfSy5UEYYdRXvK6xDNdGSztomLDClsk5Iz6dsk96wPE/hZ9VuRPd2sSydVIXBHA4/DrQB4ZHb3E4GxXZSfWtS2tWSJvOHkgMGyzcnHpV/xdoF7pkgeVy0ZHyuoIAHpisRIA0DSG5Lsp6c4A//AF0Aev6K93/Z8Ukd8A4OFOAM9Ocj0rptH8c6vHeR2l3y6NzcRvgD0+p/z6V88vqdysXkJKyJuyQpPzHjFaFtNe3WySeWbbEOCWwAPT+VAH0cdevYr5bi3u5i7jBZH9V9+n/1hS65rD3kcjP51yyoTtBwDknP868f8PzKkXmzapuZRxAx+nP+fWrNz4lvIdqyWLeQcguG3Fh9R70ATePNJu9U0wzxwlRDlupYAc9D/kV5FPC8fLKVB9fpXqU3iW71TTJIII5QzIQRg5J6c+g715zrVtfwTH7bbyRhmO0spAP0oAzNpbgU+NOSCCTyAKbyGznHpSNkE5GaAEcYbr+VLk42gmpFkUMdyA9Bk/Sm7/m6DNADGUhsH8qVHK56en0oYgjj1pnOcjvQA4nBz3FNzkUpBBOTRjI4FADT1p6IzZx7DmgRsMDbyenFbOh6TNPfRxyxsinBK45YdcY96AMu2jUzBGUuPRepNdFDpVv5EZ8qRXllAHQhRtz37nP6V1t/oUCmKOz0GQyMB+93bcDjpXTaV4XhuLiCI20G1CMRopkYtt6kfTOPp70AefReFGAQhRMzjITBODwcH0r0fwZ4aDxw+RbQpIkmJNqHk885z7V3J8H3enxCc2bSlxkFkJ4+nPvVy6uIhpbW9nGsMqnaQVAOOp7e36DoKAMHWE0/T9MZSjyOindg4A55/T9MVwcl7J/ZLSfahFbMvzbQc49Bx7V2y24m824vy7xLlfL4UdemOnbntXP+IdY0y3QRssQXIAUAHH4469D/ACoA4D+0LSymae1tZC2dwkuByRt5wDUGrC41eAZ8yJQCS0zBQefT6Y/Stu61HfcAabprXE5zuldfunA6fzxXKa9bzRXE0t3dRtKw5RSTt6flxQBRkit4MEytJnaPfGOeKksrW6P+kqpgtQ2NxGCeDx/n1qvbWkk0qyvJHGg53SHOR9K0L6eLERF3JO5AHlBflXt/KgBl4hntEWJNoZgxz36H8+cUwTNGBboQBEMccdz371VdrjH7v5QEGc88cf8A1qs3Vg9vBbs5CyOpLDv1zz+denk9X2WMhO17X/JkVFeJ9B6ZtmRoFg+0pGwCAn5146gdu2PrTNT1MxXoGo25FnGWOc5Kjkc+3A+lKtuxvGSDfbTBghYH5fxPqc5z3qDVLSd2+YS/aVJG4HAI6454zmvMLMa6eKbUxLot3MIwgY5+4GwCcg/55HpUM2pa2l1a+YBIGO0tG3yHnjPbrWtFYpayLJfQSAsgAlQ479vQcA0y4gt4oZMvO6Ec7j868/qPzoA0NVttQGnrc/2exk2rskDbww9P/wBfFUdHWxkuwNQna3nBzhhkEE9RWr4e1O5ihMNufPtXUbQ5BAX/AGsnpz/9frTtTtdIkmaaSEw3ZY8qcrj1HrjIoAknstHe3km0vUrUnDHy5kHB+n4VyDWUkWoTTyWccLYI3xMNrdwf0H45rO1yW6mlEVtaJt3ZMpwueuQfbnoc/hWlp+vPFC9pcW8bzouXZH++PUZ/D360AWb7VINJtTMZjcMrkL69B368Z/T6V0WkXkWo2Kyu0Lo4HyHkDgZHt0x3rkbG4tb65aa3MQbdkxAqTnqcD3rR8PLbCaWSF43hchJFZfv4H+NAEuv6DZ6xaymFYI5ThVlVdp7fTPI/nXk2r/D7WrGKSeQRSRrkZVxnj2Pfp+dfSmhy6UjSxX8fU71dj04GBx755Namq6NBf+XEYbHynAHD/Ng/Xv07UAfG93ouo6citcQSR7yArD6U4WUjx73kXcoIwTzwOtfZupfCDSbrTW865ljt3+YBSWPTofQf5+nlmu/DnR9JVo3TzokBJlQ/MODzz/T0oA8GmtljnUPOzJgbvLOSDjkUolk2E27EEZ+Ueg/ya7DUvCc8FzJc6es5VTuUlQwPfn865280fUWDXDxqgbOQDgjA9KAK9vr2oW6tDDeyLE4AbPOPWmPcSLcq8V4H2tlm25wPoazZ1XJ2Ek9930p8ZPkTZUBlGeaAO+tfFljaWy28/wBqeYYJaM89jUF58Q7tMm2adGySDIc5yMcj868+Zm3AsTkDj2pySyNGATuAPQ+1AHQ6h4v1HU0Md8ySwn7wI68dTWDLMI5JPJ+UMc4qq7FmJGMk9BT44S7f4nGaAJYkEj8bi2TitOa8kitBbEvE/OfTHXmtnSoIoYIbmxs3FyvyHcCQW4/xqSTw+YTNearIrOfmWMNjt3B7dqAOUKZAEUzNIex/xrQs7i6tpjBPM0SnnJ+bNIosnmaQlDEhJ2jIOOcD9K6HR/D8WsSH7FDIoJzmV85B6YHHHNAEemeLJrKALGYmmIIJaMYNZni65v75/tF9cxMNx2Ii4HbJH+fWu3vPh0Ft1mM7KEUkIijb29z7VRTwrpWq2zzLJKhViCTJgZ46DHegDzHJVt2PpShztYYHP+c12mueHbe3Ty9OtLiYruBbBYnH4f8A6q5V0S3ikIjb5sqpft60AUT94nHNA4b3FSGNmG7Hyk8n8KsJaxiRV8zc74xgdDQBV2ex96aFyOh9a69fDslvaG7ezuZ4+NoxgD6+o7/hXO3aSzXBIjYZwAqr+AoAZFal2IZkRs45PU1LHYOdpdWiz90FSS1aUumyabaQTXNr+8OHGecjtWvo0dxNqC/bIHaZhlfl4AOP8/8A66ABdGurdGnKrG8Y3ndjOeK6LwLol01xNcPIsk8rZX5SMjvg12lloyG3jSO2Ri5HyKPMPXv6/wCRXY6TodsbdWvLR4rcADYB82fY9MUARwaMkFrGyFC7jkLwBn9R1/z26rQPC93FbrLo84W7Y4Mi/wAPHBOfb3pPCI0i9upHS1M4hB8qEJ8q88bmPU5FWNU8YX9jqNxFbwmHcxyFwAnpn+XJx0oAk8VRjQ9OhTU9SuHvJECOEAYcnHU5IHP6V5lqklzbzhFlSS1LMZFGN2ScY/Ud6tapqFxdvJJqLQ4ILDD5JPGOuM9Olcf4mmWW7zJei3t0PzIuDv44Ax2NAGrcajDJbbJ7tMIpKwr1xn2/x715R401WCe72ROh2OfkAyBjPfr3qsl2i3t08bFoMHDY4I3deefSsO4MUh82PaCO56n8On/6qANh/Ed3PaRWUMixnpuAA4x3NQatNYpAsEUr3s5BLy5IAPpg/wA6xcCU8AITzuPer1ppwVZJJJkATdhAcsxGfyFAFURySSHygxxgYx0HXBqWIyRlAiF3A4x9TTrJSZnBk2oD8zk9ewFaEM9ytvssrZwG2jnqDzyKADR54bSMy3SGSYLlVbJ2++B1/wDrU3V3NzKsoUtkn5s9fw7VnyxtbO32ghpsAFQfujHr+QxToLl7iLYwjYISQGQEjPbOPau/K03ioKKu9fyZM/hPb9fvJtMVJLoz4V1KsfmUc9Pbp+NaNn4jW4s0j+1QzTiRvlJy23gdePSsrUDPeWc/2mVZMumYsBSMcYI78k9+1cvPeJoSedb27ZkZgGZCGx6H2rgKO5fVZnsm3bnWNCrICTg/QjHQmvP21i3S4eSCaWMscld3TJxkepz/ADrorLWY9R012aOMsse5wjc9j0H41ia/o91fabBeQWsEYT7zocNjd3HX160AbukXtvNCv2K9Ic7N25cZI7EdOc5r0jwraJc3C/2hHaTyF85chT06DPfg14G2pXukgxbY/JO0B9oBBx1BH0rs/CPiF5pXxKHk3AujKR04GP0oA9q8SfDOG7smuNNvre2wu4wSKNvXt+mPrXiviPwPeebM0oEQQbTJCOCMdv8AD3r0TS/Fmqy2ZtIne5QEo0EqqQB04P5cj9O0erfbbu1kyjDcmcI+SOOnPfjv6Y+oB5l4f0BLS7aOa4UyCTAbYMn681valbMsflr5ToNvO7Yx6fr06dM/lVntr+wnknjsRLbySAF0OSPRsfh/Om6xq09rGrPBHc2wH+qf5SPlH4HpQBpabIllKpS6Zk+ZPnO5egz+WPXtXoNjeeWDcJd2brhS8ZOc9Og/AV5VbS2Woaag0tY7eYDPlO5Izjrjvyf1rSt7aW2s45J2jKKmWEOeSOSABx6daAPUX8Q6ugeTSrv902RtVtwHYZ/H+fvVf+17q/kkfXbawC7GCSOmCwH44z2rC8O6xYrGzTTyxREjMbqAc9Mfn/nmtHVdUtHhhjHMUgMYJQYzjAx09uaAKVzcQSGR0QRA7gY1O4YxjOPz/OsTWdAfU4XeWNipHHyYbv144B4/OutWaC1iPn7k5G11QE456/lWrYXlvIixzj7TGFXa3ljIHPcfh19aAPmTxN4Jls7p5LQPNFuyYwvPT+VcfdWVzM00sVrIsUbYY7Tx9TX1r4o0rTUVJLOaFZBkFZJepAHU+tctNpVlLCY1WGJZCc7Y8A8Dv6c0AfMUm5jukOTwc05YScldzHPOB9K+mD8NvD1wuZHWUsuFEa4wegH9Tz2ol+GOn20JZIdydAxYLgbRkHn6cUAfNNlavcXAiXO4sF6ZrtdA8PTafN9o1KzSeBBkbzwP8/0r1G10LSdOikaOxiWZeQ/lE4J4H8j/AJ64qxTy3ztJICmdqQ7SUIK9cfn370AUrXU7EBn05VZyzFoidq59P8+tVNatdR1uydpY7O3hTkBySSMA8961bG3ms/Mmke0bA3EJHjkeo9ePrWHr/iy+2PawQRwR4+8YzhsD+EUAcPNCIb91BDxrglolIxxzwa7bwx4vv18q1htLaaVAdhaPJPXkgfhXJT6dcrIWYSEyjexGQMMOhr0z4NaBHresxW1vYusajdd3IY5VR1H1J4H1z2oA6uKLUNQsVF1DGqOu7CjaR34z/OsuHwteC5VLJN5JZzGpH0wT3r3rxP4ciutNE9pB5dxBD5UQQZyoHC474HSsnwP4cj1aE3U8rE8qA5C4bqRgHJ/z+IB5jqGk6hb6c8ZjtbTI+8AMtgdP856+9cjoHwufVx5uqoYIs7lYMS0n/Ace3P419U3Pge2uLlZndXCcKjrkYPX9c/nV+C1e3UR3NiN/CiW3jDAAdDjFAHzZqPwysJ7OSO3tjsBBXyo+CMH5hxn1/T8OK1LwYtncOFiaARyfu8Lj0IJFfR3juDUtIkaa2luI43+bDSg9ug/H0rz+z0e51+R7i8Uq23BYuRuHGP556UAeaXOo3LQ/Z2nJRBkrEgO75ehPY81XNhOUFxIsEUhO1QwGccHgDp1+uK9Wg8J29vOtvAQys4UgICS209M8+n+NdNpfwv1G4Ae4traEMQ37/wCZh0GAO3SgDyTT9Ok1CWJbqHMa8qSvGQR259eldra+CLq6WKSInB4ESLyxI6E+leueE/Cmm2QWc6YskiH5Xcg4OOvpW/canYRwE2VxaoqAlypAKj/9eaAOBh8M3Oj6bDEBFHMy73wQuPbJ56559vzuafe2Y8OudZuS0hIUQRDGMdz69M9f5VS8YeKRPcpPYJ5ttGM7Qhy+DjOc8j29K4LW/Gs91G0FvYpnsYgAduPu9j/9bigDorHVPImL2QZLTJzhTggE5HUew61zut+IIbrULhLe2i84EFpHzgKFHI7DgD/69c9c+IbgSCFo1CZO5t+0L82QM9c/41w3jbxTbTI9taM3nscMIj1GONzUAaXinVYPJaf7QjSphsLlupGTnPHNcRrXiO1vNqiKUxqwLZb73rzWLqj3IiRWXy4gOAO54zk/hWSvJJJwAeRQBp3bJNbosS4Kg55/z7UxLDEBcuCyjJA59/8A61QW/wA7Oznaqg4z1PtSSXcpiZAyhW6gD60AJJI/nq7sWK4IBNdXr3iLU/FlzbSajHZLJGhQG2to4MgZPKqADya5FbeVhuVWIPfHBq1Hb3Ea/NlOCeeDQBoRLG18xuuI1YYAxk/lWs+owEotuj/MNqomNx+9nJ7dRXOxJKbtY/lXBG6Rudp7nNWZbm1gl+SVpW427BgA80AR62qxRhpAiSOAfLXqO/zVQtzwVRnUjrgD+tMnlEz7pPvEDkntSxFYV3Et8/pz0/8A111YKcIV4ym2lrtvsTLVaHpt5NfajfyW63MTxkg+dGCAFyME/T/Gr1rdyaUiJePb39rI7rtY5xngGsZ5/JuYbcAwSeYAgiyBtPr3qG88PzzXP2me4BTLkojfMoz+RrlKOwgk8O6jtl01hb3TJ024+bnt3/Sk1ltQngW1DJMHOC6HbtGfQ9/auesdPtI7ELHKWZEBaSNwNwz+h56V2um+HI0theWN3LIh6xzEnPPXrx07elAHE674c1JLci3gEyMAxUkknP8A+s0nhvVG0S9aOW282IsQ4cZKHP6j/Cuv1Z5IrlGPmkoQTz8owfQdqpXlvax6nHciKGaSYbDvPAHB/Xj9aAOw8K6rDJM/2KaIM4J+bnIx69u/p0roBfwWwe4mhWSRhnLZxnPfqD06VxGgwxEBrmJbeQhgPLxkZyB+HP8AKuqh80QhY5Q0mwffIIPtz396ALGuQadf2ry20klvIzYMRGCPp6gevbvXHWWjwHbFKWbyz8jOpYDIHByOBXe6tZzNaos0ItmaRQHiGQcj0z6VyOvqNJ3zCdyqn+Hrx1x0NAFF9DZD5sdrEkgH8K/w4x1x9T/+urMEzieKK6h2Dkl1yF9ccHjOM/jWXd+IJCjCFpBISpKodzYxjJ654/l71paVr8aQuJ5LedAmcOMMCR1wepoA07mOC8jJjltrldxymRu6f/XH5VUgsHkkiia4mjiVc7cZGeOPpmue1V7K4uXudMjjE0eBuDEKT9P89a6G0uFe1jmdHZ1UMeT83X+Z9f5UAa1xqH2UYcQlFOC7Hrn29801NTa3gERncLIxwqJ8u7+8fQn1FZum3dvqEzwNEow20owwO2CD9DV2O4h0d2QNBKOSYn5OOpAB9elACOhZhhWaRiMoM9vr0Pf8a0ILqVENrMoC5ODjoSPUj2PFMttY0u9l89rlLV1zlShGTt6fz7HpXQ6Pdafc3Eg1GNrmzByHDAAZB545HX/PNAGUp8qIszNJA4xk/KAD/wDrH41DqNrdXao1rcQQkNuIXgDgccn2/l0r0BG8Dy25+zrJM0ZAEYLZDeh7ZH481He6Zol1B5tjp14rNwArEEDGM+1AHmEt1cWlsRcWtncyAfeD8kY5z6fjWXHNHq7yDMEDruDIVBbOPbr3/Ou2u/CepW8Qlg0CFoySW8yXDEDp39P68VjW2i3k8byLZwW4BIKQSg7hzk5/zzQB59bWGoQ6zMqXkn2cyM2wqMHsOfr3q/qdppqruvJFknI+UYwTx0zx/nt66V5pK3UbwzXEqyMMkKSSuenbpwOn6VlXgtLKUJMZZyNqopjyCR0JxwOOaAOU3pdO6TW86wKy7QpJOcDGBX1F8OPC1p4a0OKKOERXs+JbkjGd3OFJ77cn9a80+Gtibq5fXfFUdrp2m6a2Y3nYAPLgY5PZcbvXO33r17w3rmn+IbRrnSpjPbRzNCz7SuWUAnGe3zD86AOoMYNjg9QN3Xv1rAIi0e7e+tNOa6edwJViOCCeN2MHIPGfQgGuh+0f6I0uxTlsEfnWZJqUVldJB9jnk3xBzIhG1RkjBGQe3b1oA6Oynkmtg9xA1uccqx6cfpWdf+JdJs2cS3SvInVI/nI/AV5x4wuw16StwzWZwUWOUjaw7MD0xyf8Oa4i/wBWnvH8tXmhGBkCPgnGeoHTr+dAHsN3f6BrmJrotGI2zvfg+3H14qpBp2iXDsyuILMcqqNyx69vT29efSvLr24UTWiq6ywMRul2jPTP49K7fQ9bvI4s2qwfZR8xaXb+WPp/X8QDo7PQFOoQz2FlLHDG+5nnYKzEdMD0rd1y71OC2MWmWm6TZzIzZCjuc9yK5G8+I0NtEyJayG6Xhi0m4Kce3A9q43XfG9/dkzyvMIh8oiR9oLdsY49M0AdBrWu6lbWssdwptw4O+T++eB0/u9a5C+8QqImt7ZlnXdzH5W3r6/mfrVCXW/PCzXrtEzA8SuGbcR1J/wA9K8+8XeJtM06EmBzc3f8AezgH16fjQB1fjTxSlnZDMcaBceXGDkDLDn/PvXCx309xbvMkruSVyPuohOOM/nWXc6m13PG7Mnltg7WJxgkZ+uf5ik8R+I4bbT/K07y3Hyk9cdTQBQ8QwQpG0kmpSPkkFANq4yTxzz07VyNzch5EjgGM4GR1PHc0+/1Ce9YLcuzE5JJ/wqNo4UiIgMj3GR9AO34mgBL4SqB5r5ZueTz/AJ4NVA/ynauCScfSpElCEmVQ7e/NNkKTXDkABWbjHQUAMBLYJJ/H1qZYCsfmuyk54Unk1IlrK7RxQZkdiAAoPJzinSWU0D7LoMJz0TqT1oAsxajKdq7EbAwqt90cYqzZXNtFKxui1xKcc5I4rGkgkt2HmjbnBGT2xmhCpYlmOCD2oAva1qBupgI444YwcgJ+VZ43YJBAXP8A+qpJYEKeZu2jIxnqaYUQRZkD5P3QeAfegBixMyl8ZUDJ5HrUlxcu0caELtTIUAe9Ql5B0J20KS5bGD9RWlKn7SSihN2PVj4e1P7akiqCwlU7o3zhuByP7vOa7Cz8y6s1h1Gw8tCx2yDG1hyM556U+FYbu0N3Dm1Mkg3iQEnqD19+PzqHRYL+NW+2XqyhnfZs5XbnHp3IP5j1rMZyMujJpmpTFImvYtu941OGXn9a7Xw/rEM2nf8AEsuGQZJEM6YCjkHPPoagmvdPtJnDt5ExQZ+XIb2/PvWLL4hsrWSVUt0lG0BvKOMkng+tAC63rEn2hXvLZ4m4PmRORkcetOsb8XNyJDHI0ZJJXYAR06+vT9arPGPEEbJaSNblFGVPOc+uen610Gk6I8CvLcjyiSd/lYLevCfT8/woAt6dCtzdCTajFSRkjb3zj6c/rXcWMlxb3kc0dvCY1UMwYHBweh/XmuNtr25sZGa3keRDk7hHlfT5s9OmM10t/rNxJY+YYUMgAO9fk3E56Ad8fjQB3aX2k32pwnatvGADLDGS27nrjHHQdfSoPEuneG725SCOG7Du2CcfJ04/CuL8Oa5NpN6L2EJcBjhw/KsvAxz3H+eter2evaDrSRNqVnDE7HG5uAD/ALw/T/JoA8W1jwvBo+oG6t7mISOMbg2QBt49OeM1z3iTS49TRZbGa3F7CpChwADx/LrXu/ib4eQ6jN5unXMboRzEW5PHY/T2rLl8INptkJb61iUJn5XAZT/s7h7E9aAPA28OSQWwmui0TKuXCDKnv0H1rTttVaWKPNyr25jymwFSD/Trmu9utNhttSklaOKZG4aJScYx7euP88VlXo06NZEi082pc9SRgZPb8AaAOKtLi4m1OSGaYpDGQYi56gA/n0rpDGskYjUIzg8TAbcY4/8Arn8aqzabCJ/OVlOZBhww46cdPrVf7Ve2NxtvruAW75C5O3J5/lxz/WgDYtbGN7VvLeOSVuAzgf3eR7f55qNNOu7QEsyxoFZcZwRjHT0/wPvWP/b1m9zJCrKhRSGcfd4Xpn8+lRal4ggt422RS3BAIzGQUHHB560AdCZ3sJjJDHsc4J8qQA59fTPOfxNWpvFusyJHFayv8zHd5k3X5R7/AKV5tpni/wA55otUtfKZTlTjOBjAq/M6yTrdWt6mNxKqGC4GAOn0/lQB2Nz4l1GKBlnRXcnJ2uT+Y78H/PfDn8T3X2hIbdo4EXPmyOSMjk8ADj8Olch/wk1+6yksJSmQxD7cY6n+tSTa/Z39sf3ZlugScFCcnGc/lQBY1jxKtqZYYr+Z85Zyg6fQ/lTLLxHHar50y7kf5gz5DPgDn9P85rNmmhutN23NsLd8kGKPAJHbk89qptoGqX8QiWJhBuBGSMgbfX3zQBe8Wa5/aNnCsl4PsqZCQxZ4OB745PHFexfs8eKdCsPCGo217qVnaTR37uFuJgjMrRp8wB5xlSPwr5w1TR7vT5PKuVeNQ33twbJxx/I1b0G1lkc+TcQWykcyTdT244oA+208e+GntzEmr2RGf+WbFzn8BXNeLvEFvNc20mnXEsmxG3sA6BSG+U5wD3b25x3r55/tG800RtFKLq3UHcYgMgdB9T0rRPjX7WGdbsbgp/chMsOMk+1AHpjXxeR3eSDaSVDMOnTH41S1Jw+ZJb1sqB8kZC547fgPXvmvLp9WvJbV2VblQTuIyq8H9QQeePWo9P1G+SySJZzBdA5IcGTAAPBOOD1oA75dViicx3MHmSjhIwCCcKOvr2zVu3upJ7hbYssTMhfyg20dPQ9x6kCuBF5rUcinfGxLEmaVQAny9Bjkk/pipbu5hmsyZNQuZ7llxmGME9u4H6e1AHfmW0ErwRuwYNl2R9+c8Z56j6+lZfiTXLTSrblROE6qy7iOBg+v6VxVhFqUJaPTbW6h8zG+4dcHGORn8wa3rfTorO3Y3dyksjkq+5d3y8D+hHcUANuJ4tX0tmEO1COAM7se+T1+p9a5Gyh0+xldlgtHmU7Ck/zkDOQce49+1al7a3N5ezRLcInmE/u4vl4J6CsHU9Bk03y5YIW+crhi+45z0/L/AOtQBBrOq2izMph3PJyy7SiqM9h+tcverbhhJCXdARkdvXFdP9l0Xzn+0yXNxd8ZDYAPPOPxq9puip8xitQxcqSkxBC4Hf370AcU9ypgT5wNqk7NvvUSCWYlFQrnGMDvj/8AXXU6v4dkQnMkER2M7t2Ge2Pz965+7iexPlLKJcNnK8c4FAC2OjzT3jwSrhlGPl554AOR9au3ul2OmMEuC0s5I+VJB8meTnFWNDg1m4s55LG1b5VGHAx6Dr+Oayb7S5bXzXuZ4xKpGER9x5OO1ADrDVZtOkeSyGw5Kq5GSOaittWnhmaYBZLhh/rJOSvPaqYd2dhHnnir2nae0+XkMaxgZYsT/wDroAp3dxJdS5dmeR26+pNb+veDNX8NXcVr4itZLCSRPMjVypLrnHGCe+RWJM6NNkkPjoRwOnFTvdtISGlKpk55z6EYz9BQBfnm0+xjEdvbiSQIQZJTknPQgVlu5uZd8hAXd1/z2qVntCqEhpHB+Yk9eP8A9dUsB3wGO3g4FAEp8naQTkAf41HEgJbDBQKhcIF+XduxzTEkdCdrbc10YWpCnVUql7eW4pK6PoD+0Izci2MaBi4cBh8r9M8+nf8ACtNLuK2MUX2Z2kXd+7J+9nGPfvjHsa5/wlFM9pHaTOjmOQeVLt+ZcHB5/Hj/ACK9G07ZLZQm4hicjcwIH15P5e1c4zhPEEwWzEstpNLEq42FcsoP5DHH5Vzyy3GpOhsbS3lRTxk7cgE/nXtYtbHUbZoo4DGSgAzjGDxz+Y/KuJ8SeFYtOikltZDECGbavf5iPTigDgrhrjT9TjMa3Ni5ALhuV7YPHXr0rrNF1KGW6kkS4SV3IzvJwcHPQjI49qzLuUi2l8zLSwKJAScjcATkVR0TxJDqVxLaXVkocswWRAMjGB1NAHomn6hLplw08fkSoxJ2EcHgjpge/wCFXP7Wsb22mSW1e0lCFflfAxg8c84z1rl9E1xJYZo3gDJGrDLKM8jBx7Y7VNq8sUaSOsbxqQFAV/unB7UAVpWvLPUFDWjyWjSKS7HjOB83au30GFitsIVLw79xywJHT+me3FcXqeomwdWllnaEyBCq4z0z39q7Tw1qwtLeO/SFXjkb5h91sDGAMcdutAHsGlaXG2mwf2XMVmAIlBbDDp1B/wA81z/jHX7zS5/s92izBuQnKcEd/wD9Xr+Eug3N7clr6ymUBWOYphx2x078jmua8W6pFqrkT24U42l1PJHHbp3H60AZmrahayS+ZHCYt7fMGUHGOOT6Vz2r69CtvKYYftTbOhTIIycdh2NP1NTCqG3kOwnI3KO46fh9azHeWC5ZLmQNLjbvRMevvQBh3XjfymZf7NKBXwVXI3Adv1/nVZPE1vdRol5paoWYsA3IJyenHb+VaGr6a+onbAYlIAOWBHGPbNZh0iW3s3ku3jmkjyAPqM9cZ9aAM3xFoiXaG4jhuLUEEkZ6dO30qkbCBLYkSXFywVgVC4APf61taf5WpK63xnPlgMVjkwpAUH6k1rDUEtY3W3gTAXKlhk9OM/iaAODs9VmM0zNY2wG1V/eKQSMdP8KzdQnaS+leKzdMvn9yCAOB29Otd1Ndt5TXiMVB42BRzjtXI6p4nuZ/ktVEJDMNx6kcf40ALpNpK1pMBJHCj4ZpGjyynGa3re8sYbfEuqo7YYkBNm7Hp3+tedi4uHJUTPljuPJ5NbEtvDZRR3VwGuXJUEN7gmgDetLnSrq3OoNBLLcrwEkYkduRz7H8qxNR1u41K5fbI1vECAQshAxjtVe712WWJ4xBDFbEYCIvIJ75781lEnyxMP4pOCTkjgf40ATXgFtKVLNKvbLbqlsrayk3S3c+3Ib5d2Npwe3tWRJI+Sc/NwM9+lRYON+c9Cc0AbL36wp5KruiIJAU8Zznn8a3LbU7jyxb6fpdrkgHe429QAa5Swz56thWwCfm5q5Nc3K3LK0ziPAyFY5IxQB0wvr1bgxXqWyAsckfTpWha6uLSBlQPIy8n5QcDpx+Fcbb37yzK8aIrAnJI64FaNvO+He6kcrwT5eAfmB4oA6291OwvIVS7mkV9xIQNjHygYBA461HpptdPlAtdWZpX48mJCR9ck+xrkZ4reIrcNJOQWLhMA/hn8BVqwhaYGS3KxAIASCcjgDjn3oA9IGtHzI4bkPxuYeYyqOg5Pr+FZ2q6tYrC4WYSSNyRHJt9MjPU9D+dcF4plEcyqi/vCAC5OD0xVDTJVVxF5EbzMcbnJIwMcYoA72zubWPbIsA81zwxfP5D6+1Mur67aJZba3Nw+0bGYlu46Acfw1c8PeHzfuDeNEELksI15OPrXZXHh+xsAp8oO3l5HJ6Y/8ArCgDze38HXM8n27WbuO2uXIIRSCV564rotIstOtQ9vEGuLhSoLluDzg/5/nVhdr6nLL5UauufmGeBuPQfjS3tvDaFrpWlDfeJXGflPT0oAw/EmiSXWnyPDGkICsxYHn73PHpXI6eljpdsZ7yNryQuu2PHGQOATj9K665utR8TqLDTJY7OEAli+SXye5A56V06eDodM0iO61CUXTqRwF4+4ef1oA8nn8TX8xAZnRMbVijULjgen4flVbW/t8tqZJLCaGMkAuwJ689/pXdhrSwuJNQuLUMVJCIh+nc9+tReJtYu5olby4o2eQ7ArEhB83bH1/OgDzmz06TbvkPlFlyAT8x56gVXD7flVjzweff/wDVW5cfZsyzvHI0oOT8/BJPXpWCTmUgfKpO3AoAZMmOF49se1V9pJwTx6Vcu3H3I12gAE89eKgtIGubyK3QgPI4jBPQEnHNAEboyEZ7+lNPAGOpxXu3x8+GmmfDnwX4Uitf9I1O4mma9vDkGRgqfKo7KMnA69zya8JcfKPbgUAIDx354qSB1TdvOPqKYibmA74P6U5FznFdODnKFaMob/8AAFJXR//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transabdominal scans showing the head with the large posterior cephalocele. Note the cranial defects (between the arrows) and the brain, which is present within the cephalocele sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetus with posterior cephalocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Same patient showing the cephalocele using transvaginal sonography. Note that transvaginal sonography provides greater detail of the contents of the sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34200=[""].join("\n");
var outline_f33_25_34200=null;
var title_f33_25_34201="Pancreatic exocrine function tests";
var content_f33_25_34201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pancreatic exocrine function tests",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/25/34201/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/25/34201/contributors\">",
"     Tyler Stevens, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/25/34201/contributors\">",
"     Darwin L Conwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/25/34201/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/25/34201/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/25/34201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/25/34201/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/25/34201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic function tests have had a central role in the study of pancreatic disease for more than 70 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This topic review will provide a background on normal pancreatic physiology relevant to pancreatic function testing and summarize test characteristics and clinical utility of the available pancreatic function tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL PANCREATIC PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pancreas secretes approximately 1.5 liters of enzyme-rich fluid every day for the digestion of fats, starch, and protein. Normal pancreatic juice is clear, colorless, isotonic, and alkaline.",
"   </p>",
"   <p>",
"    The composition of pancreatic juice differs in basal and stimulated phases. In the fasting state, pancreatic fluid is protein-rich and has a bicarbonate concentration of 80",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    Stimulation of the pancreas after a meal increases the flow of water and the bicarbonate concentration of pancreatic juice. A large volume of alkaline, enzyme-rich fluid enters the duodenum to neutralize gastric chyme for optimal digestion.",
"   </p>",
"   <p>",
"    Pancreatic secretion is controlled by hormonal and neuronal mechanisms. The principal regulatory hormones are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    and cholecystokinin (CCK). Both are tightly regulated by negative feedback mechanisms.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     Secretin",
"    </a>",
"    is released from the duodenal mucosa in response to the presence of acid in the duodenum (",
"    <a class=\"graphic graphic_figure graphicRef53090 \" href=\"mobipreview.htm?43/4/44097\">",
"     figure 1",
"    </a>",
"    ). Secretin primarily stimulates the release of bicarbonate and water from the interlobular duct cells and causes a gradual rise in the flow of pancreatic fluid through the ducts and a typical pattern of electrolyte secretion (",
"    <a class=\"graphic graphic_figure graphicRef82081 \" href=\"mobipreview.htm?0/60/974\">",
"     figure 2",
"    </a>",
"    ). As bicarbonate concentration rises to a peak concentration of 120",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    chloride concentration decreases reciprocally to maintain isotonicity. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     \"Secretin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CCK is released from gut endocrine cells in response to the entry of fats and proteins into the proximal intestine (",
"    <a class=\"graphic graphic_figure graphicRef66575 \" href=\"mobipreview.htm?16/12/16578\">",
"     figure 3",
"    </a>",
"    ). CCK acts directly and through vagal afferents to stimulate pancreatic acinar cells to release digestive proenzymes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35638?source=see_link\">",
"     \"Physiology of cholecystokinin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS OF PANCREATIC INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced pancreatic exocrine insufficiency (PEI) results in maldigestion of fat and protein leading to steatorrhea and weight loss. Although subtle changes in exocrine function can be detected in patients with early pancreatic disease, overt steatorrhea does not occur until approximately 90 percent of glandular function has been lost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with mild PEI may have subclinical maldigestion and normal appearing bowel movements.",
"   </p>",
"   <p>",
"    Impaired enzyme secretion may be complicated by latent fat-soluble vitamin deficiencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Metabolic bone disease and impaired night vision have been observed in patients with chronic pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. PEI may cause vitamin B12 deficiency because a decreased intestinal pH adversely affects the transfer of vitamin B12 from R protein to intrinsic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As a result, some authors have advocated the dual-label Schilling test as an indirect pancreatic function test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIRECT PANCREATIC FUNCTION TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic function tests (PFTs) can be classified as direct or indirect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct PFTs involve the stimulation of the pancreas through the administration of a meal or hormonal secretagogues after which duodenal fluid is collected and analyzed to quantify normal pancreatic secretory content (ie, enzymes, and bicarbonate). Only a few specialized centers perform these tests.",
"     </li>",
"     <li>",
"      Indirect tests measure the consequences of pancreatic insufficiency and are more widely available (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Indirect pancreatic function tests'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Numerous direct PFTs have been studied; comparison among them is not straightforward since the protocols have not been adequately standardized. Fluid collection is traditionally accomplished using double-lumen collection tubes. One lumen is situated in the duodenum to collect pancreatic secretion while the other is situated in the gastric antrum to prevent gastric fluid from entering the duodenum. Pyloric and duodenal occlusion balloons have been used to prevent gastroduodenal flow and distal duodenal loss, respectively; however, these balloons increase the complexity of the already cumbersome tests and are poorly tolerated by patients. Once tube placement has been confirmed fluoroscopically (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72009 \" href=\"mobipreview.htm?41/5/42064\">",
"     image 1",
"    </a>",
"    ), the pancreatic stimulant is administered and fluid collection is performed for one to two hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lundh test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most physiologic (and inexpensive) pancreatic stimulant used for direct PFTs is a 300 cc liquid test meal comprised of 5 percent protein, 6 percent fat, and 15 percent carbohydrate (Lundh test) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/11\">",
"     11",
"    </a>",
"    ]. After oral administration of this meal, duodenal fluid is collected for two hours and analyzed for enzyme content. Because the test depends on the endogenous release of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    and CCK, it may be unreliable in the setting of altered anatomy or concomitant mucosal disease. The Lundh test has largely been abandoned because comparison studies have demonstrated improved sensitivity with hormone-stimulated tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choice of hormonal stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two hormones have been used to stimulate pancreatic secretion: cholecystokinin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    . Cholecystokinin (CCK) tests measure the ability of acinar-cells to secreted digestive enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Secretin tests measures the ability of ductal cells to produce bicarbonate. Although advanced exocrine insufficiency is characterized by abnormalities of both ductal and acinar secretion, it is not known which secretagogues offer the best sensitivity for early functional decline.",
"   </p>",
"   <p>",
"    Animal studies have suggested that the functional mass of pancreatic tissue is closely related to the maximal bicarbonate output, suggesting that the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    test may better define the functional mass of pancreatic tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/18\">",
"     18",
"    </a>",
"    ]. On the other hand, some experts favor a CCK test with quantification of enzyme output as a more sensitive test for exocrine dysfunction since at least one study found that enzyme secretion becomes impaired in chronic pancreatitis (CP) earlier than bicarbonate secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preferences regarding the choice and dosing of hormonal stimulants are endlessly debated among pancreatic physiologists. The performance of both CCK and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    tests may constitute the optimal functional reference standard.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Secretin test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies using different versions of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    test have described its role in identifying patients with chronic pancreatitis. Conventional secretin tests require the continuous collection of duodenal fluid for one to two hours. Fluid is analyzed for bicarbonate concentration, volume, and total bicarbonate output.",
"   </p>",
"   <p>",
"    Biologic and synthetic porcine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    has been used for secretin testing until recently. Supraphysiological doses ranging from 0.5 to 5",
"    <span class=\"nowrap\">",
"     CU/kg",
"    </span>",
"    have been used, administered as a bolus or as a continuous infusion. Human synthetic secretin is now available and compares favorably with the previous formulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Pancreas Research Center at the University of Florida has developed a rich experience with a protocol for the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    test, which can be considered as a reference standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. A weighted, double-lumen, gastroduodenal collection tube is placed using a guide-wire under fluoroscopic guidance so that the tip is situated in the third portion of the duodenum. Both gastric and duodenal ports are connected to low intermittent suction.",
"   </p>",
"   <p>",
"    After a test dose (0.2 mcg) of synthetic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    , a full dose (0.2",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    is administered as an intravenous bolus at time 0. Duodenal fluid is continuously collected in 15 minute aliquots for one hour. A bicarbonate concentration less than 80",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    in all of the four aliquots represents exocrine insufficiency. A peak bicarbonate cutoff of 90",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    has been advocated by some investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/24\">",
"     24",
"    </a>",
"    ]. Severe exocrine insufficiency is characterized by a peak bicarbonate concentration less than 50",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    Total volume and bicarbonate output are used as secondary diagnostic parameters when bicarbonate concentration is equivocal. Bicarbonate output and fluid volume are notoriously inaccurate measures because of the incomplete recovery of duodenal fluid.",
"   </p>",
"   <p>",
"    Modifications of the traditional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    test have been studied to simplify its performance. Measurement of bicarbonate concentration using a standard biochemical auto-analyzer correlates well with the back titration methods traditionally used in secretin testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/25\">",
"     25",
"    </a>",
"    ]. Shortened collection periods of 15 or 20 minutes have also been evaluated but are not sufficiently accurate when compared with the usual one to two hour collections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the inherent difficulties of gastroduodenal tube placement, endoscopic assisted pancreas function test methods have been developed. We developed a purely endoscopic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    test (ePFT) that offers potential advantages over traditional methods. The secretin ePFT is similar to the University of Florida method. We initially obtained duodenal aspirates at 0, 15, 30, 45, and 60 minutes after secretin; however, aspiration at 30 to 45 minutes can simplify the test and appears to be sufficient for screening subjects with chronic abdominal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/28\">",
"     28",
"    </a>",
"    ]. Other investigators have used an endoscopically placed Liguory tube for pancreas fluid collection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/29\">",
"     29",
"    </a>",
"    ]. Whether the traditional Dreiling tube, Liguory tube, or purely endoscopic (ePFT) method is utilized, the results are similar.",
"   </p>",
"   <p>",
"    Fluid is analyzed for bicarbonate concentration using a hospital auto-analyzer, which produces values that are highly concordant with back-titration bicarbonate measurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/30\">",
"     30",
"    </a>",
"    ]. A peak bicarbonate concentration &lt;80",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    is considered abnormal for the one-hour method. A cut-off of 75",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    is used for the shortened screening ePFT test. The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    ePFT method replicates the well-known pancreatic secretory patterns observed with collection tubes (",
"    <a class=\"graphic graphic_figure graphicRef66606 \" href=\"mobipreview.htm?26/31/27134\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/31\">",
"     31",
"    </a>",
"    ], and compares favorably with the traditional gastroduodenal tube PFTs method in crossover studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Standard dosages of sedation do not appear to decrease pancreas secretion but caution in interpretation of abnormal results is needed when large amounts of analgesia are needed for endoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/34\">",
"     34",
"    </a>",
"    ]. The endoscopic approach provides a method that can be more easily applied to patient care and translational research.",
"   </p>",
"   <p>",
"    Intraductal collection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    -stimulated pure pancreatic juice at the time of ERCP may be an attractive alternative to standard secretin testing because it permits simultaneous measurement of pancreatic structure and function. However, studies of intraductal secretin tests have yielded mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. A possible explanation for inferior accuracy observed in some studies of intraductal methods is that collection times are shorter than traditional methods (10 to 20 minutes after secretin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/38\">",
"     38",
"    </a>",
"    ]. These abbreviated collections may miss the peak phase of bicarbonate secretion, thus yielding false positive results. Another drawback is the risk of pancreatitis particularly since the role of diagnostic ERCP has waned with the advent of sensitive non-invasive imaging tests such as magnetic resonance cholangiopancreatography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     CCK test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of CCK receptor agonist (eg, cerulein) as a hormonal stimulant provides information on the enzyme secretory capacity of the pancreas. A rigorous methodology for CCK testing has been developed at the Mayo Clinic for measurement of enzyme secretory output and can be used as a reference standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/17\">",
"     17",
"    </a>",
"    ]. This method requires the placement of two tubes: a double-lumen duodenal tube and a single-lumen gastric tube. The gastric tube continuously collects and discards gastric fluid to prevent acidification of the duodenum. One duodenal lumen continuously collects duodenal drainage fluid. The other lumen perfuses a mannitol-saline solution with a non-absorbable marker (polyethylene glycol, PEG). An accurate determination is made of enzyme concentration, enzyme output, and fluid volume based upon recovery of the PEG marker.",
"   </p>",
"   <p>",
"    The use of perfusion markers requires a specialized laboratory, making it impractical for clinical care outside of research centers. To circumvent problems related to the quantification of enzyme output and fluid volume, we have developed a CCK test with measurement of lipase concentration from duodenal fluid collected over 80 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/39\">",
"     39",
"    </a>",
"    ]. A peak lipase concentration cutoff of 780",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    was able to discriminate healthy subjects from patients with CP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/40\">",
"     40",
"    </a>",
"    ]. An endoscopic CCK-test method has also been studied by our laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Secretin-CCK test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    -CCK test is the test of choice at most pancreatic research centers in Europe and Japan. It provides simultaneous assessment of ductal and acinar secretory capacity. Many dosing regimens have been studied for the secretin-CCK test. The two hormones have been administered as a bolus injection or continuous infusion, simultaneously, or sequentially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/42\">",
"     42",
"    </a>",
"    ]. However, whether the use of combined stimulants improves sensitivity for early exocrine dysfunction or CP is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concentration and output of bicarbonate with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    -CCK test is similar to what has been observed with the standard secretin test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/16\">",
"     16",
"    </a>",
"    ]. The secretin-induced rapid flow of water results in lower and often unreliable enzyme concentrations. CCK also induces gallbladder contraction and the release of bile, which may further dilute enzyme concentrations. As a result, the quantification of total enzyme output",
"    <span class=\"nowrap\">",
"     (units/min)",
"    </span>",
"    must be determined through continuous collection of duodenal fluid with or without the use of perfusion markers. Measurement of more than one enzyme (ie, amylase, lipase, and tryptase) and bicarbonate may improve sensitivity since some patients may possess deficiencies of one parameter and not the others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study reviewed the relative diagnostic value of enzyme and bicarbonate concentrations compared with enzyme output in 363",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    -CCK tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/45\">",
"     45",
"    </a>",
"    ]. The investigators also evaluated the requirement for perfusion markers to accurately quantify volume, and the validity of a shortened sampling time (first 20 minutes). Only 60 percent of volume was recovered with the duodenal aspiration tube, suggesting that marker perfusion to correct for distal loss of secretion is important to accurately quantify volume.",
"   </p>",
"   <p>",
"    Using a trypsin output &lt;50",
"    <span class=\"nowrap\">",
"     U/kg/h",
"    </span>",
"    as the reference standard, measurement of enzyme concentration alone misclassified approximately 10 percent of patients. Use of a shortened collection time misclassified approximately 4 percent of patients. The authors concluded that this was an unacceptably high rate of misclassification and that the standard prolonged collection of fluid using a perfusion marker must be performed to accurately measure exocrine function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Role in diagnosis of chronic pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct PFTs are considered sensitive diagnostic tests for the diagnosis of CP because they detect subtle exocrine dysfunction that accompanies early fibrosis. As with imaging tests, the lack of a reliable gold standard has hampered attempts at defining the sensitivity and specificity of PFTs for diagnosis of CP. Studies comparing PFTs with \"established CP\" defined as patients with advanced structural changes on imaging tests have demonstrated sensitivity ranging 72 to 94 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies comparing the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    -CCK test with ERCP as reference standard have reported sensitivity ranging from 83 to 100 percent and specificity ranging from 28 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/14,49-53\">",
"     14,49-53",
"    </a>",
"    ]. Many of these studies have demonstrated discordance between structure and function, particularly in the early stages of disease. This observation implies that structural changes and functional changes may precede one another, and that a combination of sensitive structural and functional tests may optimize the diagnosis of early CP. An interesting study published in abstract form followed six patients with normal ERCP and abnormal PFTs and demonstrated that CP developed in five of the patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/54\">",
"     54",
"    </a>",
"    ]. Based upon this and other limited data, some have suggested that PFTs is more sensitive than ERCP for the diagnosis of CP.",
"   </p>",
"   <p>",
"    PFTs have been compared with histology as reference standard in a limited number of studies. One of the largest, which included 108 patients who had a surgical pancreatic biopsy or resection (54 with normal histology), demonstrated 67 percent sensitivity and 90 percent specificity of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    -CCK test for CP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/55\">",
"     55",
"    </a>",
"    ]. Because most subjects underwent surgical resection for advanced CP, there is a high potential for spectrum bias, which may falsely elevate sensitivity (ie, the sensitivity might have been lower in populations with less severe pancreatitis). The secretin ePFT has been compared with histology in 17 patients undergoing surgical resection or pancreatic biopsy for painful chronic pancreatitis (13 lacking calcifications). The secretin ePFT demonstrated a sensitivity of 86 percent (95% CI 67, 100) and specificity of 67 percent (95% CI 13, 100) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PFTs have also been compared with endoscopic ultrasound, which may provide another standard for detecting early changes of chronic pancreatitis. Overall, EUS and PFTs agreed in approximately 75 percent of cases. An illustrative study compared EUS results with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    and CCK endoscopic PFT methods in 50 patients undergoing an evaluation for chronic pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/57\">",
"     57",
"    </a>",
"    ]. Both duct-cell function (secretin PFT) and acinar-cell function (CCK PFT) worsened as EUS structural changes increased. Significant inverse correlations were observed between EUS structural score and both secretin PFT bicarbonate results (r = -0.71) and CCK PFT lipase results (r = -0.54). This study also demonstrated the feasibility of performing both EUS and endoscopic PFT in the same endoscopic session as a simultaneous assessment of pancreatic structure and function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29591?source=see_link\">",
"     \"Endoscopic ultrasound in chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INDIRECT PANCREATIC FUNCTION TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect tests measure the consequence of exocrine insufficiency (maldigestion). Indirect tests are simpler and easier to perform than direct tests but their main role appears to be in diagnosis of advanced PEI since they are much less sensitive than direct tests for diagnosis of earlier stages of PEI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Serum trypsinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum trypsinogen is arguably the cheapest and easiest of the indirect tests. This test is specific for CP and sensitive for advanced exocrine insufficiency when levels are less than 20",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    However, the test is much less sensitive and specific for diagnosing earlier stages of CP and exocrine insufficiency with levels 20 to 29",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fecal fat",
"    </span>",
"    &nbsp;&mdash;&nbsp;As",
"    noted above, steatorrhea from pancreatic maldigestion implies a loss of greater than 90 percent of normal enzyme secretory output. As a result, the measurement of fecal fat is only sensitive for the diagnosis of advanced PEI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/58\">",
"     58",
"    </a>",
"    ]. Qualitative measurement (Sudan stain) of a spot stool specimen is easier to perform but less reliable than a quantitative 72-hour collection. Quantitative measurement of fecal fat may be helpful in assessing response to pancreatic enzyme therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several disadvantages that limit the use of this test in clinical practice. Fat malabsorption can also occur in small intestinal mucosal disease, diminishing the specificity for pancreatic disease. The requirement for a high fat diet and lack of exogenous enzymes for three to five days prior to collection may be difficult for patients with CP. Finally, processing and homogenization of three-day stool collections is cumbersome and unpleasant for laboratory technicians. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fecal chymotrypsin and elastase-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal chymotrypsin and elastase-1 are enzymatic products of pancreatic secretion that remain relatively stable during transport through the gastrointestinal tract. Fecal concentrations of these enzymes have been studied extensively for the non-invasive diagnosis of PEI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurements of chymotrypsin activity from spot stool samples with or without hormonal stimulation demonstrate a good correlation with those of prolonged collections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/59\">",
"       59",
"      </a>",
"      ]. Using the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"       secretin",
"      </a>",
"      -CCK test as reference standard, sensitivity is approximately 85 percent for advanced PEI, but only 49 percent for mild and moderate PEI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/60\">",
"       60",
"      </a>",
"      ]. Chymotrypsin is variably affected during intestinal transport and may be diluted in the presence of concomitant diarrhea. Patients must stop exogenous enzymes for two days prior to the collection. A low cutoff has been chosen (&lt;3",
"      <span class=\"nowrap\">",
"       U/g",
"      </span>",
"      stool) to optimize the specificity of this test.",
"     </li>",
"     <li>",
"      Pancreatic elastase-1 appears to be more stable than chymotrypsin during intestinal transit. Exogenous enzymes do not interfere with the elastase test assay as they do with the chymotrypsin assay. There is a direct correlation in pancreatic elastase 1 concentrations in pancreatic fluid and stool [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. Using direct pancreatic function testing as reference standard, fecal elastase-1 has approximately 100 percent sensitivity for severe, 77 to 100 percent for moderate, and 0 to 63 percent sensitivity for mild PEI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/63-65\">",
"       63-65",
"      </a>",
"      ]. Specificity is approximately 93 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/61\">",
"       61",
"      </a>",
"      ]. These studies suggest higher sensitivity and specificity of fecal elastase compared with fecal chymotrypsin. However, specificity of the test is compromised in patients who have small intestinal diseases such as short gut syndrome, Crohn's Disease and gluten-sensitive enteropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/66\">",
"       66",
"      </a>",
"      ]. Fecal elastase does not appear to be a reliable measure of pancreatic insufficiency in patients with type 1 diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advantages of fecal tests include the lack of requirement for tube placement, fluoroscopy, intravenous access, or oral substrates, and lower cost. Disadvantages include poor sensitivity for mild and moderate PEI, false positive results with non-pancreatic gastrointestinal diseases, and need for stool collection. Fecal tests are most commonly used to evaluate children with cystic fibrosis and steatorrhea, a setting in which \"tube\" tests are highly impractical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pancreolauryl test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pancreolauryl test (PLT) is performed by ingesting the compound",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    dilaurate with a standard breakfast. Fluorescein dilaurate is a substrate for the pancreatic enzyme cholesterol esterase. The enzymatic cleavage of this substrate results in the release of fluorescein in proportion to the activity of cholesterol esterase. Fluorescein is rapidly absorbed from the gut lumen and eventually excreted in the urine. Measurement from the serum or from a 24-hour urine collection allows a quantitative estimate of pancreatic exocrine function.",
"   </p>",
"   <p>",
"    The PLT has been called the best of the tubeless tests because it has reasonable accuracy in detecting both moderate and advanced PEI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/68\">",
"     68",
"    </a>",
"    ]. Sensitivity of PLT is &gt;85 percent for severe, and 50 percent for mild PEI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/69\">",
"     69",
"    </a>",
"    ]. In a large series of 1115 patients, PLT was 69 percent sensitive and 77 percent specific for detection of established CP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Modifications of PLT have been studied to improve sensitivity. Measuring",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    from both serum and urine improves overall sensitivity of PLT for detection of CP to 84 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/69\">",
"     69",
"    </a>",
"    ]. One study demonstrated increased sensitivity through administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    the night prior to PLT to wash out residual ductal enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/71\">",
"     71",
"    </a>",
"    ]. Similar to other indirect tests, PLT may lack specificity in the presence of non-pancreatic processes that interfere with luminal mixing (gastrectomy), digestion (bile salt deficiency), mucosal absorption (celiac disease), or urinary excretion (renal failure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Breath tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breath tests for PEI involve the oral administration of 13C-marked substrates with a test meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. These substrates are hydrolyzed within the intestinal lumen in proportion to the amount of pancreatic lipase activity. The hydrolyzed products are absorbed and metabolized, and eventually released across the pulmonary endothelium as 13CO2. Mass spectrometry or infrared analysis is used to quantify 13CO2. Like other indirect tests, breath tests quantify fat malabsorption and are therefore nonspecific and inaccurate for the diagnosis of mild PEI. The greatest use of these tests may be to quantify steatorrhea, diminishing the need for cumbersome stool collections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Secretin-enhanced MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary studies suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    -enhanced diffusion weighted magnetic resonance imaging (MRI) may be used to quantify pancreatic exocrine function. Secretin-enhanced magnetic resonance cholangiopancreatography (MRCP) also allows timed assessments of duodenal filling, which provides an estimation of pancreatic exocrine function.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     Secretin",
"    </a>",
"    stimulates both pancreatic ductal secretion of water and pancreatic blood flow. Diffusion weight MRI permits detection of the mobility of water molecules and increased capillary blood flow in pancreatic parenchyma. The apparent diffusion coefficient (ADC) is a calculated measure that integrates both diffusion and perfusion.",
"   </p>",
"   <p>",
"    One of the largest studies to evaluate this approach included nine patients with severe CP who were compared with 16 patients with a history of alcohol abuse but without CP and 38 patients without a history of pancreatic disease or alcohol use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/74\">",
"     74",
"    </a>",
"    ]. Diffusion weighted images were obtained before and for 10 minutes after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    administration. The magnitude and time of peak ADC was measured in all patients. There was significant overlap between groups in regards to magnitude of peak ADC. By contrast, the ADC peak time demonstrated excellent discrimination of patients in the CP and alcoholic group from the control patients. The investigators concluded that secretin-enhanced diffusion weighted MRI before and after secretin may allow for a non-invasive diagnosis of pancreatic exocrine dysfunction.",
"   </p>",
"   <p>",
"    One study found a reasonable correlation between the results of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    MRCP and secretin ePFT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/75\">",
"     75",
"    </a>",
"    ]. In this study, all patients with normal ePFT had normal duodenal filling on S-MRCP, and all patients with abnormal ePFT had either mild or severe impairment in duodenal filling on S-MRCP. Further study is needed particularly to compare diffusion weighted MRI with standard tube tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous conditions are associated with pancreatic exocrine insufficiency (PEI) (",
"    <a class=\"graphic graphic_table graphicRef63433 \" href=\"mobipreview.htm?7/31/7675\">",
"     table 1",
"    </a>",
"    ). (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pancreatitis (CP) is the most common cause of PEI in adults. CP is characterized by the gradual and irreversible replacement of normal pancreatic acinar cells by inflammation and fibrosis. As scarring progresses, there is a concomitant decrease in exocrine function of the duct and acinar cells. Because subtle functional changes occur at an early stage of fibrosis, direct pancreatic function tests (PFTs) represent sensitive diagnostic tests for CP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      PFTs are usually unnecessary for diagnosis of advanced CP since imaging tests often reveal pathognomonic structural changes. However, the diagnosis of early CP can be challenging since these features may not always be apparent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The term \"minimal change\" CP has been applied to early CP, in part based upon a study of 16 patients with intractable pancreatic pain and negative imaging tests [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/76\">",
"       76",
"      </a>",
"      ]. Resection specimens from all patients demonstrated histological changes diagnostic of CP.",
"      <br/>",
"      <br/>",
"      Additional studies and clinical experience have proven that a subset of patients with CP have severe pain and lack major changes that are apparent on plain films, computed tomography (CT) or magnetic resonance imaging (MRI). In these patients, a sensitive direct functional test may allow the detection of subtle exocrine decline as a surrogate marker of parenchymal inflammation and fibrosis. On the other hand, we have found that many such patients have normal results from direct pancreatic function testing suggesting that they may have another cause of upper abdominal pain.",
"      <br/>",
"      <br/>",
"      Indirect tests are of little use for diagnosis of early CP because they only reliably detect advanced PEI, which is usually associated with imaging changes. We generally perform an endoscopic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"       secretin",
"      </a>",
"      test on patients referred with possible CP and a normal pancreatic CT scan. Endoscopic ultrasound (EUS) is often performed in concert with PFTs for a sensitive structural and functional assessment of the gland. The finding of a diminished peak bicarbonate concentration (with or without EUS changes) supports the diagnosis of early CP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29591?source=see_link\">",
"       \"Endoscopic ultrasound in chronic pancreatitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      PFTs may be used to stage exocrine function in patients with established \"large duct\" or calcific CP. Patients with CP who have exocrine dysfunction may benefit from exogenous pancreatic enzymes to assist with digestion. However, approximately 10 percent of patients with advanced structural features of CP have preserved exocrine function. These patients may not need to take exogenous enzymes. Some authorities suggest that enzymes should be used in the treatment of all patients with painful CP, regardless of exocrine function making PFTs unnecessary. However, the benefit of enzymes in the management of pain from chronic pancreatitis is uncertain. Furthermore, frequent dosing and high cost make enzymes difficult for many patients with CP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"       \"Treatment of chronic pancreatitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Our approach is to institute a trial of pancreatic enzymes for all patients with the new diagnosis of CP with use of a symptom diary. If there is no appreciable response of pain to this short trial, we suggest a direct PFT to determine if exocrine insufficiency is present. If the PFT is normal, chronic enzyme therapy is not required. However, if even mild exocrine insufficiency is detected, enzymes are maintained for optimal digestion and nutrition.",
"      <br/>",
"      <br/>",
"      The finding of significant PEI in the setting of an enlarged and obstructed duct may prompt consideration for endoscopic or surgical duct decompression. Patients with CP who develop steatorrhea or weight loss may benefit from PFTs to confirm the presence of pancreatic maldigestion. In this setting, a non-invasive indirect test such as fecal elastase may be sufficient. New onset steatorrhea or weight loss should also prompt CT scan or EUS to rule out ductal adenocarcinoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"       \"Treatment of chronic pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several other settings in which PFTs may help clarify the diagnosis and thus influence management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystic fibrosis (CF) is caused by mutations in the gene that encode the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This protein regulates the transport of chloride and sodium across endothelial cell membranes in the lungs and exocrine glands. Patients with CF develop hyperviscous pulmonary secretions leading to recurrent pneumonia. Approximately 80 percent of patients also develop progressive pancreatic damage due to the blockage of ductules resulting from inspissated pancreatic secretion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients with known CF and steatorrhea, indirect PFTs may confirm PEI as the cause. Fat quantification and breath tests may be chosen both for diagnosis and to measure response to pancreatic enzyme therapy. Direct tests are difficult in young patients and are probably not necessary, since pancreatic insufficiency is most often severe and easily detectable by indirect methods.",
"     </li>",
"     <li>",
"      Gastric resection may lead to secondary PEI following due to impaired stimulation of cholecystokinin (CCK), as well as inadequate mixing of chyme with pancreatic enzymes due to rapid gastric emptying [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/77\">",
"       77",
"      </a>",
"      ]. Because of altered anatomy, direct tests are more difficult to perform and probably less reliable. Such patients are most likely to benefit from an empiric trial of pancreatic enzymes and an antidumping diet.",
"     </li>",
"     <li>",
"      Short bowel syndrome and severe undernutrition may cause silent PEI and patients may benefit from the addition of enzyme supplements [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/78-80\">",
"       78-80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=see_link\">",
"       \"Chronic complications of the short bowel syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hereditary hemochromatosis and alpha-1 antitrypsin deficiency may occasionally present with exocrine dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link\">",
"       \"Clinical manifestations of hereditary hemochromatosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6281?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pancreatic duct obstruction from a pancreatic neoplasm should always be considered in patients with pancreatic exocrine insufficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34201/abstract/81\">",
"       81",
"      </a>",
"      ]. Although functional tests may verify exocrine insufficiency as a cause of malabsorption, sensitive structural tests (dual phase CT, ERCP, EUS) are vital to rule out malignancy.",
"     </li>",
"     <li>",
"      Total pancreatic resection, or a partial resection in the setting of CP, may result in varying degrees of PEI.",
"     </li>",
"     <li>",
"      Shwachman-Diamond syndrome is a rare congenital condition consisting of PEI, cytopenias, and skeletal abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=see_link\">",
"       \"Congenital neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pancreatic function tests (PFTs) are classified as direct or indirect. Direct PFTs involve the stimulation of the pancreas through the administration of a meal or hormonal secretagogues after which duodenal fluid is collected and analyzed to quantify normal pancreatic secretory content (ie, enzymes, and bicarbonate). Only a few specialized centers perform these tests. Indirect tests measure the consequences of pancreatic insufficiency and are more widely available. However, direct pancreatic function tests are more sensitive and specific measures for pancreatic insufficiency.",
"     </li>",
"     <li>",
"      PFTs are most commonly used to assist in the diagnosis of chronic pancreatitis, the most common cause of pancreatic insufficiency in adults. Their main role is in the diagnosis of early chronic pancreatitis in patients with chronic abdominal pain or other suggestive clinical features but without characteristic radiographic findings.",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"       secretin",
"      </a>",
"      stimulation tests continue to represent a reference standard for direct pancreatic function tests, although alternatives are used in some centers. Sensitivity is in the range of 72 to 94 percent and specificity 80 to 90 percent depending upon the reference standard and the specific method of direct testing.",
"     </li>",
"     <li>",
"      Although several indirect tests have been developed, they depend upon the consequences of pancreatic maldigestion, which are generally not apparent until normal enzyme secretory output has declined by more than 90 percent. Thus, they are insensitive for early pancreatic insufficiency. Their main role is for the evaluation of fat malabsorption rather than as a diagnostic test for chronic pancreatitis. Fecal tests are most commonly used to evaluate children with cystic fibrosis and steatorrhea, a setting in which direct tests are highly impractical. The fecal elastase test is preferred in most centers in the United States.",
"     </li>",
"     <li>",
"      Access to direct PFTs may be improving with the availability of synthetic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"       secretin",
"      </a>",
"      and the development of an endoscopic collection protocol, which can be performed by gastroenterologists who perform upper endoscopy.",
"     </li>",
"     <li>",
"      We perform an endoscopic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"       secretin",
"      </a>",
"      test on most patients in whom we are considering the diagnosis of pancreatic exocrine insufficiency (PEI). However, there are occasional patients who decline or in whom the endoscopic tests may not be feasible (eg, those who have undergone a Billroth II reconstruction). In such cases, we perform an indirect test. Our indirect test of choice is fecal elastase 1 measurement. Since elastase-1 is highly stable, stool specimens may be sent overnight in an approved lab pack at ambient temperature. An enzyme-linked immunosorbent assay (ELISA) is used to determine elastase-1 concentrations. Stool concentrations &gt;200",
"      <span class=\"nowrap\">",
"       micrograms/gram",
"      </span>",
"      suggest normal exocrine function, 100 to 200",
"      <span class=\"nowrap\">",
"       micrograms/gram",
"      </span>",
"      suggest moderate exocrine dysfunction, &lt;100",
"      <span class=\"nowrap\">",
"       micrograms/gram",
"      </span>",
"      suggest severe exocrine dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/1\">",
"      Lagerlof HO. Pancreatic function and pancreatic disease: studied by means of secretin. Acta Med Scand 1942; 128:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/2\">",
"      Chiray M, Jeandel A, Salmon A. L'exploration clinique du pancreas et l'injection intraveneuse de secretine purifiee. Presse Med 1930; 38:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/3\">",
"      DREILING DA, HOLLANDER F. Studies in pancreatic function; preliminary series of clinical studies with the secretin test. Gastroenterology 1948; 11:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/4\">",
"      DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973; 288:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/5\">",
"      Dutta SK, Bustin MP, Russell RM, Costa BS. Deficiency of fat-soluble vitamins in treated patients with pancreatic insufficiency. Ann Intern Med 1982; 97:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/6\">",
"      Nakamura T, Takebe K, Imamura K, et al. Fat-soluble vitamins in patients with chronic pancreatitis (pancreatic insufficiency). Acta Gastroenterol Belg 1996; 59:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/7\">",
"      Toskes PP, Dawson W, Curington C, et al. Non-diabetic retinal abnormalities in chronic pancreatitis. N Engl J Med 1979; 300:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/8\">",
"      Mor&aacute;n CE, Sosa EG, Martinez SM, et al. Bone mineral density in patients with pancreatic insufficiency and steatorrhea. Am J Gastroenterol 1997; 92:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/9\">",
"      Chen WL, Morishita R, Eguchi T, et al. Clinical usefulness of dual-label Schilling test for pancreatic exocrine function. Gastroenterology 1989; 96:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/10\">",
"      Glasbrenner B, Malfertheiner P, B&uuml;chler M, et al. Vitamin B12 and folic acid deficiency in chronic pancreatitis: a relevant disorder? Klin Wochenschr 1991; 69:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/11\">",
"      Dotevall G, Rolny P. [Examination of the exocrine function of pancreas after stimulation with secretin and CCK]. Lakartidningen 1976; 73:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/12\">",
"      Gyr K, Agrawal NM, Felsenfeld O, Font RG. Comparative study of secretin and Lundh tests. Am J Dig Dis 1975; 20:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/13\">",
"      Braganza JM, Herman K, Hine P, et al. Pancreatic enzymes in human duodenal juice--a comparison of responses in secretin pancreozymin and Lundh Borgstr&ouml;m tests. Gut 1978; 19:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/14\">",
"      Rolny P, Jagenburg R. The secretin-CCK test and a modified Lundh test. A comparative study. Scand J Gastroenterol 1978; 13:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/15\">",
"      Banwell JG, Northam BE, Cooke WT. Secretory response of the human pancreas to continuous intravenous infusion of pancreozymin-cholecystokinin (Cecekin). Gut 1967; 8:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/16\">",
"      Ribet A, Tournut R, Duffaut M, Vaysse N. Use of caerulein with submaximal doses of secretin as a test of pancreatic function in man. Gut 1976; 17:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/17\">",
"      Go VL, Hofmann AF, Summerskill WH. Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique. Gastroenterology 1970; 58:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/18\">",
"      HANSKY J, TISCORNIA OM, DREILING DA, JANOWITZ HD. RELATIONSHIP BETWEEN MAXIMAL SECRETORY OUTPUT AND WEIGHT OF THE PANCREAS IN THE DOG. Proc Soc Exp Biol Med 1963; 114:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/19\">",
"      Lankisch PG, Schreiber A, Otto J. Pancreolauryl test. Evaluation of a tubeless pancreatic function test in comparison with other indirect and direct tests for exocrine pancreatic function. Dig Dis Sci 1983; 28:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/20\">",
"      Jowell PS, Robuck-Mangum G, Mergener K, et al. A double-blind, randomized, dose response study testing the pharmacological efficacy of synthetic porcine secretin. Aliment Pharmacol Ther 2000; 14:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/21\">",
"      Somogyi L, Ross SO, Cintron M, Toskes PP. Comparison of biologic porcine secretin, synthetic porcine secretin, and synthetic human secretin in pancreatic function testing. Pancreas 2003; 27:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/22\">",
"      Toskes PP. Diagnosis of chronic pancreatitis and exocrine insufficiency. Hosp Pract (Off Ed) 1985; 20:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/23\">",
"      Chowdhury RS, Forsmark CE. Review article: Pancreatic function testing. Aliment Pharmacol Ther 2003; 17:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/24\">",
"      Dreiling DA. Pancreatic secretory testing in 1974. Gut 1975; 16:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/25\">",
"      Ceryak S, Steinberg WM, Marks ZH, Ruiz A. Feasibility of an endoscopic secretin test: preliminary results. Pancreas 2001; 23:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/26\">",
"      Catalano MF, Lahoti S, Geenen JE, Hogan WJ. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. Gastrointest Endosc 1998; 48:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/27\">",
"      Draganov P, George S, Toskes PP, Forsmark CE. Is a 15-minute collection of duodenal secretions after secretin stimulation sufficient to diagnose chronic pancreatitis? Pancreas 2004; 28:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/28\">",
"      Stevens T, Conwell DL, Zuccaro G Jr, et al. The efficiency of endoscopic pancreatic function testing is optimized using duodenal aspirates at 30 and 45 minutes after intravenous secretin. Am J Gastroenterol 2007; 102:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/29\">",
"      Moolsintong P, Burton FR. Pancreatic function testing is best determined by the extended endoscopic collection technique. Pancreas 2008; 37:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/30\">",
"      Xiao Z, Stevens T, Dodig M. M1275 Bicarbonate analysis of pancreatic fluid: Back titration versus autoanalyzer (abstract). Gastroenterology 2009; 136:A387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/31\">",
"      Stevens T, Conwell DL, Zuccaro G, et al. Electrolyte composition of endoscopically collected duodenal drainage fluid after synthetic porcine secretin stimulation in healthy subjects. Gastrointest Endosc 2004; 60:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/32\">",
"      Stevens T, Conwell DL, Zuccaro G Jr, et al. A randomized crossover study of secretin-stimulated endoscopic and dreiling tube pancreatic function test methods in healthy subjects. Am J Gastroenterol 2006; 101:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/33\">",
"      Stevens T, Conwell DL, Zuccaro G Jr, et al. A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis. Gastrointest Endosc 2008; 67:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/34\">",
"      Conwell DL, Zuccaro G, Purich E, et al. The effect of moderate sedation on exocrine pancreas function in normal healthy subjects: a prospective, randomized, cross-over trial using the synthetic porcine secretin stimulated Endoscopic Pancreatic Function Test (ePFT). Am J Gastroenterol 2005; 100:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/35\">",
"      Denyer ME, Cotton PB. Pure pancreatic juice studies in normal subjects and patients with chronic pancreatitis. Gut 1979; 20:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/36\">",
"      Ochi K, Harada H, Mizushima T, et al. Intraductal secretin test is as useful as duodenal secretin test in assessing exocrine pancreatic function. Dig Dis Sci 1997; 42:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/37\">",
"      Gregg JA, Sharma MM. Endoscopic measurement of pancreatic juice secretory flow rates and pancreatic secretory pressures after secretin administration in human controls and in patients with acute relapsing pancreatitis, chronic pancreatitis, and pancreatic cancer. Am J Surg 1978; 136:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/38\">",
"      Draganov P, Patel A, Fazel A, et al. Prospective evaluation of the accuracy of the intraductal secretin stimulation test in the diagnosis of chronic pancreatitis. Clin Gastroenterol Hepatol 2005; 3:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/39\">",
"      Conwell DL, Zuccaro G, Morrow JB, et al. Analysis of duodenal drainage fluid after cholecystokinin (CCK) stimulation in healthy volunteers. Pancreas 2002; 25:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/40\">",
"      Conwell DL, Zuccaro G, Morrow JB, et al. Cholecystokinin-stimulated peak lipase concentration in duodenal drainage fluid: a new pancreatic function test. Am J Gastroenterol 2002; 97:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/41\">",
"      Conwell DL, Zuccaro G Jr, Vargo JJ, et al. An endoscopic pancreatic function test with cholecystokinin-octapeptide for the diagnosis of chronic pancreatitis. Clin Gastroenterol Hepatol 2003; 1:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/42\">",
"      Lankisch PG. Exocrine pancreatic function tests. Gut 1982; 23:777.",
"     </a>",
"    </li>",
"    <li>",
"     Lankisch PG. Secretin test or secretin-CCK test&mdash;gold standard in pancreatic function testing? Pancreatitis&mdash;concepts and classifications. In: Excerpta Medica, ICS 642, Gyre K, Singer MV, Sarles H (Eds), Amsterdam 1994. p.247.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/44\">",
"      Gullo L, Costa PL, Fontana G, Lab&ograve; G. Investigation of exocrine pancreatic function by continuous infusion of caerulein and secretin in normal subjects and in chronic pancreatitis. Digestion 1976; 14:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/45\">",
"      Schibli S, Corey M, Gaskin KJ, et al. Towards the ideal quantitative pancreatic function test: analysis of test variables that influence validity. Clin Gastroenterol Hepatol 2006; 4:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/46\">",
"      Valentini M, Cavallini G, Vantini I, et al. A comparative evaluation of endoscopic retrograde cholangiopancreatography and the secretin-cholecystokinin test in the diagnosis of chronic pancreatitis: a multicentre study in 124 patients. Endoscopy 1981; 13:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/47\">",
"      Dobrilla G, Fratton A, Valentini M, et al. Endoscopic retrograde pancreatography and secretin-pancreozymin test in diagnosis of chronic pancreatitis: a comparative evaluation. Endoscopy 1976; 9:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/48\">",
"      Mee AS, Girdwood AH, Walker E, et al. Comparison of the oral (PABA) pancreatic function test, the secretin-pancreozymin test and endoscopic retrograde pancreatography in chronic alcohol induced pancreatitis. Gut 1985; 26:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/49\">",
"      Rolny P, Lukes PJ, Gamklou R, et al. A comparative evaluation of endoscopic retrograde pancreatography and secretin-CCK test in the diagnosis of pancreatic disease. Scand J Gastroenterol 1978; 13:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/50\">",
"      Malfertheiner P, B&uuml;chler M, Stanescu A, Ditschuneit H. Exocrine pancreatic function in correlation to ductal and parenchymal morphology in chronic pancreatitis. Hepatogastroenterology 1986; 33:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/51\">",
"      Braganza JM, Hunt LP, Warwick F. Relationship between pancreatic exocrine function and ductal morphology in chronic pancreatitis. Gastroenterology 1982; 82:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/52\">",
"      Heij HA, Obertop H, Schmitz PI, et al. Evaluation of the secretin-cholecystokinin test for chronic pancreatitis by discriminant analysis. Scand J Gastroenterol 1986; 21:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/53\">",
"      Bozkurt T, Braun U, Leferink S, et al. Comparison of pancreatic morphology and exocrine functional impairment in patients with chronic pancreatitis. Gut 1994; 35:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/54\">",
"      Lambiase L, Forsmark CE, Toskes PP. Secretin test diagnoses chronic pancreatitis earlier than ERCP (abstract). Gastroenterology 1993; 104:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/55\">",
"      Hayakawa T, Kondo T, Shibata T, et al. Relationship between pancreatic exocrine function and histological changes in chronic pancreatitis. Am J Gastroenterol 1992; 87:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/56\">",
"      Albashir S, Bronner MP, Parsi MA, et al. Endoscopic ultrasound, secretin endoscopic pancreatic function test, and histology: correlation in chronic pancreatitis. Am J Gastroenterol 2010; 105:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/57\">",
"      Stevens T, Dumot JA, Zuccaro G Jr, et al. Evaluation of duct-cell and acinar-cell function and endosonographic abnormalities in patients with suspected chronic pancreatitis. Clin Gastroenterol Hepatol 2009; 7:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/58\">",
"      Luk GD. Same questions, different answers. Gastroenterology 1979; 76:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/59\">",
"      Haverback BJ, Dyce BJ, Gutentag PG, Montgomery DW. Measurement of trypsin and chymotrypsin in stool: a diagnostic test for pancreatic exocrine function. Gastroenterology 1963; 44:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/60\">",
"      Niederau C, Grendell JH. Diagnosis of chronic pancreatitis. Gastroenterology 1985; 88:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/61\">",
"      L&ouml;ser C, M&ouml;llgaard A, F&ouml;lsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut 1996; 39:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/62\">",
"      Stein J, Jung M, Sziegoleit A, et al. Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Clin Chem 1996; 42:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/63\">",
"      Dom&iacute;nguez-Mu&ntilde;oz JE, Hieronymus C, Sauerbruch T, Malfertheiner P. Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol 1995; 90:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/64\">",
"      Gullo L, Ventrucci M, Tomassetti P, et al. Fecal elastase 1 determination in chronic pancreatitis. Dig Dis Sci 1999; 44:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/65\">",
"      Beharry S, Ellis L, Corey M, et al. How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease? J Pediatr 2002; 141:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/66\">",
"      Carroccio A, Verghi F, Santini B, et al. Diagnostic accuracy of fecal elastase 1 assay in patients with pancreatic maldigestion or intestinal malabsorption: a collaborative study of the Italian Society of Pediatric Gastroenterology and Hepatology. Dig Dis Sci 2001; 46:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/67\">",
"      Hahn JU, Kerner W, Maisonneuve P, et al. Low fecal elastase 1 levels do not indicate exocrine pancreatic insufficiency in type-1 diabetes mellitus. Pancreas 2008; 36:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/68\">",
"      DiMagno EP. A perspective on the use of tubeless pancreatic function tests in diagnosis. Gut 1998; 43:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/69\">",
"      Lankisch PG, Brauneis J, Otto J, G&ouml;ke B. Pancreolauryl and NBT-PABA tests. Are serum tests more practicable alternatives to urine tests in the diagnosis of exocrine pancreatic insufficiency? Gastroenterology 1986; 90:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/70\">",
"      Rosemeyer D, Brackmann P, de Boer H, et al. [1,000 pancreolauryl tests: evaluation of sensitivity, specificity and use in clinical routine]. Z Gastroenterol 1986; 24:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/71\">",
"      Dom&iacute;nguez-Mu&ntilde;oz JE, Malfertheiner P. Optimized serum pancreolauryl test for differentiating patients with and without chronic pancreatitis. Clin Chem 1998; 44:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/72\">",
"      Sun DY, Jiang YB, Rong L, et al. Clinical application of 13C-Hiolein breath test in assessing pancreatic exocrine insufficiency. Hepatobiliary Pancreat Dis Int 2003; 2:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/73\">",
"      Ritz MA, Fraser RJ, Di Matteo AC, et al. Evaluation of the 13C-triolein breath test for fat malabsorption in adult patients with cystic fibrosis. J Gastroenterol Hepatol 2004; 19:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/74\">",
"      Erturk SM, Ichikawa T, Motosugi U, et al. Diffusion-weighted MR imaging in the evaluation of pancreatic exocrine function before and after secretin stimulation. Am J Gastroenterol 2006; 101:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/75\">",
"      Balci NC, Smith A, Momtahen AJ, et al. MRI and S-MRCP findings in patients with suspected chronic pancreatitis: correlation with endoscopic pancreatic function testing (ePFT). J Magn Reson Imaging 2010; 31:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/76\">",
"      Walsh TN, Rode J, Theis BA, Russell RC. Minimal change chronic pancreatitis. Gut 1992; 33:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/77\">",
"      Bae JM, Park JW, Yang HK, Kim JP. Nutritional status of gastric cancer patients after total gastrectomy. World J Surg 1998; 22:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/78\">",
"      Sauniere JF, Sarles H. Exocrine pancreatic function and protein-calorie malnutrition in Dakar and Abidjan (West Africa): silent pancreatic insufficiency. Am J Clin Nutr 1988; 48:1233.",
"     </a>",
"    </li>",
"    <li>",
"     Stevens T, Conwell DL. Pancreatic enzyme replacement and bile salt therapy (Chapter 12). In: Intestinal Failure and Rehabilitation, Seidner D, Steiger E, Matarese L (Eds), CRC Press, Boca Raton 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/80\">",
"      Descos L, Duclieu J, Minaire Y. Exocrine pancreatic insufficiency and primitive malnutrition. Digestion 1977; 15:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34201/abstract/81\">",
"      Perez MM, Newcomer AD, Moertel CG, et al. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 1983; 52:346.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4779 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34201=[""].join("\n");
var outline_f33_25_34201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL PANCREATIC PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS OF PANCREATIC INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIRECT PANCREATIC FUNCTION TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lundh test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choice of hormonal stimulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Secretin test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - CCK test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Secretin-CCK test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Role in diagnosis of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INDIRECT PANCREATIC FUNCTION TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Serum trypsinogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fecal fat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fecal chymotrypsin and elastase-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pancreolauryl test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Breath tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Secretin-enhanced MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4779\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4779|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/5/42064\" title=\"diagnostic image 1\">",
"      Dreiling tube",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4779|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/4/44097\" title=\"figure 1\">",
"      Secretin regulation of HCO3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/60/974\" title=\"figure 2\">",
"      Electrolyte patterns PFTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/12/16578\" title=\"figure 3\">",
"      CCK regulation enzyme release",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/31/27134\" title=\"figure 4\">",
"      Electrolyte patterns EGD PFT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4779|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/31/7675\" title=\"table 1\">",
"      Causes panc exocrine insuffic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=related_link\">",
"      Chronic complications of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29591?source=related_link\">",
"      Endoscopic ultrasound in chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35638?source=related_link\">",
"      Physiology of cholecystokinin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=related_link\">",
"      Secretin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_25_34202="Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer";
var content_f33_25_34202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/25/34202/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/25/34202/contributors\">",
"     Michael G Muto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/25/34202/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/25/34202/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/25/34202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/25/34202/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/25/34202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk-reducing bilateral salpingo-oophorectomy is an important option for decreasing the risk of epithelial ovarian and fallopian tubal cancer in women who have the highest likelihood of developing this malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/1\">",
"     1",
"    </a>",
"    ]. Other preventive measures and surveillance measures are available, but are of limited efficacy in reducing the high rates of cancer mortality.",
"   </p>",
"   <p>",
"    Emerging data suggest that some apparent ovarian cancers, particularly in women with",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutations, are initiated in the fallopian tubes, thus risk-reducing surgery must include bilateral removal of the tubes as well as the ovaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, women with a hereditary ovarian cancer syndrome may also be at risk for other malignancies, including breast and peritoneal cancer in",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutation carriers and endometrial or colon cancer in those with Lynch syndrome (hereditary nonpolyposis colorectal cancer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/3\">",
"     3",
"    </a>",
"    ]. Decisions regarding various cancer risk reduction must take into account prevention or surveillance of these other tumors.",
"   </p>",
"   <p>",
"    Risk-reducing bilateral salpingo-oophorectomy results in sterility and surgical menopause. Patient must be counseled about these implications of this procedure and alternative reproductive and hormone therapy options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk-reducing bilateral salpingo-oophorectomy as a strategy to prevent ovarian and fallopian tubal cancer in high risk women will be reviewed here. Elective oophorectomy at the time of hysterectomy in women at average risk of ovarian cancer and strategies to reduce breast cancer or endometrial cancer in women with hereditary cancer syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15706?source=see_link\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18233?source=see_link\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12497987\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Risk-reducing salpingo-oophorectomy",
"      </strong>",
"      &ndash; Removal of the ovaries and fallopian tubes in a woman with a hereditary ovarian cancer syndrome. Risk reduction requires removal of the tubes as well as the ovaries because some malignancies currently categorized as ovarian cancers may arise in the tubal epithelium.",
"     </li>",
"     <li>",
"      <strong>",
"       Elective salpingo-oophorectomy",
"      </strong>",
"      &ndash; Removal of the ovaries and fallopian tubes in a woman who has no known indication for this procedure (eg, ovarian pathology, hereditary ovarian cancer syndrome). Ovaries and tubes are typically removed, rather than the ovaries alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term",
"    <strong>",
"     prophylactic salpingo-oophorectomy",
"    </strong>",
"    has been used inconsistently. It has been used variously to refer to salpingo-oophorectomy for the prevention of ovarian cancer in either women at an average risk or those with a hereditary ovarian cancer syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2750355\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR RISK-REDUCING BSO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk-reducing bilateral salpingo-oophorectomy (rrBSO) is reserved for women at the highest risk of epithelial ovarian and fallopian tubal cancer. The lifetime risk of ovarian cancer is 35 to 46 percent in women with",
"    <em>",
"     BRCA1",
"    </em>",
"    gene mutations, 13 to 23 percent in those with",
"    <em>",
"     BRCA2",
"    </em>",
"    mutations (",
"    <a class=\"graphic graphic_table graphicRef68548 \" href=\"mobipreview.htm?7/40/7821\">",
"     table 1",
"    </a>",
"    ), and 3 to 14 percent in those with Lynch syndrome (hereditary nonpolyposis colorectal cancer syndrome) (",
"    <a class=\"graphic graphic_figure graphicRef57830 \" href=\"mobipreview.htm?2/0/2049\">",
"     figure 1",
"    </a>",
"    ). In the general population, the lifetime risk is 1.5 percent. Women at average risk or who have isolated risk factors for ovarian cancer are not candidates for rrBSO. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link&amp;anchor=H13#H13\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Ovarian cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18233?source=see_link&amp;anchor=H8#H8\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Ovarian cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision of whether to perform a BSO in women at time of hysterectomy for benign indications may depend upon whether ovarian cancer risk factors are present (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"mobipreview.htm?11/59/12221\">",
"     table 2",
"    </a>",
"    ). This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10474?source=see_link&amp;anchor=H22#H22\">",
"     \"Screening for ovarian cancer\", section on 'Lower-risk family history'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15706?source=see_link&amp;anchor=H8214913#H8214913\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\", section on 'Clinical decision-making'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familial or inherited syndromes account for approximately 13 percent of cases of invasive epithelial ovarian and fallopian tubal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/6\">",
"     6",
"    </a>",
"    ]. Clues to the presence of a hereditary cancer syndrome include the presentation of ovarian cancer in a family member at any age, premenopausal breast cancer, male breast cancer and the occurrence of cancers in multiple members of two to four generations. In addition, peritoneal and fallopian tubal cancers can be associated with hereditary syndromes.",
"   </p>",
"   <p>",
"    The familial cancer syndromes include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Breast-ovarian cancer syndrome",
"     </li>",
"     <li>",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women in whom a familial cancer syndrome is suspected should be offered genetic counseling and testing (",
"    <a class=\"graphic graphic_table graphicRef56222 \" href=\"mobipreview.htm?21/58/22445\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57434 \" href=\"mobipreview.htm?27/17/27931\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65717 \" href=\"mobipreview.htm?41/49/42779\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59832 \" href=\"mobipreview.htm?3/37/3675\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Identification of individuals with Lynch syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common hereditary syndrome is the breast-ovarian cancer syndrome. Most of these families have germ-line mutations in one of the breast cancer susceptibility genes,",
"    <em>",
"     BRCA1",
"    </em>",
"    or",
"    <em>",
"     BRCA2",
"    </em>",
"    .",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers are also at increased risk of fallopian tubal cancer (lifetime risk about 0.6 percent) and peritoneal cancer (lifetime risk about 1.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/9\">",
"     9",
"    </a>",
"    ]. However, as new evidence emerges that the fallopian tube may be the site of origin for ovarian cancer, the estimates of fallopian tubal cancer are probably inaccurately low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25978?source=see_link&amp;anchor=H6092142#H6092142\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28121?source=see_link&amp;anchor=H10#H10\">",
"     \"Adenocarcinoma of unknown primary site\", section on 'Women with peritoneal carcinomatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lynch syndrome is associated with a 13 percent lifetime risk of ovarian cancer and 60 percent lifetime risk of endometrial cancer (",
"    <a class=\"graphic graphic_table graphicRef52285 \" href=\"mobipreview.htm?19/25/19869\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, women defer rrBSO until they are finished with childbearing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/11\">",
"     11",
"    </a>",
"    ]. The desire for future reproduction is not an absolute contraindication to the procedure since there are alternative reproductive options (see",
"    <a class=\"local\" href=\"#H2754911\">",
"     'Timing of surgery'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    There are few contraindications to rrBSO, except for women who cannot tolerate a surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CANCER RISK REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk-reducing bilateral salpingo-oophorectomy (rrBSO) is the most effective approach to reducing the risk of ovarian and fallopian tubal cancer in high risk women (see",
"    <a class=\"local\" href=\"#H2754508\">",
"     'Alternatives to risk-reducing BSO'",
"    </a>",
"    below). The procedure also decreases the risk of breast cancer in women with",
"    <em>",
"     BRCA",
"    </em>",
"    mutations.",
"   </p>",
"   <p>",
"    This effect has been best studies in women with",
"    <em>",
"     BRCA",
"    </em>",
"    mutations. Accumulating data support the efficacy of risk-reducing bilateral salpingo-oophorectomy (rrBSO) in significantly reducing the risk of both gynecologic cancers (ovary, fallopian tube, peritoneum) and breast cancer in women who carry",
"    <em>",
"     BRCA1",
"    </em>",
"    or",
"    <em>",
"     BRCA2",
"    </em>",
"    mutations (",
"    <a class=\"graphic graphic_table graphicRef68548 \" href=\"mobipreview.htm?7/40/7821\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/12-21\">",
"     12-21",
"    </a>",
"    ]. As an example, in one study the relative risk of",
"    <span class=\"nowrap\">",
"     ovarian/fallopian",
"    </span>",
"    <span class=\"nowrap\">",
"     tubal/peritoneal",
"    </span>",
"    cancer after rrBSO was 0.04 (95% CI 0.01-0.16) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/14\">",
"     14",
"    </a>",
"    ] and in another study the relative risk of",
"    <span class=\"nowrap\">",
"     breast/ovarian/fallopian",
"    </span>",
"    <span class=\"nowrap\">",
"     tubal/peritoneal",
"    </span>",
"    cancer was 0.25 (95% CI 0.08-0.74) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with Lynch syndrome have a lower risk of ovarian cancer than those with",
"    <em>",
"     BRCA",
"    </em>",
"    mutations, and their risk of breast cancer is controversial. Thus, clinical decision-making regarding oophorectomy and the effects of premature menopause may differ from those with",
"    <em>",
"     BRCA",
"    </em>",
"    . In addition, because the risk of endometrial cancer is so much higher in women with Lynch syndrome, risk-reducing surgery usually involves removal of the uterus and the tubes and ovaries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18233?source=see_link&amp;anchor=H24#H24\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Choosing a management strategy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Extracolonic cancers in Lynch syndrome'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Based upon this rationale and the available evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For premenopausal women with",
"      <em>",
"       BRCA",
"      </em>",
"      mutations who have completed childbearing, we recommend rrBSO rather than ovarian or fallopian tubal cancer screening or chemoprevention. &nbsp;",
"     </li>",
"     <li>",
"      For premenopausal women with Lynch syndrome who have completed childbearing, we suggest rrBSO rather than ovarian cancer screening or chemoprevention. Women who wish to avoid the risks of surgery and premature menopause and who understand the risk of ovarian cancer and the limitations of ovarian cancer screening may reasonable choose ovarian cancer screening. Women with Lynch syndrome should also undergo hysterectomy due to their markedly increased risk of endometrial cancer. The approach to reducing the risk of endometrial cancer in this patient population is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18233?source=see_link\">",
"       \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ovarian and fallopian tubal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a meta-analysis of 10 comparative observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/22\">",
"     22",
"    </a>",
"    ] and a subsequent large prospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/21\">",
"     21",
"    </a>",
"    ] show that rrBSO reduced the lifetime risk of developing ovarian cancer. The meta-analysis included six comparative studies that showed that the risk of ovarian cancer was reduced significantly in women who underwent rrBSO (HR 0.21; 95% CI 0.12-0.39) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data regarding the finding of occult fallopian tubal cancers in women who have undergone rrBSO suggest that at least some apparent ovarian cancers were initiated in the tubes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/2\">",
"     2",
"    </a>",
"    ]. Since",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers rarely present with a tumor that is recognized as a primary tubal cancer (0.6 percent lifetime incidence), it has not been possible to calculate the risk reduction for fallopian tubal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25978?source=see_link&amp;anchor=H26443084#H26443084\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Fallopian tubal carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk reduction may vary by mutation type, as suggested by a subgroup analysis of",
"    <em>",
"     BRCA1",
"    </em>",
"    and",
"    <em>",
"     BRCA2",
"    </em>",
"    carriers in a prospective cohort study that included 939 women who underwent rrBSO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/21\">",
"     21",
"    </a>",
"    ]. Ovarian or peritoneal cancer occurred following rrBSO in 1 to 2 percent of",
"    <em>",
"     BRCA1",
"    </em>",
"    carriers (compared with 7 to 8 percent of those who did not undergo rrBSO), but there were no cases in",
"    <em>",
"     BRCA2",
"    </em>",
"    carriers who underwent rrBSO (compared with 3 percent of those who did not undergo rrBSO). This is in concert with the increased risk of ovarian cancer associated with",
"    <em>",
"     BRCA1",
"    </em>",
"    mutations (",
"    <a class=\"graphic graphic_table graphicRef68548 \" href=\"mobipreview.htm?7/40/7821\">",
"     table 1",
"    </a>",
"    ); however, further study is needed to evaluate whether this difference in risk persists following rrBSO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peritoneal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who undergo rrBSO still have a possibility of developing &ldquo;ovarian-like&rdquo; cancers in the peritoneum, also known as serous carcinoma of the peritoneum (SCP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/16,23,24\">",
"     16,23,24",
"    </a>",
"    ]. SCP refers to diffuse involvement of the peritoneal surfaces with a neoplasm identical to serous carcinoma of the ovary; the ovaries may or may not be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/25\">",
"     25",
"    </a>",
"    ]. Clinically this malignancy is associated with high mortality, similar to that of stage III epithelial ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, the risk of SCP in",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers is substantially lower than the risk of ovarian cancer. SCP should be considered a phenotypic variant of ovarian cancer that is relatively rare, but diminishes the efficacy of either screening programs or of rrBSO.",
"   </p>",
"   <p>",
"    A review of five studies including 846 patients concluded the risk of SCP after rrBSO was 1.7 percent (range 0.5 to 10.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/28\">",
"     28",
"    </a>",
"    ]. Subsequently, a large prospective study including 1045 patients estimated a 4.3 percent cumulative incidence of SCP in",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers at 20 years after rrBSO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/29\">",
"     29",
"    </a>",
"    ]. The risk appears to be highest in",
"    <em>",
"     BRCA1",
"    </em>",
"    carriers, although an association with",
"    <em>",
"     BRCA2",
"    </em>",
"    cannot be excluded; SCP tumors have been reported in a few women with",
"    <em>",
"     BRCA2",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three sources been proposed for extra-ovarian malignancies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microscopic rests of residual ovary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Preexisting carcinomatosis not detected at the time of risk-reducing surgery, from the ovaries or fallopian tubes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Multifocal origin of peritoneal tissue, with disease starting de novo in the peritoneum, which shares a common embryonic origin with m&uuml;llerian duct epithelium (fallopian tubes, uterus, cervix, and the upper two thirds of the vagina derive from the m&uuml;llerian ducts) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral oophorectomy in premenopausal women with",
"    <em>",
"     BRCA",
"    </em>",
"    mutations has the additional benefit of significantly reducing the risk of breast cancer by 30 to 75 percent. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2754508\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO RISK-REDUCING BSO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a hereditary predisposition to ovarian and tubal cancer should understand potential alternatives to risk-reducing bilateral salpingo-oophorectomy (rrBSO). rrBSO is the most effective option and 70 percent of women who are",
"    <em>",
"     BRCA",
"    </em>",
"    mutations carriers undergo this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/36\">",
"     36",
"    </a>",
"    ]. Other options include intensive screening and chemoprophylaxis with estrogen-progestin contraceptives. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6058329\">",
"    <span class=\"h2\">",
"     Surgical options",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility that the fallopian tubes are the primary site of carcinogenesis in",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers has given rise to proposals for surgical alternatives to rrBSO (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Ovarian and fallopian tubal cancer'",
"    </a>",
"    above). Some experts advocate performing bilateral salpingectomy in these women, followed by a bilateral oophorectomy after menopause, thereby preserving the oocytes and avoiding premature menopause. In addition, one regional cancer agency recommends salpingectomy at the time of hysterectomy in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, until there are more data regarding the potential tubal origin of apparent ovarian cancers, in our opinion, rrBSO is the most appropriate procedure in this population. &nbsp;",
"   </p>",
"   <p>",
"    Hysterectomy and tubal ligation are associated with a decrease in ovarian cancer risk in the general population. Hysterectomy has not been evaluated in a high risk population. Data are scarce regarding tubal ligation in high risk women and have not consistently found to be protective against ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Neither of these procedures is an appropriate risk-reducing surgery, since the ovaries and tubes are not removed. (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Scope of surgery'",
"    </a>",
"    below)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487380\">",
"    <span class=\"h2\">",
"     Intensive screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some expert groups have recommended screening with pelvic sonography plus CA 125 assays every six months, starting at age 35 years or five to ten years earlier than the earliest age of first diagnosis of ovarian cancer in the family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/43\">",
"     43",
"    </a>",
"    ]. Screening has not been found to improve survival in this patient population, and clinicians and patients should not be falsely reassured by negative screening test results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/44\">",
"     44",
"    </a>",
"    ]. Most studies show that even with intensive screening, ovarian cancers are usually diagnosed at an advanced stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If an adnexal mass if found prior to rrBSO and fertility is not desired, surgical exploration with BSO is typically performed. The only exceptions to this are masses that are clearly benign (eg, a small paratubal cyst) and women who wish to preserve fertility. If fertility preservation is desired and the sonographic appearance is consistent with a benign mass (eg, physiologic cyst), in our practice, we counsel the patient about the risk of malignancy and offer to follow the patient with serial ultrasounds. Any mass that has features of malignancy requires surgical exploration.",
"   </p>",
"   <p>",
"    Screening of women with hereditary ovarian cancer syndromes is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10474?source=see_link&amp;anchor=H23#H23\">",
"     \"Screening for ovarian cancer\", section on 'High-risk family history'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18233?source=see_link&amp;anchor=H14#H14\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Ovarian cancer surveillance'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H789661\">",
"    <span class=\"h2\">",
"     Early detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cancer most commonly presents at an advanced stage. However, early symptoms are often present, and recognizing these can aid in earlier detection. Bloating, increased abdominal size, urinary urgency or frequency, difficulty eating or feeling full, and abdominal or pelvic pain occur in many gastrointestinal disorders, but are also common in women with ovarian cancer. In particular, ovarian cancer should be suspected when these symptoms coexist with other symptoms, occur almost daily, and are more severe than expected. Therefore, high risk women should be counseled to report this pattern of symptoms to their clinician. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23927?source=see_link\">",
"     \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2754530\">",
"    <span class=\"h2\">",
"     Chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptive use in",
"    <em>",
"     BRCA1",
"    </em>",
"    and",
"    <em>",
"     BRCA2",
"    </em>",
"    mutation carriers appears to decrease the risk of ovarian cancer. A meta-analysis of 18 comparative retrospective studies of oral contraceptive use in",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers included 1503 cases of ovarian cancer and 2855 cases of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/48\">",
"     48",
"    </a>",
"    ]. Ever use of oral contraceptives in",
"    <em>",
"     BRCA1",
"    </em>",
"    and",
"    <em>",
"     BRCA2",
"    </em>",
"    mutation carriers was associated with a significantly reduced risk of ovarian cancer (RR&nbsp;0.50, 95% CI 0.33-0.75); this effect was found to a similar degree in both",
"    <em>",
"     BRCA1",
"    </em>",
"    and",
"    <em>",
"     BRCA2",
"    </em>",
"    mutation carriers. The protective effect increased with longer duration of use. The largest study in the meta-analysis, a case-control study that included 798 women with ovarian cancer, found a 5 percent decrease in risk of ovarian cancer per year of oral contraceptive use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, oral contraceptive use appears to be associated with a decreased risk of fallopian tubal cancer in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been concern that oral contraceptives may increase the risk of breast cancer in mutation carriers. In the meta-analysis described above, there was no evidence of a significantly increased breast cancer risk in oral contraceptive users overall, for users of current formulations of oral contraceptives, or in the first 10 years after cessation of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\", section on 'Oral contraceptives for prevention of ovarian cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One limitation of these studies is that all the data are for use of oral contraceptives. Other formulations or estrogen-progestin contraceptives (patch, vaginal ring) have not been studied in this clinical context; however, it seems likely that they would have a similar effect.",
"   </p>",
"   <p>",
"    Estrogen-progestin contraceptives have not been evaluated in women with Lynch syndrome. Since these medications have been found to have protective effect against both ovarian and endometrial cancer in the general population, some experts advise their use in women with Lynch syndrome who have not had risk-reducing BSO or hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18233?source=see_link&amp;anchor=H17#H17\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Chemoprevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the available data, we suggest use of oral contraceptives in women with a hereditary ovarian cancer syndrome who have not undergone rrBSO and who are not trying to conceive a pregnancy.",
"   </p>",
"   <p>",
"    Chemoprevention of ovarian cancer with agents other than estrogen-progestin contraceptives (eg, vitamin D) is under investigation. &nbsp;",
"   </p>",
"   <p>",
"    Protective factors against ovarian cancer in the general population are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25978?source=see_link&amp;anchor=H6092303#H6092303\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Protective factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2754202\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2754210\">",
"    <span class=\"h2\">",
"     Counseling patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be counseled regarding the expected cancer risk reduction of the procedure, and other approaches to risk reduction should be discussed. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Cancer risk reduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2754508\">",
"     'Alternatives to risk-reducing BSO'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2754911\">",
"    <span class=\"h2\">",
"     Timing of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timing of risk-reducing bilateral salpingo-oophorectomy (rrBSO) requires balancing the procedure-related consequences of sterility and premature menopause against the risk of ovarian and tubal cancer. Generally, rrBSO should be performed as soon as childbearing is complete or by age 35 to 40 years since the benefit diminishes with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/19,26\">",
"     19,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis of hereditary ovarian cancer before age 40 is uncommon, and diagnosis before age 30 is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The average age of ovarian cancer diagnosis varies with type of mutation. Women who carry",
"    <em>",
"     BRCA1",
"    </em>",
"    mutations have a significant rise in ovarian cancer risk beginning at 35 years of age, with 2 to 3 percent of these women developing ovarian cancer by age 40 years; the average age at diagnosis is 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/51-57\">",
"     51-57",
"    </a>",
"    ].",
"    <em>",
"     BRCA2",
"    </em>",
"    mutation carriers reach a 2 to 3 percent incidence of ovarian cancer a decade later, by age 50 years; the average age at diagnosis is 60 years, similar to the general population. Based upon this difference in the likely age of onset of ovarian cancer,",
"    <em>",
"     BRCA2",
"    </em>",
"    carriers may wish to delay risk-reducing surgery, but by doing so, they would not benefit from the reduced risk of breast cancer afforded by salpingo-oophorectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Breast cancer'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Gains in life expectancy after rrBSO have been estimated using decision analysis, with results ranging from 0.3 to 2.6 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Life expectancy gains declined with age at the time of surgery and were minimal for 60 year-old women, although there was little loss in life expectancy if the surgery was performed at age 40 rather than age 30.",
"   </p>",
"   <p>",
"    Women considering rrBSO who have not completed childbearing should be counseled about alternative reproductive options. For women who wish to preserve their ability to have a genetic child, embryo cryopreservation is a well established approach, while preservation of ovarian tissue is investigational. Gestation may be carried out by a gestational carrier. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link&amp;anchor=H2#H2\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\", section on 'Methods to preserve fertility in women'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521473\">",
"    <span class=\"h2\">",
"     Preoperative evaluation and informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should have a routine preoperative evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a 4 to 8 percent chance of detecting occult malignancy either at the time of surgery or in the final pathology report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/28,59-64\">",
"     28,59-64",
"    </a>",
"    ]. The risk is higher (20 percent) in older women (rrBSO at age 45 years or older). Thus, prior to rrBSO, women should undergo evaluation for the presence of an ovarian malignancy with pelvic sonography and serum CA 125. An intraoperative finding of a malignancy necessitates full surgical staging for ovarian cancer (",
"    <a class=\"graphic graphic_table graphicRef75194 \" href=\"mobipreview.htm?40/8/41099\">",
"     table 8",
"    </a>",
"    ). Thus, it is important to counsel patients preoperatively about the potential need for additional surgery and to obtain informed consent. Although some patients prefer a two stage approach, most will give consent for additional surgery at the time of the initial operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SURGICAL PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical route may be by laparoscopy or laparotomy. Laparoscopy is generally preferable since it is associated with less morbidity and allows for an outpatient procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Scope of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum operation required for risk reduction for ovarian and tubal cancer is a bilateral salpingo-oophorectomy. Both the fallopian tubes and ovaries should be removed during risk reduction surgery to reduce the risk of development of cancer in either organ.",
"   </p>",
"   <p>",
"    Studies of rrBSO in women carrying",
"    <em>",
"     BRCA",
"    </em>",
"    mutations have consistently noted occult primary fallopian tubal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/14,15,29,50,59,60,65-72\">",
"     14,15,29,50,59,60,65-72",
"    </a>",
"    ]. As an example, in one large series (n = 159",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers), occult malignancies were detected in seven women; three involved both the ovary and fallopian tube, three involved only the fallopian tubes, and one involved only the ovary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/60\">",
"     60",
"    </a>",
"    ]. In another series, there was a 120-fold increased risk of primary fallopian tubal cancer in 483",
"    <em>",
"     BRCA1",
"    </em>",
"    mutation carriers compared with population-based estimates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/70\">",
"     70",
"    </a>",
"    ]. In a review of the literature, 14 of the 36 cases of occult cancer found during rrBSO were primary fallopian tubal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding of early fallopian tube cancers in",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers has raised the question of performing risk-reducing salpingectomy alone, particularly for women who wish to preserve fertility. The strategies proposed include bilateral salpingectomy alone or salpingectomy followed by delayed oophorectomy to avoid premature menopause and preserve oocytes for assisted reproduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/73\">",
"     73",
"    </a>",
"    ]. These models are based upon few data, since the impact on ovarian cancer risk reduction of salpingectomy alone or delayed oophorectomy has not been studied. Also, delaying or not performing oophorectomy is likely to diminish or eliminate the prophylactic effect on breast cancer associated with oophorectomy. Procedural concerns include: (1) it is unclear whether the surgeon can remove the entire fimbriated end of the fallopian tube without performing oophorectomy, and this may be the most likely site of tubal malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/65\">",
"     65",
"    </a>",
"    ]; (2) tubal epithelium and endosalpingiosis implants are often present on the adjacent surface of the ovary and across the mesovarium; and (3) use of bipolar cautery devices to perform salpingectomy may cause unintended damage to ovarian cortex or collateral vessels. Some have proposed a &ldquo;radical salpingectomy&rdquo; in which the adjacent ovarian cortex is resected in continuity with the tube. Thus, while the question of a more limited procedure for risk reduction is certainly worthy of study, the standard of care is still BSO.",
"   </p>",
"   <p>",
"    When rrBSO is performed, a methodical survey should be conducted of the abdomen (diaphragm, liver, omentum, bowel, paracolic gutters, appendix), pelvis (ovaries, tubes, uterus, posterior cul de sac), and the entire peritoneum. As noted above, there is a 4 to 8 percent prevalence of occult ovarian or fallopian tubal cancer diagnosed as a result of this surgery (see",
"    <a class=\"local\" href=\"#H521473\">",
"     'Preoperative evaluation and informed consent'",
"    </a>",
"    above). Suspicious areas noted at the time of the risk reduction procedure should be biopsied with liberal use of frozen section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/74\">",
"     74",
"    </a>",
"    ]. Some surgeons also perform an omental biopsy and cytologic smear of the diaphragm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritoneal lavage is also performed, although the sensitivity, specificity, and prognostic value of positive lavage cytology have not been determined. Multiple small series of woman at high risk for ovarian cancer undergoing risk reduction BSO or hysterectomy reported finding several women with occult malignancy in the ovary or fallopian tube, and most had malignant cells identified in lavage fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/59,65-68,77\">",
"     59,65-68,77",
"    </a>",
"    ]. One patient had malignant cells confined to the peritoneal lavage specimen with no evidence of carcinoma in the uterus, tubes, or ovaries. No long-term follow-up data are available.",
"   </p>",
"   <p>",
"    All ovarian tissue should be removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/78\">",
"     78",
"    </a>",
"    ]. If adhesions between the ovary and other peritoneal structures are present, the entire adhesion should be resected with the ovary to ensure that no residual ovarian cells remain attached to the peritoneal surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/28\">",
"     28",
"    </a>",
"    ]. The ovarian artery and vein should be clamped and cut at least 2 cm proximal to the ovary, and preferably at the pelvic brim, to avoid leaving any ovarian tissue behind [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/76\">",
"     76",
"    </a>",
"    ]. The pelvic peritoneum should be opened to visualize the ureter and isolate the infundibulopelvic ligament before transection. Complications are infrequent in experienced hands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12393?source=see_link\">",
"     \"Oophorectomy and ovarian cystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgeon should remove as much of the fallopian tube as possible, but complete cornual resection does not appear to be necessary, particularly during laparoscopic procedures. Although the intramural (interstitial) portion of the fallopian tube is typically left behind after BSO, there have been no reports of malignant transformation in the tubal remnant after this type of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/62\">",
"     62",
"    </a>",
"    ]. A large clinicopathologic study of 105 fallopian tubal cancers reported 92 percent of the tumors were situated within the ampullary and isthmic portion and 8 percent were confined to the infundibulum and fimbriae, none were interstitial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/79\">",
"     79",
"    </a>",
"    ]. Another series of 122",
"    <em>",
"     BRCA",
"    </em>",
"    -positive women undergoing rrBSO reported that seven had a malignancy discovered at the time of prophylactic surgery; six of the seven tumors were not appreciated at the time of surgery and five of these six malignancies originated in the fimbrial portion of the fallopian tube [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Concurrent hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hysterectomy may be performed along with BSO when there are other gynecologic indications for this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/80\">",
"     80",
"    </a>",
"    ]. The disadvantage of adding hysterectomy to a BSO is that it increases the morbidity of the procedure and may require a short hospital stay. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/22/14698?source=see_link\">",
"     \"Laparoscopic approach to hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk reduction hysterectomy may be beneficial in some groups of women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with Lynch syndrome - Endometrial cancer is the second most common malignancy (after colorectal cancer) in women with Lynch syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/81\">",
"       81",
"      </a>",
"      ]. Thus, total hysterectomy in addition to rrBSO is the appropriate recommendation in women with this disorder who desire surgical risk reduction.",
"     </li>",
"     <li>",
"      Women planning to take",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      - Women with",
"      <em>",
"       BRCA",
"      </em>",
"      mutations may want to take the selective estrogen receptor modulator tamoxifen for chemoprophylaxis of breast cancer. Tamoxifen use is associated with an increased risk of endometrial cancer. Thus, women planning to use tamoxifen after rrBSO may consider risk reduction hysterectomy at the time of ovarian extirpation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"       \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=see_link&amp;anchor=H843977#H843977\">",
"       \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Tamoxifen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women who wish to take unopposed estrogen therapy - Postmenopausal hormone therapy with unopposed estrogen can be given after hysterectomy without endometrial monitoring, since endometrial carcinoma is not a concern. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Systemic postmenopausal hormone therapy'",
"      </a>",
"      below.) Estrogen alone appears to be associated with a lower breast cancer risk than combined (estrogen with progestin) therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"       \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear whether there is an increased risk of endometrial adenocarcinoma among women who are carriers of",
"    <em>",
"     BRCA",
"    </em>",
"    mutations. Two cases of serous carcinoma of the endometrium in women with",
"    <em>",
"     BRCA1",
"    </em>",
"    mutations; the mutation sites were 5385 ins C and 187delAG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. A retrospective series suggested that serous carcinoma of the endometrium is a part or an expression of the hereditary breast-ovarian cancer syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/85\">",
"     85",
"    </a>",
"    ]. Others have not found an association with",
"    <em>",
"     BRCA",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=see_link&amp;anchor=H14#H14\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'BRCA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These data regarding endometrial cancer risk in",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers are inconclusive; any increase in cancer risk appears to be small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/87\">",
"     87",
"    </a>",
"    ]. Therefore, we feel performance of a risk reduction hysterectomy along with the BSO in",
"    <em>",
"     BRCA",
"    </em>",
"    carriers is discretionary at this time. The risks and benefits of hysterectomy should be discussed with the patient prior to performing rrBSO. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32490?source=see_link\">",
"     \"Abdominal hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It appears that few women require hysterectomy for other indications following rrBSO, and thus, concurrent hysterectomy is not required to avoid future surgery. In one series of 44 women who underwent rrBSO without concurrent hysterectomy, four subsequently underwent hysterectomy (two for uterine myomas, one for menorrhagia, and one for unknown reasons) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOLOGY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple two to three millimeter sections of ovaries and fallopian tubes removed from women at high risk for ovarian and tubal cancer should be examined microscopically for occult carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/26,50,59,66\">",
"     26,50,59,66",
"    </a>",
"    ]. Noninvasive tubal intraepithelial carcinomas have been discovered in tubal fimbria, and may represent a precursor of invasive cancer in the tube and ovary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/50\">",
"     50",
"    </a>",
"    ]. Therefore, sectioning of the fallopian tubes from women who undergo risk-reducing bilateral salpingo-oophorectomy is longitudinal; we use the Sectioning and Extensively Examining the FIMbria (SEE-FIM) protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases in which an occult malignancy is discovered based upon postoperative pathology evaluation, the woman must be counseled about appropriate surgical and medical treatment of ovarian cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H893618\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H893626\">",
"    <span class=\"h2\">",
"     Postoperative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women should have routine postoperative follow-up to evaluate for surgical complications and review pathology. Postoperative instructions for patients following gynecologic surgery can be found separately. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/27/28083?source=see_link\">",
"     \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surveillance for peritoneal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have undergone risk-reducing bilateral salpingo-oophorectomy (rrBSO) had a 1.7 percent chance of developing serous carcinoma of the peritoneum in one prospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/28\">",
"     28",
"    </a>",
"    ]. There are no high quality data regarding surveillance for peritoneal cancer following rrBSO. In our practice, we follow women after rrBSO with an annual pelvic examination and serum CA 125. Some data suggest that a lower CA 125 concentration should be used as the cutoff for concern for malignancy in women following rrBSO, but this issue requires further study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H422399\">",
"    <span class=\"h1\">",
"     ISSUES RELATED TO PREMATURE MENOPAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are considering risk-reducing bilateral salpingo-oophorectomy (rrBSO) should be counseled about the effects of premature menopause and available management strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/5,90\">",
"     5,90",
"    </a>",
"    ]. Menopausal effects include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menopausal symptoms &ndash; eg, hot flashes, sleep disturbance, mood changes, hair and skin changes",
"     </li>",
"     <li>",
"      Sexual health issues &ndash; dyspareunia related to vaginal atrophy, decreased libido",
"     </li>",
"     <li>",
"      Long-term health effects &ndash; osteoporosis, cardiovascular disease, effects on cognitive function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women who undergo rrBSO differ in several important ways from the general menopausal population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They undergo surgical rather than natural menopause. As a result, ovarian hormone levels drop abruptly and all hormone production ceases. In contrast, in women with natural menopause, hormone levels decrease gradually and the ovaries continue to produce some hormones, eg, androgens. Whether these hormones should be replaced in women after natural or surgical menopause is controversial. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=see_link\">",
"       \"Androgen production and therapy in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They are typically younger than the average age of menopause (51 years old). Thus, they will be exposed to the detrimental effects of hypoestrogenism (eg, effects on bone density, cardiovascular health) for a longer period of time. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Duration of estrogen therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15706?source=see_link&amp;anchor=H24792988#H24792988\">",
"       \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\", section on 'Risks of elective oophorectomy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=see_link&amp;anchor=H171785533#H171785533\">",
"       \"Clinical manifestations and diagnosis of menopause\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical impact of surgical versus natural menopause in a topic of debate and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15706?source=see_link\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Menopausal effects can be managed either with hormone therapy or with other approaches. Estrogen therapy is the most effective treatment available for relief of menopausal symptoms. The use of hormone therapy in women who have undergone rrBSO will be discussed in this section. Nonhormonal options for the treatment of menopausal symptoms and effects are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link&amp;anchor=H12#H12\">",
"     \"Menopausal hot flashes\", section on 'Other therapies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest study (n = 846) on quality of life in women who underwent rrBSO found that the quality of life at three years after surgery was comparable to that in women who were managed with periodic screening (pelvic examination, ultrasound, CA 125) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic postmenopausal hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of postmenopausal hormone therapy (HT) in women with hereditary ovarian",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    breast cancer syndromes is controversial. The main concern regarding use of such therapy in this patient population is the potential for increasing the risk of breast cancer, particularly in women with",
"    <em>",
"     BRCA",
"    </em>",
"    mutations. The risk of breast cancer in women with Lynch syndrome is controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Extracolonic cancers in Lynch syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The unique characteristics of women who undergo rrBSO, as described in the preceding section, make it uncertain whether the data regarding the use of HT in the general menopausal population are applicable. There are few studies of use of HT in women with hereditary ovarian cancer syndromes. Thus, women with menopausal symptoms or effects following rrBSO must be counseled about nonhormonal options and about the lack of relevant data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Risk of breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies that demonstrate an increased risk of breast cancer with HT in women who undergo rrBSO prior to menopause, but few studies have been performed and there are no high quality data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/92-95\">",
"     92-95",
"    </a>",
"    ]. The largest study was a prospective cohort study that included 321",
"    <em>",
"     BRCA1",
"    </em>",
"    and",
"    <em>",
"     BRCA2",
"    </em>",
"    mutation carriers who had undergone rrBSO and were followed for an average of three to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. There was no significant increase in the incidence of breast cancer among women who received hormone therapy compared with those who did not (14 versus 12 percent) but the duration of follow-up was short. A subset analysis of estrogen-progestin and estrogen-only therapy found no increase in breast cancer risk for either preparation.",
"   </p>",
"   <p>",
"    The type of",
"    <em>",
"     BRCA",
"    </em>",
"    mutation may impact the risk of breast cancer with HT, since breast cancers in women with",
"    <em>",
"     BRCA1",
"    </em>",
"    mutations are commonly negative for estrogen and progesterone receptors, and thus are potentially less likely to be influenced by hormones than the breast cancers that develop in",
"    <em>",
"     BRCA2",
"    </em>",
"    mutation carriers who are usually positive for these receptors. However, there are insufficient data to evaluate this potential differential effect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link&amp;anchor=H10#H10\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a substantial body of evidence regarding the association of exogenous hormone therapy with breast cancer, predominantly hormone receptor-positive breast cancer. The most influential data come from the Women's Health Initiative trial, which showed that the use of combined estrogen-progestin HT resulted in a significantly increased risk of breast cancer in postmenopausal women over the age of 50. In contrast, there was no increase in breast cancer risk in women who received unopposed estrogen. The relationship between HT and breast cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In breast cancer survivors, data from randomized trials show a significant increase in rates of breast cancer recurrence with the use of HT; this risk appears to be present for both estrogen-progestin and estrogen-alone therapy, although data regarding specific regimens are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link&amp;anchor=H22#H22\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Personal history of breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The generalizability of these data to",
"    <strong>",
"     premenopausal",
"    </strong>",
"    women who undergo rrBSO is unclear. As noted above, these women differ from the postmenopausal population studied in the Women's Health Initiative trial: they are likely to be younger than age 51 and have had surgical rather than natural menopause. Although these women are at a high risk of breast cancer, they cannot be equated with women who have been diagnosed with breast cancer. (See",
"    <a class=\"local\" href=\"#H422399\">",
"     'Issues related to premature menopause'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Risk of ovarian or peritoneal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data regarding the impact of postmenopausal HT on the risk of ovarian or peritoneal cancer following rrBSO. In women who have been treated for epithelial ovarian cancer, there does not appear to be an increased risk of ovarian cancer recurrence or death in women using estrogen or an",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    combination, although data are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/98-101\">",
"     98-101",
"    </a>",
"    ]. However, it is uncertain whether these data from women with a history of ovarian cancer apply to women at high risk of ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/25/34202/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19878850\">",
"    <span class=\"h3\">",
"     Osteoporosis prevention and screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who undergo rrBSO are at an increased risk of developing osteoporosis. These women should be counseled about osteoporosis prevention and screening. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16623386\">",
"    <span class=\"h2\">",
"     Vaginal estrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal estrogen therapy is the most effective treatment for vaginal atrophy. It alleviates symptoms of dyspareunia and vaginal dryness, and may also result in decreased incidence of urinary tract infections and overactive bladder symptoms. Low dose vaginal estrogen therapy for treatment of local symptoms typically does not raise the serum estrogen concentration above the average level following natural menopause. There are no data regarding the risk of breast cancer in high risk women treated with vaginal estrogen therapy. Studies of women with breast cancer have not found an increase in cancer recurrence with use of vaginal estrogen, but data are limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link&amp;anchor=H2203764#H2203764\">",
"     \"Treatment of vaginal atrophy\", section on 'Treatment of women with breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the available data, it appears that vaginal estrogen therapy has a low likelihood of increasing the risk of breast cancer and most clinicians have a low threshold for using this therapy, even for women at high risk of breast cancer. For women with symptomatic vaginal atrophy, nonhormonal options may be used as first line therapy. It is reasonable to use vaginal estrogen to treat persistent symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19878887\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of postmenopausal HT in women who have undergone rrBSO requires further investigation. A shared decision-making process regarding management of menopausal symptoms and effects must include counseling women about nonhormonal options and the lack of population-specific data regarding HT.",
"   </p>",
"   <p>",
"    Given the available data, we suggest nonhormonal options as first line therapy for menopausal symptoms and osteoporosis prevention and treatment in women who have undergone rrBSO. HT is a reasonable option for women who are not adequately treated with nonhormonal approaches and who are willing to accept a potentially increased risk of breast cancer. We do not treat women with a personal history of breast cancer with systemic HT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link&amp;anchor=H12#H12\">",
"     \"Menopausal hot flashes\", section on 'Other therapies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who plan to take systemic HT after rrBSO despite the potential breast cancer risk should be counseled about the risks and benefits of approaches that potentially lower, but do not eliminate, the risk of HT-associated breast cancer. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limiting the duration of HT &ndash; Some clinicians begin HT after surgery and then make a plan with the patient to taper it within several years. Another approach is to stop HT at 51 years old, the average age of natural menopause. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Duration of estrogen therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concurrent hysterectomy &ndash; To enable use of unopposed estrogen, which appears to incur a lower risk of breast cancer than estrogen-progestin therapy; unopposed estrogen therapy in a women with a uterus leads to endometrial cancer. A potential alternative is an ultra low dose transdermal estrogen formulation (eg, Menostar&reg; 14",
"      <span class=\"nowrap\">",
"       mcg/d),",
"      </span>",
"      with which progestin opposition is required only periodically (eg, every six to 12 months). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Concurrent hysterectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link&amp;anchor=H6#H6\">",
"       \"Preparations for postmenopausal hormone therapy\", section on 'Transdermal estrogen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prophylactic mastectomy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\", section on 'Mastectomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk-reducing bilateral salpingo-oophorectomy (rrBSO) is the removal of the ovaries and tubes in women at high risk for epithelial ovarian and fallopian tubal cancer. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emerging data suggest that some apparent ovarian cancers, particularly in women with",
"      <em>",
"       BRCA",
"      </em>",
"      gene mutations, are initiated in the fallopian tubes, thus risk-reducing surgery must include bilateral removal of the tubes as well as the ovaries. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ovarian and fallopian tubal cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      rrBSO is reserved for women at the highest risk of epithelial ovarian and fallopian tubal cancer. The lifetime risk of ovarian cancer is 35 to 46 percent in women with",
"      <em>",
"       BRCA1",
"      </em>",
"      gene mutations, 13 to 23 percent in those with",
"      <em>",
"       BRCA2",
"      </em>",
"      mutations (",
"      <a class=\"graphic graphic_table graphicRef68548 \" href=\"mobipreview.htm?7/40/7821\">",
"       table 1",
"      </a>",
"      ), and 3 to 14 percent in those with Lynch syndrome (hereditary nonpolyposis colorectal cancer syndrome) (",
"      <a class=\"graphic graphic_figure graphicRef57830 \" href=\"mobipreview.htm?2/0/2049\">",
"       figure 1",
"      </a>",
"      ). In the general population, the lifetime risk is 1.5 percent. Women at average risk or who have isolated risk factors for ovarian cancer are not candidates for rrBSO. (See",
"      <a class=\"local\" href=\"#H2750355\">",
"       'Candidates for risk-reducing BSO'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In carriers of",
"      <em>",
"       BRCA",
"      </em>",
"      mutations, rrBSO is associated with an 80 percent reduction in ovarian cancer and a 30 to 75 percent reduction in breast cancer. The benefit of risk-reducing surgery decreases with advancing age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cancer risk reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the prevention of ovarian and fallopian tubal cancer in women with hereditary ovarian cancer syndromes (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cancer risk reduction'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with",
"      <em>",
"       BRCA",
"      </em>",
"      mutations who have completed childbearing, we recommend rrBSO rather than ovarian or fallopian tubal cancer screening or chemoprevention (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For premenopausal women with Lynch syndrome who have completed childbearing, we suggest rrBSO rather than ovarian cancer screening or chemoprevention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Women who wish to avoid the risks of surgery and premature menopause and who understand the risk of ovarian cancer and the limitations of ovarian cancer screening may reasonable choose ovarian cancer screening. Women with Lynch syndrome should also undergo hysterectomy due to their markedly increased risk of endometrial cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18233?source=see_link\">",
"       \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest use of oral contraceptives in women with a hereditary ovarian cancer syndrome who have not undergone rrBSO and who are not trying to conceive a pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2754530\">",
"       'Chemoprevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who have undergone rrBSO appear to have an approximately two percent chance of developing serous carcinoma of the peritoneum. We follow women after rrBSO with an annual pelvic examination and serum CA 125. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10474?source=see_link&amp;anchor=H23#H23\">",
"       \"Screening for ovarian cancer\", section on 'High-risk family history'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H487380\">",
"       'Intensive screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Surveillance for peritoneal cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candidates for concurrent hysterectomy include women with Lynch syndrome, those with other indications for hysterectomy, and those who wish to take",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or unopposed estrogen therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Concurrent hysterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest nonhormonal options as first line therapy for menopausal symptoms and osteoporosis prevention and treatment in women who have undergone rrBSO (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). HT is a reasonable option for women who are not adequately treated with nonhormonal approaches and who are willing to accept a potentially increased risk of breast cancer. We do not treat women with a personal history of breast cancer with systemic HT. (See",
"      <a class=\"local\" href=\"#H19878887\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/1\">",
"      Berek JS, Chalas E, Edelson M, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol 2010; 116:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/2\">",
"      Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/3\">",
"      Shulman LP. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. Obstet Gynecol Clin North Am 2010; 37:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/4\">",
"      Campfield Bonadies D, Moyer A, Matloff ET. What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salipingo-oophorectomy. Fam Cancer 2011; 10:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/5\">",
"      Finch A, Metcalfe KA, Chiang JK, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011; 121:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/6\">",
"      Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; 121:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/7\">",
"      Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/8\">",
"      ACOG Committee on Practice Bulletins. Hereditary breast and ovarian cancer syndrome. Gynecol Oncol 2009; 113:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/9\">",
"      Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003; 21:4222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/10\">",
"      Lynch HT, Casey MJ, Shaw TG, Lynch JF. Hereditary Factors in Gynecologic Cancer. Oncologist 1998; 3:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/11\">",
"      Skytte AB, Gerdes AM, Andersen MK, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet 2010; 77:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/12\">",
"      Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993; 71:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/13\">",
"      Weber BL, Punzalan C, Eisen A, et al. Ovarian cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers (abstract). Am Soc Hum Genet 2000; 67(Suppl2):251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/14\">",
"      Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/15\">",
"      Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/16\">",
"      Struewing JP, Watson P, Easton DF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995; :33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/17\">",
"      Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993; 71:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/18\">",
"      Rosen B, Kwon J, Fung Kee Fung M, et al. Systematic review of management options for women with a hereditary predisposition to ovarian cancer. Gynecol Oncol 2004; 93:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/19\">",
"      Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/20\">",
"      Grann VR, Panageas KS, Whang W, et al. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998; 16:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/21\">",
"      Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/22\">",
"      Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/23\">",
"      Menczer J, Chetrit A, Barda G, et al. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. Gynecol Oncol 2003; 88:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/24\">",
"      Karlan BY, Baldwin RL, Lopez-Luevanos E, et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999; 180:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/25\">",
"      Bandera CA, Muto MG, Schorge JO, et al. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 1998; 92:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/26\">",
"      Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 2000; 18:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/27\">",
"      Zhou J, Iwasa Y, Konishi I, et al. Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study. Cancer 1995; 76:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/28\">",
"      Dowdy SC, Stefanek M, Hartmann LC. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am J Obstet Gynecol 2004; 191:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/29\">",
"      Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/30\">",
"      Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002; 94:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/31\">",
"      Casey MJ, Synder C, Bewtra C, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005; 97:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/32\">",
"      Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/33\">",
"      Salazar H, Godwin AK, Daly MB, et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996; 88:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/34\">",
"      Muto MG, Welch WR, Mok SC, et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 1995; 55:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/35\">",
"      Schorge JO, Muto MG, Welch WR, et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998; 90:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/36\">",
"      Miller SM, Roussi P, Daly MB, Scarpato J. New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res 2010; 16:5094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/37\">",
"      Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol 2011; 204:19.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Salpingectomy recommended in British Columbia: file://www.ovcare.ca/news_practice%20changes.php (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/39\">",
"      McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007; 8:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/40\">",
"      Modugno F, Moslehi R, Ness RB, et al. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control 2003; 14:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/41\">",
"      McGuire V, Felberg A, Mills M, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 2004; 160:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/42\">",
"      Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001; 357:1467.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/44\">",
"      Evans DG, Gaarenstroom KN, Stirling D, et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2009; 46:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/45\">",
"      Hermsen BB, Olivier RI, Verheijen RH, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007; 96:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/46\">",
"      Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004; 22:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/47\">",
"      Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010; 119:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/48\">",
"      Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010; 46:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/49\">",
"      Jordan SJ, Green AC, Whiteman DC, et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer 2008; 122:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/50\">",
"      Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25:3985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/51\">",
"      Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/52\">",
"      King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/53\">",
"      Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8:3776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/54\">",
"      Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997; 60:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/55\">",
"      Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/56\">",
"      Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/57\">",
"      Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 2012; 124:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/58\">",
"      Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy. Gynecol Oncol 2005; 98:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/59\">",
"      Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005; 23:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/60\">",
"      Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006; 100:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/61\">",
"      Powell CB. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy. Gynecol Oncol 2006; 100:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/62\">",
"      Kauff ND, Barakat RR. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here? Gynecol Oncol 2004; 93:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/63\">",
"      Lamb JD, Garcia RL, Goff BA, et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol 2006; 194:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/64\">",
"      Manchanda R, Abdelraheim A, Johnson M, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG 2011; 118:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/65\">",
"      Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/66\">",
"      Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002; 87:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/67\">",
"      Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001; 80:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/68\">",
"      Colgan TJ, Boerner SL, Murphy J, et al. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 2002; 85:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/69\">",
"      H&eacute;bert-Blouin MN, Koufogianis V, Gillett P, Foulkes WD. Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening. Am J Obstet Gynecol 2002; 186:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/70\">",
"      Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/71\">",
"      McEwen AR, McConnell DT, Kenwright DN, et al. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy. Gynecol Oncol 2004; 92:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/72\">",
"      Rose PG, Shrigley R, Wiesner GL. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol Oncol 2000; 77:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/73\">",
"      Kwon JS, Tinker A, Pansegrau G, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013; 121:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/74\">",
"      Rabban JT, Mackey A, Powell CB, et al. Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation. Gynecol Oncol 2011; 121:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/75\">",
"      Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000; 18:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/76\">",
"      Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006; 24:4642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/77\">",
"      Olivier RI, van Beurden M, Lubsen MA, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004; 90:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/78\">",
"      Cass I, Walts A, Karlan BY. Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? Gynecol Oncol 2010; 117:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/79\">",
"      Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 1999; 72:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/80\">",
"      Gabriel CA, Tigges-Cardwell J, Stopfer J, et al. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Fam Cancer 2009; 8:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/81\">",
"      Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/82\">",
"      Hornreich G, Beller U, Lavie O, et al. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol 1999; 75:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/83\">",
"      Lavie O, Hornreich G, Ben Arie A, et al. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 2000; 96:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/84\">",
"      Lavie O, Hornreich G, Ben-Arie A, et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004; 92:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/85\">",
"      Biron-Shental T, Drucker L, Altaras M, et al. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol 2006; 32:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/86\">",
"      Goshen R, Chu W, Elit L, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 2000; 79:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/87\">",
"      Rubinstein WS. Surgical management of BRCA1 and BRCA2 carriers: bitter choices slightly sweetened. J Clin Oncol 2005; 23:7772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/88\">",
"      Villella JA, Parmar M, Donohue K, et al. Role of prophylactic hysterectomy in patients at high risk for hereditary cancers. Gynecol Oncol 2006; 102:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/89\">",
"      van Altena AM, Holtsema H, Hendriks JC, et al. Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level? Menopause 2011; 18:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/90\">",
"      Chapman JS, Powell CB, McLennan J, et al. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecol Oncol 2011; 122:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/91\">",
"      Madalinska JB, Hollenstein J, Bleiker E, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005; 23:6890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/92\">",
"      Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23:7804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/93\">",
"      Eisen A, Lubinski J, Gronwald J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008; 100:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/94\">",
"      Armstrong K, Schwartz JS, Randall T, et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004; 22:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/95\">",
"      Domchek SM, Friebel T, Neuhausen SL, et al. Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? (abstract). J Clin Oncol 2011; 29:S1501.",
"     </a>",
"    </li>",
"    <li>",
"     Goff B, University of Washington, 2011, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/97\">",
"      Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008; 100:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/98\">",
"      Eeles RA, Tan S, Wiltshaw E, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991; 302:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/99\">",
"      Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999; 86:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/100\">",
"      Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 2001; 8:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/101\">",
"      Hopkins ML, Fung MF, Le T, Shorr R. Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecol Oncol 2004; 92:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/25/34202/abstract/102\">",
"      Noruzinia M, Coupier I, Pujol P. Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent? Cancer 2005; 104:1567.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3250 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34202=[""].join("\n");
var outline_f33_25_34202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12497987\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2750355\">",
"      CANDIDATES FOR RISK-REDUCING BSO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CANCER RISK REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2754508\">",
"      ALTERNATIVES TO RISK-REDUCING BSO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6058329\">",
"      Surgical options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H487380\">",
"      Intensive screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H789661\">",
"      Early detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2754530\">",
"      Chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2754202\">",
"      PREOPERATIVE EVALUATION AND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2754210\">",
"      Counseling patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2754911\">",
"      Timing of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521473\">",
"      Preoperative evaluation and informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SURGICAL PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Scope of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Concurrent hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOLOGY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H893618\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H893626\">",
"      Postoperative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surveillance for peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H422399\">",
"      ISSUES RELATED TO PREMATURE MENOPAUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Risk of ovarian or peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19878850\">",
"      - Osteoporosis prevention and screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16623386\">",
"      Vaginal estrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19878887\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3250\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3250|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/0/2049\" title=\"figure 1\">",
"      Lynch syndrome cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3250|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/40/7821\" title=\"table 1\">",
"      Cancer risks BRCA1 and BRCA2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/59/12221\" title=\"table 2\">",
"      Risk factors ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/58/22445\" title=\"table 3\">",
"      BRCA testing NCCN criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/17/27931\" title=\"table 4\">",
"      BRCA testing USPSTF guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/49/42779\" title=\"table 5\">",
"      Risk assess crit breast ovar CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/37/3675\" title=\"table 6\">",
"      Revised Amsterdam criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/25/19869\" title=\"table 7\">",
"      Cancer risk Lynch genotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/8/41099\" title=\"table 8\">",
"      Steps in staging ovarian cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32490?source=related_link\">",
"      Abdominal hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28121?source=related_link\">",
"      Adenocarcinoma of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23927?source=related_link\">",
"      Early detection of epithelial ovarian cancer: Role of symptom recognition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15706?source=related_link\">",
"      Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/51/18233?source=related_link\">",
"      Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25978?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/22/14698?source=related_link\">",
"      Laparoscopic approach to hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/27/28083?source=related_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_25_34203="Early complics female circumcis";
var content_f33_25_34203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Short-term complications of female circumcision",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oliguria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cellulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic inflammatory disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetanus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gangrene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor healing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Urethral injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethral edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary retention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clavicle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Femur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Humerus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34203=[""].join("\n");
var outline_f33_25_34203=null;
var title_f33_25_34204="Ped causes of hypernatremia due to urine loss";
var content_f33_25_34204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F88819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F88819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric causes of hypernatremia due to free urinary water losses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Conditions with urinary concentration defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Central diabetes insipidus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Central nervous system malformations (eg, holoprosencephaly)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Genetic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Central nervous system tumors (eg, craniopharyngioma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Infiltrative processes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Postneurosurgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Nephrogenetic diabetes insipidus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        X-linked (Xp28)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Autosomal (12q13)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Other inherited disorders or syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Bardet-Biedl syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Bartter syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Familial hypomagnesemia with hypercalciuria and nephrocalcinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Drug induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Lithium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Amphotericin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Demeclocycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Ifosfamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Foscarnet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Cidofovir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Electrolyte abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypercalcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypokalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Obstructive uropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sickle cell nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nephronophthisis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cystinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Osmotic diuresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mannitol use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperglycemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34204=[""].join("\n");
var outline_f33_25_34204=null;
var title_f33_25_34205="Age of onset of infantile spasms";
var content_f33_25_34205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Ages at onset of infantile spasms for 257 infants studied during the period 1963-1980",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 375px; background-image: url(data:image/gif;base64,R0lGODlhyQF3AcQAAP///wAz/4CAgAAZfwAAAMDAwEBAQPDw8CAgIKCgoODg4BAQEDAwMNDQ0GBgYHBwcJCQkFBQULCwsAAMPwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADJAXcBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVKwUCmZqZBZaen3qYm5kGAqCnqHmZqaytcKuusbJmsLO2t1y1uLu8Urq9wMFIv8LFxj7Ex8rLNMnMz9AqztHU1dPV2MzX2dzF293gvN/h5LPj5eis5+nsn+vt8JPv8fSGoqOl9fqS95v5+wArzQtIMNDAggj5HEzI8M7ChhDlPIxIsc3EihjRXMzIcczGjiC9fAxJMsvIkiip/5xMyfLJypYwlbyMSZPFgQI4cR4AcCCBgAQ7V8ysSfREAQJIkXZiQMAAAQYshhadKuJmgQRIFUggEAFABAIShJqiSvaHAwIOAAggYGrt2BRSyxZVkFUtW7tv+2n6J7fvjbNpAUAg8ADAAwIQRugl9dav4xhHCSgQQRdBAQSSxbpZPKqz506PPTktPCIBZgQJojZWI2DCgNewY8uePWDC6tDB4jYRMCCA79/AgwsPMOA27l66mfAeznx48ePGki9Z3ry67+fQhUmX2dt6dezZgW1PQt07c/DhxRk/U968cPTpcY0f1t39+/XxY80/0t7+b/j5mYNfGf35R9yAAaayn/8RBfoHYIKuLFhEg/Y9CKE6CHpUn4HXZXihJxISQaF7Fn54SohDjGheiSa642EYKnrHYouOcMbXGjFaNyONjNj4Ihg5fvcjj4+gKESQze1IZCRGBoHkeUMuyUiTQDzpXJRSKkLlD1bel+WJWOayIYdKfjllmDxw5tmanJTQZXBlmqklmju0RtudtNnm5pgGxiknIlS+CRx8gv5H558GHZpDoR3uyeGgiiLqR6B8OrgaowdKSgmljxrqaKeZaioJp6ASWmmFkYqqB6mdmgpqqKoWmaoNmLpa6qyx2sHqo7a2imuudOxK5qWnkvgrsBL9qCaba4I2Qq3EvuonsnX4+IL/nXhmC5ueJED7qa/UEmKtC5jCKoK33Ra74rHhurFOub3yGu2t7c55rbrrfiuvvsPWm8i7+Mo4L7jpSsuuv6z9CO/A+xZML8KGAPyquWoFLCS/fR4MMXsKW3yxwwQ/6zGUGxciscEYW5oyqiUTcvLDIqMMcsMtJ3rvxPH2O7PONQPycsjnjnzlysb2bDO5Qg+9c8ZE52v0Hz/THLTMMcP8tEId48wwz1NbffWqWVPdNdAVi/21KmF7jW7VZJ/tUNpkrz221G6/fbPZcpftdd11RM213nEnDafGfEcxbgsLNy2w4joSXvgTh0cl+OCMf8w23Y8ne7fak3u6tMqZ9w03/9155x36K6P/XXrnjZ4+h99Mf86y7EW7rjnSWlee5Nax24765oHjzTrFvrMBO+iXqz78tMV/cfzsyfc+99/NJww86cvzjnz1QCQAVASBiZi69IBjbzb3PSAAwVmITTj+9uUrfz76OxBQAAMGPGCA+9fLz/n89MvBAtwigP3RQAEFmIxq+ke+1QEwgDc4jP0YED4VJAUpImAfWhaIO+F5cG8QxMEBICCBAwigAS1AiiYA0ICnAIApKJTG+6A3vQZmL4Q9eEBqBOMhFUJgJ27Bi2Y6+L8itg2HNLgJBXESAQOuYAEGOI0J7xJEEUROKMOjmANBiEQZROaCFWQBUzBBxf+7WNEzN8Ji7mjntOjBr4szUIAAEFAKAfyQBQ14wFUWIJkWQgWGQ0RcFnNmwwfCEQYNUKALWpiUHWowjCd4Xu3cSMP4ke+QM2hAEw2QvxZYJSiUSSDiZjjJGsLPdJiMAWaS4sQjkbKNpqwkKlP5Aq6Q55WLY2MuKVlKWsYgAqThDy4bpzuS6ZKYvpyBA6DIyWC6koGnvOExLZdMGDiFlfwjYvCMiLlqXkGSsLRkNA3pzROMUBM7TNEwqSlOWUqznC74CjbFB013fvCI8EQBYeyXxiqtc3fFVBovw5nPFNhvAXJspZP+acyB7jKWvSwoChaQgAggAIrZFOQaHYpMjrL/U6In8F4DFrCAGKqznr3cIj5BCgADNCCRt0RpOFXaTZYCACz9PKk2zcdN6tkUAKu8oEJxcEVpDFJ79uQiSzW5ADo2swdFhctRA+qlaQL0pyF1FoMYKlCIzvSdWCWBJjnZSXru1H/bXKlNg9qUjEpuo159aDsjGlZbDoOrVfXoVfXa0LCOAJgxPWshe3rJsC6TrM5cqEzlSlOfYvWaSBkql/BKOav2da4E9atMKAspqlaWr10NawEO0ICcFMCkzxTsOAn7xp/yU6huVeM9eapWiQpAAT5BZ2yNClfMMhasmp0OZz0H2rzGtaPBFe5iketb5s4yubuVam8bW1ibuhSm/3ddLjup21qb4tRxkRxu64r72eN+9KdsjWx0UZA4y4b2uSBlqlPLuoOosneq7jVuc8+L1QRoFapoFK8WgQtfmzbAjorUqUZni9aa/hQrSCnpeiOJX/J2Nr/l1ewCIlAACTCgK2ZdMGuTWluQ2u9ckkWGgAm52hJLlAEIEMADFpBYf2p3r+bF8X517NeRIoUBoEytiNNKWwdj9bTCvPFluVtJ6CZZtSQusmOdrOC3MniwLqZyD8D52yt396cPqHGVZTvilALXrw5IsWKhbGYvNzmsEBhgJtIpZCuX+avkBClk2xpiOxO5wVM2sGlRu+YhSxnLRrapBG57wgmboL0WJv9uji/rVwkWAHyO9myGmUxXrC7AAQzAhJppYF8KT5fAZ65rAQxQgDQDuDM5ve+p3dzpnxoAxl9JTJ/J/GdEB3qpfHxKkAvt50O3ONE2RfJWlfxeVOdZogfQXwTCkmkMb9rZSrXuBak9Zt7SGs/ZZuldDoC/akda0jtecqofS+0CmnvS6v62XB97a6ciAMTdlq68nbtucV9Qvbv29p27HG4tq5jZ+uV0ZrF6zjm/O93xHjhz/crWUddpxUhtc8ElypWcENrGbAZ3r79s0wdAMt+y3vd2+21TCAN8BRBoogNi2IA0z5yDhga0r6vrWmbS14JRJAACeEJSAZB02I/GuKb/0V1gkMY4BgokwAIAgJW0nIXO4UX4tVXO47A+IMYOb0ECmBKWIFYRLkq3NtNZztI9W1wxRgey2c0IgFI/usLwTjjb4ztomwRljFUHwNXhDuu0n3vAzza4FZvClAUc4ABFP3ogi63zY/9az7BdQbQ56QAF1twAN588r40dZa4ti1md+W/z9MdJwjwc0nnfutWwpa1scSuEDADvuQwf+wsfHj2wp98B6Ph6vENc72ILfvP2fPKDh5zgI6eh8ovHetAjfbJa933v15584yv+Wbw/vuyBNn3XLQbrIM/5zi0vvfKfbi3/fvuiwq/wh7o/dAi8CmYWoGuUm5rrEUd+3lc8/3GGFglWZ6NXeaXXfgPoOg3AFKGWXc/HbwDYVfeXOfBHVj9HbAm4fgu4PRf4OPCXef53d7MmcdQUgk7GZRSIgjimgtDFgitXgcYFgyxld0vHfS7YVzYIUjiodjoYfaXUg5olgzpWf8hFhH5lhAFIekPYgIrHhM1Gg+WlhGElhci3gxYIhQaHhePnhLBkhVjlhdonfmUoN2L4U2QYhGBof1yoZWs4Xtsnh2YoaWloU3GIeFpYg29IZXnIYh8ofX24gvSHbQLYW9+3e9nHhgr4hIiYiH+YcSInNXfIUpGYg3p4iImXXJcIhJlIiYMYg4VIhdpXiSDVib8niW74iMH1g/+H94mNGIaheIMBtoh0iIQpOIvBhYpzCIsMyIpROIp7WIW6WITCKISyCIxdeIxtmITFuITMGIuruIm7GI0e6IjUaIy26IvsB4LPeIXW2I2CqIxwGI6BiI0bJ4rbCIgap4npyInm2I6gSI5+GI+TyDWmaFv2CH3zmI3QuI6q2ILumGXwCJCYyI7JSDWnh3qaoHqYxIt1eItgBWm0V3t5ontGA5G4+IIV1nTF44q9yI3nmJAw45G+A5IRKZGkaIcduXchpJGG2I8l6ZIQBJMrKYcUSZMBZJPDWIot6Y/Vw5PIOI0zCZTNI5TNmIsbZZI7uY8CKZMhw5T0g5TS6IxLqZP/U+mUMzh7P/mOWWmQnoiQRBmVWIk+VHmNJEmWRlk8ZymO6KiWXmmWWnmEE9mVBPmVE7iVQ2mVVCOVNaNsPOETQIFzlIeW/IiPdolsRnNgfPZCTeFCoidwe6mXUEkzfrkx12RAW9EVX8Ft7DWXTYiYV7mW/nIUBjR3CNKWIzmWllmWJWOa51JGeVGLeUmXN2kuOUma9QKbguF6h9F/KBl8G8mDiXl5izkYoXYAlXEZmSFDYJmKB9kYuRmXmHlBnWAaQod+SfecvSiWfFmU1BmUoDmFXDma4XmU45mFA9mauuk6qimPotmXrime3JmS3qmU8ik2C8mQbXI273mPv5if/7PnGhaJJ7d3Nf95mAEKnutpnP6SoE8ZnwxamQ5aLxBKmRIKlw3KcyVzobZZngK6oSS3MR4amguqoRTKoSSanl+YoewJoueZKyVKniIKPWj4jS+wnwzpLDq6owExo+qZoshzo/RIKwRaoLNxexWJpLFxoPUApC16oi9ao7W2KO+Uj9rAomdYl+ZJpQunA2uDpb0QnMY3nFvYpUL6ZnVypTh6DGR6gpPJkWjqohU6A2HaptQApVvafXMqpXUqA3dapOSgp4zop71DpO0pmTwjpspAqCoJoyhKpyp6A4GaqFlan2bKh33qjYLaDGzaqeDgqCL5llOaplWKA5Uao3mqpf+FyqkhaqpfaqWvqpiDyqqP6qW7hKiqWpg2iqfRIKr3KaezaqgjSqmfaqnLAKwBiZ8TKqnFSivHuqvQoKzR6Ymwoqt3CajRmq3cQK1hKZ3FSaxqCqbbSqvh4K3Q+Yrgga3maqfl+qfdaqujmpal6qw01KPMolWpyq3ZgK7dCa6bOo7Jd6RMui0A26zw2q/yGqzEGbCkaq/0eqi+Oq0Lu6zCirCuCqkQm6sT+wz+ap8Hi7ECq7Hi2kaMegwfy66LyqV8SrJD2rHAYCN1xJ8GQLAF+xoTMLOkYLMFm7P4wLNM6rN7AbRBO7M1e7NNqrNHi7TborREW6BCu7NMi7NG+7T/UKuz/Jm1Wru1XMsmDikG+Nq1e4G1YosPZFu2Y4u2a8JJamu2bQtrZ4u2bPu2aUu3pBC3cou3Yju3dsu3n+EILxG4x3ISgssDK3G4g/sriAsKhWu4iXtxW6a4kuu4kUu5kOsilWu5lzt/mQumk7u5nqu5nIu5oju6oEupj3u6qFu6qPq5oUu6qru6rFsDjfu6tmu6t9u6s8sPX1sDOAFVvUtqwQsZw+tFxQsDv1tfx5ujy8u8adK8LZC8iTi91Fu9H9ITP3F9CgABdnR9R6ATKLC9P4EE2HtHKACY2DuYQlBaJLBoAtC7CBRkVgEE7Nu+mXCAI1C/IuC++IsD4mu+/+mrvdwLwLnVv6fAFE4BFSYAWQq8BBDmkFgBRfhGBOT2mI5nAozpRAgMmT+AW3ykGNtmAgfgYSc2AuzjAx5MACNQwQwQgSWQwib8FHwEvS3AwCKwwQ1MAjZsFxFmwJ6wmV4BFiZQQsNXwkmgAMGmepXhvUFwFFDhFKqXmftrS51ZJUkxAgjUm0P1Rc6yFRi0ZVecQe3DXmF8UwQwRcdCxJjRYVQsxCWgxicmSl+BkasimymAGT4sBGRlxCOAnHzUfxQMgQjQfLyJmkLwxSQQeCcAxVUxQIjcA4jMRwlswIh8FgjQwkx8A3hsyCiAxyQweK2AmiPoLIMhZkQQZwrAyP+jvBYOIAF8lMc8cADLhBlA9kVjUch2HASPzBMXNRnz1FIlHAFQscv1o8IioBSAYcaNicjIKXUflwOlLERuYct97Hr5y8GsEM2/mX+jJQKH0XxEsGf2w80jdBeMXASDYQpzbBWiVHd8ps1jDASP3AAXFUMeNwLn/G/GDMn7/MGwec/HbMwttD+DIX8x8M0iAM8/lBMKhNClsQBAFgvL6ckl8BVgR8M5UFr3gxjDVhmufMFFgBWhxhTo1wDIOVoT3ZwoHBmiVAB85ADEoESIgUI5oRQ9gEBKMRlnIQA7bQI4Pc50sQASkMw8YNGckNL4a9Tv25s0Nr6ugJ2ocQL/Rsf/i8zHpXEazxwEMyZ0xrFn13ka2gmmF9QW/2YCX9SYZowMY80T8iRmI3gX2PlpmTwDU011YC3Va+121rvXfN3Xfv3XgB3Ygj3YhF3Yhn3YiJ3YaTC/M5AALoUEDWAAYa3YTiBBnpmjtxXOxnwUVE3ZLrBK4SMBoAcLl5Y/QYYJk/ETEGB9JCBHQ+1Sok0amxd6qm19zPm+RxFm/yABMofRnn0DW1GAO7EVuYcZALCZhzHBa9EJP4YZFRQZTtFUmJEaDDBA1e3LT+HcCSDJ/hVZfOQ9XCEAEdDZv30WCjB4TjEZThHEmWDcz3JibXUAaM3ZwOzOJ+R6wX1T+yPf+7PeuvZ93GyBnE7920Yg301By/Vd306xCd0C3wY03+aswpxN3/TNZ23l3xRORddkygTuA4MB00ZHAHnEFhJg3IPBYUPd4Mz94K1E3+tN3011aSKu38fc32BRWnfB2RCgR1gxwR0eBEwRFIfxAAfgFAjg3nOEFMrt4DVOAi4u4XfxgNnZ5DTuyoiR4QJQ4ko+1z8eBLi1Rznc5YrgY1yR1WJ+5mie5mq+5mze5m7+5nAe53I+53Re53Z+5wYXAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parents and physicians often do not recognize infantile spasms as seizures, particularly when they first occur, and it is probable that the age distribution should be shifted somewhat to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kellaway, P, Frost, JD Jr, Hrachovy, RA, Infantile spasms. In: Antiepileptic Drug Therapy in Pediatrics, Morselli, PL, Pippenger, CE, Penry, JK (Eds), Raven Press, New York 1983.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34205=[""].join("\n");
var outline_f33_25_34205=null;
var title_f33_25_34206="Rapid overview ACS";
var content_f33_25_34206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview: Management of acute coronary syndrome (ACS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Initial assessment:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Consider the diagnosis: Women, the elderly, and patients with diabetes may have atypical presentations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Obtain 12 lead ECG within 10 minutes of arrival; repeat every 10 minutes if initial ECG nondiagnostic but clinical suspicion remains high (initial ECG often",
"        <strong>",
"         NOT",
"        </strong>",
"        diagnostic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. STEMI: ST segment elevations of 1 mm (0.1 mV) in 2 anatomically contiguous leads or 2 mm (0.2 mV) in 2 contiguous precordial leads,",
"        <strong>",
"         OR",
"        </strong>",
"        new left bundle branch block and presentation consistent with ACS. If ECG suspicious but not diagnostic, consult cardiology early.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Non-STEMI or unstable angina: ST segment depressions or deep T wave inversions without Q waves or possibly no ECG changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Obtain emergent cardiology consultation for ACS patients with cardiogenic shock, left heart failure, or sustained ventricular tachyarrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Initial interventions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Assess and stabilize airway, breathing, and circulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Provide oxygen; attach cardiac and oxygen saturation monitors; establish IV access",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Treat sustained ventricular arrhythmia rapidly according to ACLS protocols",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Give aspirin 162 to 325 mg (non-enteric coated), to be chewed and swallowed (unless aortic dissection is being considered). If oral administration not feasible, give as rectal suppository.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Perform focused history and examination: Look for signs of hemodynamic compromise and left heart failure; determine baseline neurologic function, particularly if fibrinolytic therapy is to be given",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Obtain blood for cardiac biomarkers (troponin preferred), electrolytes, coagulation studies, hematocrit/hemoglobin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Treat left heart failure if present: Give afterload reducing agent (eg, nitroglycerin sublingual tablet and/or IV drip at 40 mcg/minute provided no phosphodiesterase inhibitors [eg, for erectile dysfunction]); titrate drip up quickly based on response; give loop diuretic (eg, furosemide 80 mg IV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Give three sublingual nitroglycerin tablets (0.4 mg) one at a time, spaced five minutes apart, or one aerosol spray under tongue every&nbsp;five minutes for three doses",
"        <strong>",
"         IF",
"        </strong>",
"        patient has persistent chest discomfort, hypertension, or signs of heart failure",
"        <strong>",
"         AND",
"        </strong>",
"        there is no sign of hemodynamic compromise (eg, right ventricular infarction) and no use of phosphodiesterase inhibitors (eg, for erectile dysfunction); add IV nitroglycerin for persistent symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Give beta blocker (eg, metoprolol 25 mg orally)",
"        <strong>",
"         IF",
"        </strong>",
"        no signs of heart failure and not at high risk for heart failure, and no signs of hemodynamic compromise, bradycardia, or severe reactive airway disease. If hypertensive, may initiate beta blocker IV instead (eg, metoprolol 5 mg intravenous every 5 minutes times three doses as tolerated).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Give morphine sulfate (2 to 4 mg slow IV push every 5 to 15 minutes) for persistent discomfort or anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Start 80 mg of atorvastatin as early as possible, and preferably before PCI, in patients not on statin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute management STEMI:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Select reperfusion strategy: Primary percutaneous coronary intervention (PCI) strongly preferred, especially for patients with cardiogenic shock, heart failure, late presentation, or contraindications to fibrinolysis. Activate cardiac catheterization team as indicated. For patients with symptoms of &gt;12 hours, fibrinolytic therapy is not indicated, but emergent PCI may be considered, particularly for patients with evidence of ongoing ischemia or those at high risk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Treat with fibrinolysis if PCI unavailable within 90-120 minutes, symptoms &lt;12 hours, and no contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Give antiplatelet therapy (in addition to aspirin) to all patients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Patients treated with fibrinolytic therapy: Give clopidogrel loading dose 300 mg if age less than 75 years; if age 75 years or older, give loading dose of 75 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Patients treated with no reperfusion therapy: Give ticagrelor loading dose 180 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Patients treated with primary percutaneous coronary intervention: Give ticagrelor loading dose of 180 mg or prasugrel loading dose of 60 mg (if no contraindications: prior stroke or TIA, or relative contraindications for prasugrel such as those age 75 years or older, weight less than 60 kg). For patients at high risk of bleeding, clopidogrel 300 to 600 mg (600 mg preferred) is preferred to ticagrelor or prasugrel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Give anticoagulant therapy to all patients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <p>",
"         1. Unfractionated heparin (UFH):",
"        </p>",
"        <p>",
"         For patients undergoing primary PCI , we suggest an initial intravenous (IV) bolus of 50 to 70 units/kg up to a maximum of 5000 units. Additional heparin may be given in the catheterization laboratory based on the results of activated clotting time (ACT) monitoring.",
"        </p>",
"        <p>",
"         For patients treated with fibrinolysis, we suggest an IV bolus of 60 to 100 units/kg up to a maximum of 4000 units and for patients treated with medical therapy (no reperfusion) an IV bolus of 50 to 70 units/kg up to a maximum of 5000 units. Both should be followed by an IV drip of 12 units/kg per hour (goal aPTT time of 1.5 to 2 times control or approximately 50 to 75 seconds). The use of an a glycoprotein (GP) IIb/IIIa inhibitor should be discussed with a cardiologist.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Bivalirudin is an acceptable alternative to heparin plus GP IIb/IIIa inhibitor in patients undergoing primary PCI. Initial bolus of 0.75 mg/kg IV followed by IV infusion of 1.75 mg/kg per hour; can be discontinued after PCI.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Enoxaparin: For patients not managed with PCI and &lt;75 years give 30 mg IV bolus followed immediately by 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for first two doses only) followed by 1 mg/kg for the remaining doses. In patients &ge;75 years of age, do not use an initial IV bolus. Initiate dosing with 0.75 mg/kg subcutaneous every 12 hours (maximum 75 mg for the first two doses only), followed by 0.75 mg/kg dosing for the remaining doses. In patients with a creatinine clearance &lt;30 mL/min using the Cockroft-Gault formula, irrespective of age, we give 1 mg/kg every 24 hours without a loading dose. A Cockcroft-Gault calculator is available in UpToDate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute management of unstable angina or non-STEMI:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Give antiplatelet therapy (in addition to aspirin) to all patients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Patients not treated with an invasive approach: Give ticagrelor loading dose 180 mg. For these patients who are at very high-risk (eg, recurrent ischemic discomfort, dynamic ECG changes, or hemodynamic instability), consider adding a GP IIb/IIIa inhibitor (either eptifibatide or tirofiban).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <p>",
"         2. For patients managed with an early invasive approach: Give ticagrelor loading dose of 180 mg (at presentation) or prasugrel loading dose of 60 mg (after diagnostic coronary angiography)",
"        </p>",
"        <p>",
"         For patients managed with a delayed invasive approach (coronary angiography after four hours): give ticagrelor loading dose 180 mg",
"        </p>",
"        <p>",
"         For patients with age 75 years or older, weight less than 60 kg, or past stroke or transient ischemic attack, ticagrelor (or clopidogrel 300 to 600 mg, with 600 mg preferred) is preferred to prasugrel. For patients otherwise at high risk for bleeding due to prior hemorrhagic stroke, ongoing bleeding, bleeding diathesis, or clinically relevant anemia or thrombocytopenia, clopidogrel 300 to 600 mg is an option.",
"        </p>",
"        <p>",
"         For patients treated with an invasive approach and who receive bivalirudin, we do not recommend routinely give a GP IIb/IIIa inhibitor; for those patients treated with heparin and who are troponin positive, we suggest adding a GP IIb/IIIa inhibitor (either abciximab or eptifibatide) given after diagnostic angiography. For those undergoing an invasive approach who are at very high-risk (eg, recurrent ischemic discomfort, dynamic ECG changes, or hemodynamic instability), consider adding a GP IIb/IIIa inhibitor prior to diagnostic angiography (either eptifibatide or tirofiban) or after diagnostic angiography (abciximab or eptifibatide).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Give anticoagulant therapy in all patients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. UFH (in combination with a GP IIb/IIIa inhibitor) or bivalirudin are the preferred anticoagulants for patients undergoing an early invasive approach. If heparin (plus GP IIb/IIIa) is chosen, give an initial IV bolus of 50 to 70 units/kg (maximum dose 5000 units) by IV push followed by 12 units/kg per hour by intravenous route (goal aPTT time of 1.5 to 2 times control or approximately 50 to 75 seconds).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Enoxaparin is an alternative to UFH for patients not undergoing an early invasive approach. No loading dose is necessary. Dosing is 1 mg/kg subcutaneously every 12 hours, or for patients with an estimated creatine clearance of less than 30 mL/min, 1 mg/kg subcutaneously daily.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Fondaparinux is an alternative to enoxaparin in patients at increased risk of bleeding being managed without PCI. The dose is 2.5 mg subcutaneously. This drug should be avoided in patients with a creatinine clearance &lt;30 mL/min.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Bivalirudin is an acceptable alternative to UFH (plus GP IIb/IIIa inhibitor) in patients undergoing an early invasive approach. It is given as an IV bolus of 0.1 mg/kg and an infusion of 0.25 mg/kg per hour before angiography. For patients undergoing PCI give an additional bolus of 0.5 mg/kg and increase infusion rate to 1.75 mg/kg per hour.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Cocaine-related ACS: Give benzodiazepines (eg, Lorazepam 2 to 4 mg IV every 15 minutes or so) as needed to alleviate symptoms; do",
"        <strong>",
"         NOT",
"        </strong>",
"        give beta blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Stop NSAID therapy if possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Correct any electrolyte abnormalities, especially hypokalemia and hypomagnesemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCI: percutaneous intervention; UFH: unfractionated heparin; NSAID: nonsteroidal anti-inflammatory drug.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34206=[""].join("\n");
var outline_f33_25_34206=null;
var title_f33_25_34207="Trochanteric bursa injection";
var content_f33_25_34207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trochanteric bursa injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trochanteric bursa injection, which may be multiple, not single as shown, may be made up of a standard large joint dose such as 40 mg of triamcinolone acetonide mixed with several mL of xylocaine without epinephrine. After localizing the points of maximum tenderness by deep palpation, a 1.5- to 4-inch needle is used as a probe and the points of maximum tenderness are determined. The injection should be done by redirecting several places within the same coronal plane close to bone. The operator should not wander off the coronal plane of the maximal bony protuberance in order to be absolutely sure of avoiding neurovascular structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley WN, Harris ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia, 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_25_34207=[""].join("\n");
var outline_f33_25_34207=null;
